

## SUBJECT INDEX

Original articles are indicated by (O), editorials (E), correspondence (C), news and notes (N), obituaries (Ob), reprinted article (R), special section (SS), abstracts (A), and book reviews (B).

**Acid, fatty,**

- Purification and characterization of an unusually large fatty acid synthase from *M. tuberculosis* var. *bovis* BCG. Kikuchi, S., *et al.* ..... (A) 513

**Acquired immunodeficiency syndrome (AIDS),**

- Absence of *M. avium* complex disease in patients with AIDS in Uganda. Morrissey, A. B., *et al.* ..... (A) 325
- Activity of antimicrobial agents against *M. avium intracellulare* complex (MAC) strains isolated in Italy from AIDS patients. Fattorini, L., *et al.* ..... (A) 699
- Activity of clarithromycin against *M. avium* infection in patients with the acquired immune deficiency syndrome; a controlled clinical trial. Dautzenberg, B., *et al.* ..... (A) 153
- Clarithromycin-ciprofloxacin-amikacin for therapy of *M. avium-M. intracellulare* bacteremia in patients with AIDS. Delalla, R., *et al.* ..... (A) 699
- Clofazimine crystals in alveolar macrophages from a patient with the acquired immunodeficiency syndrome. Sandler, E. D., *et al.* ..... (A) 297
- Disseminated "*Mycobacterium genavense*" infection in patients with AIDS. Bottger, E. C., *et al.* ..... (A) 697
- Immunophenotypic analysis of histiocytes involved in AIDS-associated *M. scrofulaceum* infection: similarities with lepromatous lepra. Delabie, J., *et al.* ..... (A) 125
- Reduced anti-*M. tuberculosis* antibody response in tuberculosis patients with acquired immunodeficiency syndrome. Figueiredo, J. F. A. and Machado, A. A. .... (A) 700
- Survival of patients with acquired immune deficiency syndrome and disseminated *M. avium* complex infection with and without antimycobacterial chemotherapy. Horsburgh, C. R., Jr., *et al.* ..... (A) 156
- Time course of anti-SL-IV immunoglobulin-G antibodies in patients with tuberculosis and tuberculosis-associated AIDS. Martin-Casabona, N., *et al.* ..... (A) 324
- Tuberculous abscesses in patients with AIDS. Lupatkin, H., *et al.* ..... (A) 324

**Africa,**

- Duration of multidrug therapy in paucibacillary leprosy patients; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Becx-Bleumink, M. .... (O) 436
- Evolution of the leprosy problem in some African areas during the 1980-89 decade. Pattyn, S. R. .... (A) 149
- Leprosy treatment in Africa with the Flying Doctor Service of East Africa. Kloehn, G. (A) 118
- Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Becx-Bleumink, M. and Berhe, D. .... (O) 173
- Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses. Becx-Bleumink, M. .... (O) 465
- Relapses in leprosy patients after release from dapsone monotherapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Becx-Bleumink, M. .... (O) 161
- [Surveys of prevalence of leprosy in 5 countries of Central Africa.] Louis, J. P., *et al.* .. (A) 148

**Albania,**

- Albanian Dermatological Association founded. .... (N) 493

**Allergy(ies),**

- [A thermoindicative nasal test for detecting allergy to antituberculosis drugs.] Buseva, T. A. and Koryakin, V. A. .... (A) 152

**Amikacin,**

- Clarithromycin-ciprofloxacin-amikacin for therapy of *M. avium*-*M. intracellulare* bacteremia in patients with AIDS. Delalla, R., *et al.* ..... (A) 699

**Amoxicillin,**

- The activity of amoxicillin plus clavulanic acid against *M. leprae* in mice. Gelber, R. H. .... (A) 121

**Antibody,**

- Antibody responses to the 18-kDa protein of *M. leprae* in leprosy and tuberculosis patients. Roche, P. W., *et al.* ..... (O) 201
- [Antituberculous antibodies in enzyme immunoassay in relation to the efficacy of tuberculosis chemotherapy.] Chukanov, V. I., *et al.* ..... (A) 131
- [Autoantibodies in lepromatous leprosy.] Graninger, W., *et al.* ..... (A) 126
- Central nervous system lesions in leprosy—immunohistochemical study using anti-PGL-I antibody. Goto, M., *et al.* ..... (A) 718
- Detection of antibodies to human nerve antigens in sera from leprosy patients by ELISA. Park, J. Y., *et al.* ..... (A) 307
- Detection of high titres of *Toxoplasma gondii* antibodies in sera of patients with leprosy in Pakistan. Hussain, R., *et al.* ..... (A) 683
- Disease association of antibodies to human and mycobacterial hsp70 and hsp60 stress proteins. Elsaghier, A., *et al.* ..... (A) 682
- Distribution of anti-PGL-I and anti-LAM-B antibodies among inhabitants of leprosy-endemic villages in South Sulawesi, Indonesia. Izumi, S., *et al.* ..... (A) 719
- [Evaluation of MLPA for determination of antibody to PG-I of MB leprosy.] Meng, M.-B., *et al.* ..... (A) 136
- Evaluation of gelatin particle agglutination assay for the detection of anti-PGL-I antibodies. Comparison with ELISA method and applicability on a large scale study using blood collected on filter paper. Chanteau, S., *et al.* ..... (A) 131
- [GPAT with dried blood specimens for detection of antibody to PGI of *M. leprae*.] Weng, S.-M., *et al.* ..... (A) 679
- High antibody levels to the mycobacterial fibronectin-binding antigen of 30-31 kD in tuberculosis and lepromatous leprosy. Espitia, C., *et al.* ..... (A) 303
- Immune complexes and antibody levels in blisters over human leprosy skin lesions with or without erythema nodosum leprosum. Scollard, D. M., *et al.* ..... (A) 510
- Immunoglobulin-A (IgA) and IgG serum antibodies to mycobacterial antigens in Crohn's disease patients and their relatives. Wayne, L. G., *et al.* ..... (A) 707
- Major proteins of mycobacterial strain ICRC and *M. leprae* identified by antibodies in sera from leprosy patients and their contacts. Chiplunkar, S. V., *et al.* ..... (A) 301
- Mapping of T helper cell epitopes by using peptides spanning the 19-kDa protein of *M. tuberculosis*: evidence for unique and shared epitopes in the stimulation of antibody and delayed-type hypersensitivity. Ashbridge, K. R., *et al.* ..... (A) 314
- Prevalence of IgM antibodies to phenolic glycolipid-I among household contacts and controls in Korea and The Philippines. Cho, S.-N., *et al.* ..... (A) 507
- Reduced anti-*M. tuberculosis* antibody response in tuberculosis patients with acquired immunodeficiency syndrome. Figueiredo, J. F. A. and Machado, A. A. .... (A) 700
- Relationships between titers of antibodies immunoreacting against glycolipid antigens from *M. leprae* and *M. tuberculosis*, the Mitsuda and Mantoux reactions, and bacteriological loads: implications in the pathogenesis, epidemiology and serodiagnosis of leprosy and tuberculosis. David, H. L., *et al.* ..... (O) 208
- Serology and leprosy: immunoassays comparing immunoglobulin G antibody responses to 28- and 30-kilodalton proteins purified from *M. bovis*. Pessolani, M. C. V., *et al.* (A) 136
- Specific binding of phenolic glycolipid antigens from *M. bovis* BCG with antibodies. Vercellone, A., *et al.* ..... (A) 706
- Specificity of IgG subclass antibodies in different clinical manifestations of leprosy. Dhandayuthanpani, S., *et al.* ..... (A) 302
- Susceptibility to infection with *M. avium* is paradoxically correlated with increased synthesis of specific anti-bacterial antibodies. Ferreira, P., *et al.* ..... (A) 155
- The antibody repertoire to proteins of *M. leprae*: genetic influences at the antigen and epitope level. Adeleye, T. A., *et al.* ..... (A) 679

- The pathogenesis of leprosy in the nine-banded armadillo and the significance of IgM antibodies in PGL-I. Job, C. K., *et al.* ..... (A) 515
- Time course of anti-SL-IV immunoglobulin-G antibodies in patients with tuberculosis and tuberculosis-associated AIDS. Martin-Casabona, N., *et al.* ..... (A) 324
- [UltramicroELISA assay for the detection of human IgM antibodies to *M. leprae*.] Laferte, J., *et al.* ..... (A) 508
- Use of serum antibody and lysozyme levels for diagnosis of leprosy and tuberculosis. Near, K. A. and Lefford, M. J. .... (A) 306
- Antibodies, monoclonal,**
- Characterization of circulating lymphocytes by monoclonal antibodies in childhood and adult leprosy. Sehgal, V. N., *et al.* ..... (A) 138
- Isolation and structural characteristics of monoclonal antibody-defined cross-reactive phospholipid antigen from *M. tuberculosis* and *M. leprae*. Fournie, J. J., *et al.* ..... (A) 132
- Monoclonal antibody epitopes of mycobacterial 65-kD heat-shock protein defined by epitope scanning. Hajeer, A. H., *et al.* ..... (A) 683
- Antigen(s),**
- [A comparison of serological activities of synthetic leprosy antigens—F/NT, ND and NT.] Wu, Q.-X., *et al.* ..... (A) 140
- A major T cell antigen of *M. leprae* is a 10-kD heat-shock cognate protein. Mehra, V., *et al.* ..... (A) 305
- [A preliminary analysis of antigen components of *M. leprae* with SDS-PAGE.] Li, X.-Y., *et al.* ..... (A) 135
- Analysis of circulating immune complexes from leprosy patients for *M. leprae* antigens. Sinha, S., *et al.* ..... (O) 396
- Antigens of *M. leprae* in the cerebrospinal fluid of leprosy patients: detection by monoclonal-antibody-based sandwich immunoradiometric assay and avidin/biotin immunoblotting. Patil, S. A., *et al.* ..... (A) 127
- Assessment of the diagnostic value of the native PGLTB1, its synthetic neoglycoconjugate PGLTB0 and the sulfolipid IV antigens for the serodiagnosis of tuberculosis. Chanteau, S., *et al.* ..... (O) 1
- Association of HLA antigens with differential responsiveness to *Mycobacterium w* vaccine in multibacillary leprosy patients. Rani, R., *et al.* ..... (A) 308
- Avidin-biotin immunoblotting studies on reactivity of leprosy sera with *M. leprae* antigen. Patil, S. A., *et al.* ..... (C) 280
- Characterization of the specific antigenicity of *M. fortuitum*. Besra, G. S., *et al.* ..... (A) 696
- Cloning and expression of the gene for the Avi-3 antigen of *M. avium* and mapping of its epitopes. Yamaguchi, R., *et al.* ..... (A) 330
- Comparison of bis-di-octadecylamide of trehalose dicarboxylic acid (BDA.TDA) with glycolipid SL-IV as ELISA antigens for the serodiagnosis of leprosy. Laszlo, A., *et al.* (O) 376
- Composition and immunogenicity of the polysaccharide components of the thermostable macromolecular antigen group of mycobacterial antigens. Bruneteau, M., *et al.* ..... (A) 512
- Dendritic cells efficiently immunoselect mycobacterial-reactive T-cells in human blood, including clonable antigen-reactive precursors. Pancholi, P., *et al.* ..... (A) 684
- Detection of a *M. leprae* cell wall antigen in the urine of untreated and treated patients. Sharma, V. K., *et al.* ..... (A) 511
- Detection of antibodies to human nerve antigens in sera from leprosy patients by ELISA. Park, J. Y., *et al.* ..... (A) 307
- Does previous BCG vaccination interfere with the serodiagnosis of tuberculosis using *M. tuberculosis*-specific glycolipid antigens?. Salem, J. I., *et al.* ..... (C) 87
- Dot-ELISA for detection of phenolic glycolipid PGL-Tb1 and diacyl-trehalose antigens of *M. tuberculosis*. Papa, F., *et al.* ..... (A) 326
- Effect of skin test with *M. leprae* soluble antigen on reaction to a subsequent test with the same antigen. Gupte, M. D., *et al.* ..... (O) 54
- Heat shock proteins and antigens of *M. tuberculosis*. Young, D. B. and Garbe, T. R. .... (A) 145
- Heterogeneity of the repertoire of T cells of tuberculosis patients and healthy contacts to *M. tuberculosis* antigens separated by high-resolution techniques. Schoel, B., *et al.* (A) 326
- High antibody levels to the mycobacterial fibronectin-binding antigen of 30-31 kD in tuberculosis and lepromatous leprosy. Espitia, C., *et al.* ..... (A) 303

Humoral response to nerve glycolipid antigen in sera of leprosy patients. Sahasrabudhe, R. V., <i>et al.</i> . . . . .	(C)	488
Humoral responses against the 85A and 85B antigens of <i>M. bovis</i> BCG in patients with leprosy and tuberculosis. Van Vooren, J. P., <i>et al.</i> . . . . .	(A)	688
IA antigen-positive epithelioid cells in experimentally induced granulomatous inflammations. Izaki, S., <i>et al.</i> . . . . .	(A)	157
Immunization of mice with the antigen A60 of <i>M. bovis</i> BCG. Hubbard, R. D., <i>et al.</i> . . . . .	(A)	322
Immunoglobulin-A (IgA) and IgG serum antibodies to mycobacterial antigens in Crohn's disease patients and their relatives. Wayne, L. G., <i>et al.</i> . . . . .	(A)	707
Immunoreactivity of a 120-kDa antigen of <i>M. tuberculosis</i> . Barnes, P. F., <i>et al.</i> . . . . .	(A)	315
Immunoreactivity of nerve lipid antigens in leprosy. Vemuri, N. and Mukherjee, R. . . . .	(A)	140
Isolation and structural characteristics of monoclonal antibody-defined cross-reactive phospholipid antigen from <i>M. tuberculosis</i> and <i>M. leprae</i> . Fournie, J. J., <i>et al.</i> . . . . .	(A)	132
<i>M. leprae</i> 65hsp antigen expressed from a retroviral vector in a macrophage cell line is presented to T cells in association with MHC class II in addition to MHC class I. Silva, C. L., <i>et al.</i> . . . . .	(A)	511
<i>M. leprae</i> express extracellular homologs of the antigen 85 complex. Pessolani, M. C. V. and Brennan, P. J. . . . .	(A)	723
Modulation of expression of delayed hypersensitivity by mycobacterial antigen-85 fibronectin-binding proteins. Godfrey, H. P., <i>et al.</i> . . . . .	(A)	682
Modulation of pristane-induced arthritis by mycobacterial antigens. Thompson, S. J., <i>et al.</i> . . . . .	(A)	327
Molecular and immunological analysis of a fibronectin-binding protein antigen secreted by <i>M. leprae</i> . Thole, J. E. R., <i>et al.</i> . . . . .	(A)	312
Molecular cloning of the alpha-antigen gene from <i>M. leprae</i> and its application to serodiagnosis of leprosy. Makino, M. and Suzuki, Y. . . . .	(A)	721
Mycobacterial protein antigens: a compilation. Young, D. B., <i>et al.</i> . . . . .	(A)	312
Nucleotide sequence analysis and serologic characterization of the <i>M. intracellulare</i> homologue of the <i>M. tuberculosis</i> 19-kDa antigen. Nair, J., <i>et al.</i> . . . . .	(A)	603
Protein antigens of mycobacteria studied by quantitative immunologic techniques. Harboe, M., <i>et al.</i> . . . . .	(A)	304
Relationships between titers of antibodies immunoreacting against glycolipid antigens from <i>M. leprae</i> and <i>M. tuberculosis</i> , the Mitsuda and Mantoux reactions, and bacteriological loads: implications in the pathogenesis, epidemiology and serodiagnosis of leprosy and tuberculosis. David, H. L., <i>et al.</i> . . . . .	(O)	208
Secreted antigens of <i>Mycobacterium tuberculosis</i> and <i>Mycobacterium bovis</i> BCG by H. G. Wiker. . . . .	(B)	665
Secreted antigens of <i>M. tuberculosis</i> —characterization with lymphocytes-T from patients and contacts after two-dimensional separation. Daugeat, S., <i>et al.</i> . . . . .	(A)	698
Sero-Immunoreactivity of cloned protein antigens of <i>M. leprae</i> . Khan, M. B., <i>et al.</i> . . . . .	(O)	195
Serological reactivity to <i>M. bovis</i> protein antigens in cattle. Fifis, T., <i>et al.</i> . . . . .	(A)	319
Soluble CD4 suppress the antigen driven proliferative response of certain T cell clones specific for mycobacteria and for peptides by monoclonal heat shock proteins. Gidlund, M., <i>et al.</i> . . . . .	(A)	507
Specific binding of phenolic glycolipid antigens from <i>M. bovis</i> BCG with antibodies. Vercellone, A., <i>et al.</i> . . . . .	(A)	706
Specific inhibition of mRNA accumulation for lymphokines in human T cell line Jurkat by mycobacterial lipoarabinomannan antigen. Chujor, C. S. N., <i>et al.</i> . . . . .	(A)	301
T-cell mediated cytotoxicity against mycobacterium antigen-pulsed autologous macrophages in leprosy patients. Sasiain, M. D., <i>et al.</i> . . . . .	(A)	687
T-cell responses of leprosy patients and healthy contacts toward separated protein antigens of <i>M. leprae</i> . Gulle, H., <i>et al.</i> . . . . .	(O)	44
T-cell responses to fractionated antigens of <i>Mycobacterium w</i> , a candidate anti-leprosy vaccine, in leprosy patients. Yadava, A., <i>et al.</i> . . . . .	(A)	141
The 14,000-molecular-weight antigen of <i>M. tuberculosis</i> is related to the alpha-crystallin family of low-molecular-weight heat shock proteins. Verbon, A., <i>et al.</i> . . . . .	(A)	309
The antibody repertoire to proteins of <i>M. leprae</i> : genetic influences at the antigen and epitope level. Adeleye, T. A., <i>et al.</i> . . . . .	(A)	679
The genes coding for the antigen 85 complexes of <i>M. bovis</i> BCG are members of a gene family: cloning, sequence determination, and genomic organization of the gene coding for antigen 85-C of <i>M. tuberculosis</i> . Content, J., <i>et al.</i> . . . . .	(A)	153

**Armadillo(s),**

- An attempt to produce experimental tuberculoid leprosy in the nine-banded armadillo.  
 Job, C. K., *et al.* ..... (A) 145
- Comparison of polymerase chain reaction technique with other methods for detection of *M. leprae* in tissues of wild nine-banded armadillos. Job, C. K., *et al.* ..... (A) 145
- Improved method for purification of *M. leprae* from armadillo tissues. Rodde, C., *et al.* ..... (C) 277
- Isolation of cultivable mycobacteria from feces and lungs of armadillos infected with *M. leprae*. Dhople, A. M., *et al.* ..... (O) 244
- Nine-banded armadillo (*Dasypus novemcinctus*) as an animal model for leprosy. Job, C. K. .... (A) 515
- Phospholipase activity of *M. leprae* harvested from experimentally infected armadillo tissue. Wheeler, P. R. and Ratledge, C. .... (A) 144
- Seasonal and spatial trends in the detectibility of leprosy in wild armadillos. Truman, R. W., *et al.* ..... (A) 150
- The pathogenesis of leprosy in the nine-banded armadillo and the significance of IgM antibodies in PGL-I. Job, C. K., *et al.* ..... (A) 515

**Arthritis,**

- Modulation of pristane-induced arthritis by mycobacterial antigens. Thompson, S. J., *et al.* ..... (A) 327
- Prevention of adjuvant arthritis in rats by a nonapeptide from the 65-kDa mycobacterial heat shock protein: specificity and mechanism. Yang, X.-D., *et al.* ..... (A) 331
- Treatment of early rheumatoid arthritis with rifampicin. Cox, N. L., *et al.* ..... (A) 318

**Asia,**

- Third Asian Dermatological Congress 1993 in Hong Kong. .... (N) 111

**Assay(s) (see also ELISA),**

- Antigens of *M. leprae* in the cerebrospinal fluid of leprosy patients: detection by monoclonal-antibody-based sandwich immunoradiometric assay and avidin/biotin immunoblotting. Patil, S. A., *et al.* ..... (A) 127
- [Antituberculous antibodies in enzyme immunoassay in relation to the efficacy of tuberculosis chemotherapy.] Chukanov, V. I., *et al.* ..... (A) 131
- Diagnostic accuracy of a *M. phlei*-absorbed serum enzyme-linked immunosorbent assay for diagnosis of bovine paratuberculosis in dairy cows. Bech-Nielsen, S., *et al.* ..... (A) 315
- Double-blind evaluation of BACTEC and Buddemeyer-type radiorespirometric assays for *in vitro* screening of antileprosy agents. Franzblau, S. G., *et al.* ..... (A) 513
- Evaluation of gelatin particle agglutination assay for the detection of anti-PGL-I antibodies. Comparison with ELISA method and applicability on a large scale study using blood collected on filter paper. Chanteau, S., *et al.* ..... (A) 131
- Serology and leprosy: immunoassays comparing immunoglobulin G antibody responses to 28- and 30-kilodalton proteins purified from *M. bovis*. Pessolani, M. C. V., *et al.* (A) 136

**Australia,**

- Pattern of leprosy in Queensland, Australia, 1865–1990. Ree, G. H. .... (A) 149

**Bacilli,**

- Significance of neither green nor red (NGR) bacilli in FDA-EB staining. Bhatia, V. N. and Mirmaladevi, B. .... (A) 142

**Bacilli, ICRC,**

- Major proteins of mycobacterial strain ICRC and *M. leprae* identified by antibodies in sera from leprosy patients and their contacts. Chiplunkar, S. V., *et al.* ..... (A) 301

**Bacterial index (BI),**

- BI of patient vs BI of individual sites. Porichha, D., *et al.* ..... (A) 506

**Bacteremia,**

- Clarithromycin-ciprofloxacin-amikacin for therapy of *M. avium-M. intracellulare* bacteremia in patients with AIDS. Delalla, R., *et al.* ..... (A) 699
- Incidence of *M. avium intracellulare* complex bacteremia in human immunodeficiency virus positive patients. Nightingale, S. D., *et al.* ..... (A) 703

**Bacteriology,**

- Is bacteriological examination by skin smear necessary in all paucibacillary leprosy patients in mass control programmes? Rao, P. S., *et al.* ..... (A) 127
- Relationships between titers of antibodies immunoreacting against glycolipid antigens from *M. leprae* and *M. tuberculosis*, the Mitsuda and Mantoux reactions, and bacteriological loads: implications in the pathogenesis, epidemiology and serodiagnosis of leprosy and tuberculosis. David, H. L., *et al.* ..... (O) 208

**Bacteriophage,**

- Identification of expression signals of the mycobacteriophages Bxb1, L1 and TM4 using the *Escherichia-Mycobacterium* shuttle plasmids pYUB75 and pYUB76 designed to create translational fusions to the lacZ gene. Barletta, R. G., *et al.* ..... (A) 309
- [Pathomorphological evaluation of therapeutic effect of mycobacteriophages in tuberculosis.] Zemskova, Z. S. and Dorozhkova, I. R. .... (A) 331

**BCG (bacille Calmette-Guérin),**

- Cellular oxidative responses and mycobacterial growth inhibition in aerosol and intradermal BCG-immunized guinea-pigs. Lagranderie, M., *et al.* ..... (A) 323
- Does Convit vaccine (BCG + *M. leprae*) afford protection against biochemical changes in renal brush border membrane in experimental leprosy? Kohli, M., *et al.* ..... (A) 135
- Does previous BCG vaccination interfere with the serodiagnosis of tuberculosis using *M. tuberculosis*-specific glycolipid antigens? Salem, J. I., *et al.* ..... (C) 87
- Effect of local ultraviolet irradiation on infections of mice with *Candida albicans*, *M. bovis* BCG, and *Schistosoma mansoni*. Jeevan, A., *et al.* ..... (A) 702
- Efficacy of BCG vaccine against leprosy and tuberculosis in Malawi. Ponnighaus, J. M., *et al.* ..... (A) 307
- Evidence for an alpha/beta T cell-independent mechanism of resistance to mycobacteria. Bacillus Calmette-Guérin causes progressive infection in severe combined immunodeficient mice, but not in nude mice or in mice depleted of CD4+ and CD8+ T cells. Izzo, A. A. and North, R. J. .... (A) 507
- Human phagocyte respiratory burst by *M. bovis* BCG and *M. leprae*: functional activation by BCG is mediated by complement and its receptors on monocytes. Launois, P., *et al.* ..... (O) 225
- Humoral immune response of tuberculous patients against the three components of the *M. bovis* BCG 85 complex separated by isoelectric focusing. Van Vooren, J. P., *et al.* (A) 159
- Humoral responses against the 85A and 85B antigens of *M. bovis* BCG in patients with leprosy and tuberculosis. Van Vooren, J. P., *et al.* ..... (A) 688
- Immunization of mice with the antigen A60 of *M. bovis* BCG. Hubbard, R. D., *et al.* (A) 322
- Immunoprophylactic trial with combined *M. leprae*/BCG vaccine against leprosy: preliminary results. Convit, J., *et al.* ..... (A) 301
- Improving on BCG. Stanford, J. L. .... (A) 688
- Mycobacterial brain abscess possibly due to bacille Calmette-Guérin in an immunocompromised child. Coppes, M. J., *et al.* ..... (A) 318
- Mycobacterial heat-shock proteins as carrier molecules. 2. The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and bacillus-Calmette-Guérin priming. Barrios, C., *et al.* ..... (A) 695
- Protective effect of intradermal BCG against leprosy; a case-control study in central Brazil. Rodrigues, M. L. O., *et al.* ..... (O) 335
- Purification and characterization of an unusually large fatty acid synthase from *M. tuberculosis* var. *bovis* BCG. Kikuchi, S. *et al.* ..... (A) 513
- Secreted antigens of *Mycobacterium tuberculosis* and *Mycobacterium bovis* BCG by H. G. Wiker. .... (B) 665
- Sensitization potential and reactogenicity of BCG with and without various doses of killed *M. leprae*. Gupte, M. D., *et al.* ..... (O) 340
- Specific binding of phenolic glycolipid antigens from *M. bovis* BCG with antibodies. Vercellone, A., *et al.* ..... (A) 706
- The genes coding for the antigen 85 complexes of *M. bovis* BCG are members of a gene family: cloning, sequence determination, and genomic organization of the gene coding for antigen 85-C of *M. tuberculosis*. Content, J., *et al.* ..... (A) 153
- Thin-layer chromatography systems for the identification of *M. tuberculosis*, *M. bovis* BCG, *M. kansasii*, *M. gastri*, and *M. marinum*. Laszlo, A., *et al.* ..... (A) 703

**Beta-glucuronidase,**

- On the cross-immunoreactivity of the receptor for beta-glucuronidase (BGR) of *M. leprae* with the extracts of beans. Matsuo, E., *et al.* ..... (A) 721

**Biopsy,**

- Detection of *M. leprae* in biopsy specimens from leprosy patients by polymerase chain reaction. Yoon, K.-H., *et al.* ..... (A) 727
- Polymerase chain reaction applied to biopsies from paucibacillary leprosy. Pattyn, S. R., *et al.* ..... (C) 482
- Species-specific assessment of *M. leprae* in skin biopsies by *in situ* hybridization and polymerase chain reaction. Arnoldi, J., *et al.* ..... (A) 689
- Suggested new technique for skin biopsy under field conditions. Chaturvedi, R. M. and Kartikeyan, S. .... (A) 677

**Blood,**

- Comparison of a urine spot test and blood tests as indicators of patient compliance. Yoder, L. J., *et al.* ..... (A) 124
- Dendritic cells efficiently immunoselect mycobacterial-reactive T-cells in human blood, including clonable antigen-reactive precursors. Pancholi, P., *et al.* ..... (A) 684
- Evaluation of *M. leprae* particle agglutination test, using eluates of filter paper blood spots. Sekar, B. and Anadan, D. .... (A) 510
- Evaluation of gelatin particle agglutination assay for the detection of anti-PGL-I antibodies. Comparison with ELISA method and applicability on a large scale study using blood collected on filter paper. Chanteau, S., *et al.* ..... (A) 131
- [GPAT with dried blood specimens for detection of antibody to PGI of *M. leprae*.] Weng, S.-M., *et al.* ..... (A) 679
- Isolation of a DOPA positive rapid growing mycobacterium from blood of a leprosy patient. Bhatia, V. N. and Rathinavel, L. .... (A) 310
- Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood. Shannon, E. J., *et al.* ..... (A) 510

**Bone,**

- [Analysis of roentgenograms of bones and joints in leprosy.] Lu, T.-C., *et al.* ..... (A) 678
- Skin, soft tissue, and bone infections due to *M. chelonae chelonae*—importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. Wallace, R. J., *et al.* ..... (A) 707

**Book reviews,**

- A Fresh Look at Hansen's Disease* by M. J. de Mallac. Yoder, L. J. .... (B) 491
- An Epidemiological Review of Pune Urban Leprosy Investigation Centre* by J. M. Mehta, M. P. Dandare and D. G. Jogaikar ..... (B) 491
- Leprosy Diagnosis and Management* by C. K. Job, A. J. Selvapandian, and D. K. Rao. Yoder, L. J. .... (B) 664
- Leprosy in India; a Compendium of Statistics, 1992.* Hastings, R. C. .... (B) 664
- Secreted Antigens of Mycobacterium tuberculosis and Mycobacterium bovis BCG* by H. G. Wiker ..... (B) 665
- Social Sciences Research and Social Action for Better Leprosy Control* edited by H. Srinivasan. Frist, T. F. .... (B) 491
- WHO Model Prescribing Information; Drugs Used in Mycobacterial Diseases.* ..... (B) 117

**Borderline leprosy,**

- Risk factors for type-1 reactions in borderline leprosy patients. Roche, P. W., *et al.* ... (A) 128

**Brazil,**

- Protective effect of intradermal BCG against leprosy; a case-control study in central Brazil. Rodrigues, M. L. O., *et al.* ..... (O) 335

**Burma (see Myanmar),****Catalase,**

- The catalase peroxidase gene and isoniazid resistance of *M. tuberculosis*. Zhang, Y., *et al.* ..... (A) 709

**Cell(s),**

Autoradiographic evidence of reduced epidermal cell proliferation in leprosy patients. Palmero, M. H. R., <i>et al.</i> . . . . . (C)	283
Cellular immune response to the cell walls of <i>M. leprae</i> in leprosy patients and healthy subjects exposed to leprosy. Roche, P. W., <i>et al.</i> . . . . . (A)	686
Cellular oxidative responses and mycobacterial growth inhibition in aerosol and intradermal BCG-immunized guinea-pigs. Lagranderie, M., <i>et al.</i> . . . . . (A)	323
Comparison of the intracellular activities of clarithromycin and erythromycin against <i>M. avium</i> complex strains in J774 cells and in alveolar macrophages from human immunodeficiency virus type 1-infected individuals. Yajko, D. M., <i>et al.</i> . . . . . (A)	708
Cyclophosphamide treatment antagonizes the <i>in vitro</i> development of <i>M. lepraemurium</i> -induced suppressor cell precursors. Gosselin, D., <i>et al.</i> . . . . . (A)	701
Delipidified cell components of <i>M. leprae</i> and its applications. Mahadevan, P. R., <i>et al.</i> (A)	509
Dendritic cells efficiently immunoselect mycobacterial-reactive T-cells in human blood, including clonable antigen-reactive precursors. Pancholi, P., <i>et al.</i> . . . . . (A)	684
Detection of a <i>M. leprae</i> cell wall antigen in the urine of untreated and treated patients. Sharma, V. K., <i>et al.</i> . . . . . (A)	511
Extracellular and intracellular activities of sparfloxacin against <i>M. avium</i> complex and <i>M. xenopi</i> . Gevandan, M. J., <i>et al.</i> . . . . . (A)	701
Fusidic acid is highly active against extracellular and intracellular <i>M. leprae</i> . Franzblau, S. G., <i>et al.</i> . . . . . (A)	296
Giant cell myocarditis and myositis associated with thymoma and leprosy. Butany, J. W., <i>et al.</i> . . . . . (A)	125
Increase in tumor necrosis factor alpha- and interleukin-6-secreting cells in peripheral blood mononuclear cells from subjects infected with <i>M. tuberculosis</i> . Ogawa, T., <i>et al.</i> . . . . . (A)	158
Intracellular growth of <i>M. avium</i> in human macrophages is linked to the increase synthesis of prostaglandin E2 and inhibition of the phagosome-lysosome fusions. Rastogi, N., <i>et al.</i> . . . . . (A)	685
Location of the mycolyl ester substituents in the cell walls of mycobacteria. McNeil, M., <i>et al.</i> . . . . . (A)	143
<i>M. leprae</i> express extracellular homologs of the antigen 85 complex. Pessolani, M. C. V. and Brennan, P. J. . . . . . (A)	723
Mycobacterial spindle cell pseudotumor of lymph nodes. Chen, K. T. K. . . . . . (A)	318
On structural aspects of peptidoglycan of bacterial cell wall with special attention on mycobacteria by computer modeling. Pain, S., <i>et al.</i> . . . . . (A)	311
Squamous cell carcinoma in chronic ulcers in leprosy: a review of 38 consecutive cases. Richardus, J. H. and Smith, T. C. . . . . . (A)	128
Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood. Shannon, E. J., <i>et al.</i> . . . . . (A)	510
Unusual cell of leprous neuritis. Shetty, P. C. and Antia, N. H. . . . . . (C)	483

**Cells, B,**

Characterization of the B-cell epitope on hsp65 in the immunized mice and autoimmune patients. Nomaguchi, H., <i>et al.</i> . . . . . (A)	723
Identification of a novel B-cell epitope of restricted specificity on the hsp 65-kDa protein of <i>M. tuberculosis</i> . Rambukkana, A., <i>et al.</i> . . . . . (A)	137

**Cells, epithelioid,**

IA antigen-positive epithelioid cells in experimentally induced granulomatous inflammations. Izaki, S., <i>et al.</i> . . . . . (A)	157
Macrophage and epithelioid cell nuclear morphology in leprosy. Campbell, G. and Cree, I. A. . . . . . (A)	680

**Cells, mononuclear,**

Increase in tumor necrosis factor alpha- and interleukin-6-secreting cells in peripheral blood mononuclear cells from subjects infected with <i>M. tuberculosis</i> . Ogawa, T., <i>et al.</i> . . . . . (A)	158
TNF-alpha failed to reverse the <i>M. leprae</i> -induced defective chemiluminescence response of human mononuclear cells. Launois, P., <i>et al.</i> . . . . . (A)	305

**Cells, Schwann,**

- An ultrastructural study of Schwann cells in peripheral nerves of leprosy patients. Kumar, V., *et al.* ..... (A) 305
- Hsp 70 synthesis in Schwann cells in response to heat shock and infection with *M. leprae*. Mistry, Y., *et al.* ..... (A) 684
- Lysis of interferon-gamma activated Schwann cell by cross-reactive CD8 + alpha/beta T cells with specificity for the mycobacterial 65 kd heat shock protein. Steinhoff, U., *et al.* ..... (A) 139

**Cells, T,**

- A lectin-binding, protease-resistant mycobacterial ligand specifically activates Vgamma9+ and human gamma/delta T cells. Pfeffer, K., *et al.* ..... (A) 307
- A major T cell antigen of *M. leprae* is a 10-kD heat-shock cognate protein. Mehra, V., *et al.* ..... (A) 305
- Binding of a major T-cell epitope of mycobacteria to a specific pocket within HLA-DRw17 (DR3) molecules. Geluk, A., *et al.* ..... (C) 304
- Dendritic cells efficiently immunoselect mycobacterial-reactive T-cells in human blood, including clonable antigen-reactive precursors. Pancholi, P., *et al.* ..... (A) 684
- Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Salgame, P., *et al.* ..... (A) 137
- Evidence for an alpha/beta T cell-independent mechanism of resistance to mycobacteria. Bacillus Calmette-Guérin causes progressive infection in severe combined immunodeficient mice, but not in nude mice or in mice depleted of CD4+ and CD8+ T cells. Izzo, A. A. and North, R. J. .... (A) 507
- Evidence for clonal selection of gamma/delta T cells in response to a human pathogen. Uyemura, K., *et al.* ..... (A) 140
- Gamma-Delta T cells and bacteria. Gatrill, A. J., *et al.* ..... (A) 133
- Heterogeneity of the repertoire of T cells of tuberculosis patients and healthy contacts to *M. tuberculosis* antigens separated by high-resolution techniques. Schoel, B., *et al.* (A) 326
- Human T-cell subsets in leprosy. Salgame, P. and Bloom, B. R. .... (A) 724
- Identification of B- and T-cell epitopes within the MTP40 protein of *M. tuberculosis* and their correlation with the disease course. Falla, J. C., *et al.* ..... (A) 154
- Increase of T-cell receptor gamma/delta-bearing T cells in cord blood of newborn babies obtained by *in vitro* stimulation with mycobacterial cord factor. Tsuyuguchi, I., *et al.* (A) 139
- Increased proportions of peripheral blood gamma/delta T cells in patients with pulmonary tuberculosis. Ito, M., *et al.* ..... (A) 701
- Induction and expression of protective T cells during *M. avium* infections in mice. Appelberg, R. and Pedrosa, J. .... (A) 313
- Interferon-gamma and macrophage inflammatory proteins (MIP)-1 and (MIP)-2 are involved in the regulation of the T-cell-dependent chronic peritoneal neutrophilia of mice infected with mycobacteria. Appelberg, R. .... (A) 679
- Limited T-cell receptor repertoire in the delayed-type hypersensitivity response to *M. leprae*. Wang, X.-H., *et al.* ..... (A) 726
- Lysis of interferon-gamma activated Schwann cell by cross-reactive CD8 + alpha/beta T cells with specificity for the mycobacterial 65 kd heat shock protein. Steinhoff, U., *et al.* ..... (A) 139
- M. leprae* 65hsp antigen expressed from a retroviral vector in a macrophage cell line is presented to T cells in association with MHC class II in addition to MHC class I. Silva, C. L., *et al.* ..... (A) 511
- M. tuberculosis*-complex specific T-cell stimulation and DTH reactions induced with a peptide from the 38-kDa protein. Vordermeier, H. M., *et al.* ..... (A) 707
- Mouse T cell clones against *M. avium*: identification of clones that modify resistance against atypical mycobacteria infection. Denis, M. .... (A) 302
- Peptide recognition, T-cell receptor usage and HLA restriction elements of human heat-shock protein (hsp)-60 and mycobacterial 65-kDa hsp-reactive T-cell clones from rheumatoid synovial fluid. Quayle, A. J., *et al.* ..... (A) 684
- Protection of mice from *M. leprae* infection by T cells and protein vaccines. Gelber, R. H., *et al.* ..... (A) 715
- Screening gene expression libraries for epitopes recognized in *M. leprae* by mouse T cells. Villarreal-Ramos, B., *et al.* ..... (A) 688

Selection of a human T helper type 1-like T cell subset by mycobacteria. Haanen, J. B. A. G., <i>et al.</i> . . . . . (A)	133
Soluble CD4 suppress the antigen driven proliferative response of certain T cell clones specific for mycobacteria and for peptides by monoclonal heat shock proteins. Gidlund, M., <i>et al.</i> . . . . . (A)	507
Specific inhibition of mRNA accumulation for lymphokines in human T cell line Jurkat by mycobacterial lipoarabinomannan antigen. Chujor, C. S. N., <i>et al.</i> . . . . . (A)	301
Stigma variations—observations on suppressor T cells and leprosy. Bloom, B. R., <i>et al.</i> (A)	300
T-cell mediated cytotoxicity against mycobacterium antigen-pulsed autologous macrophages in leprosy patients. Sasiain, M. D., <i>et al.</i> . . . . . (A)	687
T-cell responses of leprosy patients and healthy contacts toward separated protein antigens of <i>M. leprae</i> . Gulle, H., <i>et al.</i> . . . . . (O)	44
T-cell responses to fractionated antigens of <i>Mycobacterium w</i> , a candidate anti-leprosy vaccine, in leprosy patients. Yadava, A., <i>et al.</i> . . . . . (A)	141
<b>Cell-mediated immunity (CMI),</b>	
Cell-mediated immunity to mycobacteria: the effect of cytolysis on parasite viability. Molloy, A., <i>et al.</i> . . . . . (A)	722
Hansen's disease, cell-mediated immunity, and recombinant lymphokines. Cohn, Z. A. and Kaplan, G. . . . . (A)	131
Leprosy and cell-mediated immunity. Kaplan, G. and Cohn, Z. A. . . . . (A)	134
Preliminary study of cellular immunity to <i>M. leprae</i> protein in contacts and leprosy patients. Rada S., E. M., <i>et al.</i> . . . . . (O)	189
<b>Chemotherapy (see also Therapy),</b>	
A quantitative basis for sustainable anti- <i>M. leprae</i> chemotherapy in leprosy control programs. Almeida, J. G. . . . . (E)	255
Ambulatory treatment of multibacillary leprosy with a regimen of 8 months duration. Pattyn, S. R., <i>et al.</i> . . . . . (A)	502
[Antituberculous antibodies in enzyme immunoassay in relation to the efficacy of tuberculosis chemotherapy.]. Chukanov, V. I., <i>et al.</i> . . . . . (A)	131
Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against <i>M. avium</i> complex infection induced in mice. Tomioka, H., <i>et al.</i> . . . . . (A)	297
Chemotherapy of leprosy in multibacillary nude mice. Hastings, R. C. and Chehl, S. K. (A)	501
Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis. Pretet, S., <i>et al.</i> . . . . . (A)	705
Consensus Development Statement on the Chemotherapy of Leprosy . . . . . (SS)	644
Current concepts in the pathogenesis of leprosy; clinical, pathological, immunological and chemotherapeutic aspects. Meyers, W. M. and Marty, A. M. . . . . (A)	119
Immunological upgrading with combined immunotherapy and chemotherapy in a lepromatous leprosy patient: a case report. Zaheer, S. A., <i>et al.</i> . . . . . (A)	130
Patient treatment compliance in leprosy; a critical review. Vadher, A. and Lalljee, M. (E)	587
Survival of patients with acquired immune deficiency syndrome and disseminated <i>M. avium</i> complex infection with and without antimycobacterial chemotherapy. Horsburgh, C. R., Jr., <i>et al.</i> . . . . . (A)	156
Treatment of multibacillary leprosy with a regimen of 13 weeks duration. Pattyn, S. R., <i>et al.</i> . . . . . (A)	502
<b>Children,</b>	
Early detection of leprosy in children. Dayal, R. . . . . (A)	693
Immunoepidemiological studies on subclinical infection in leprosy. I. Clinical and immunological findings in schoolchildren and adults in Okinawa. Abe, M., <i>et al.</i> . . . . . (A)	692
[Immunogenetic grounds for the development of local forms of primary tuberculosis in children.] Vasilyev, A. V. and Dovgalyuk, I. F. . . . . (A)	329
Increase of T-cell receptor gamma/delta-bearing T cells in cord blood of newborn babies obtained by <i>in vitro</i> stimulation with mycobacterial cord factor. Tsuyuguchi, I., <i>et al.</i> (A)	139
<b>China, People's Republic of,</b>	
[An observation of multibacillary cases of leprosy the second year after stopping MDT in Xichang City, Sichuan Province.] Hu, L.-F., <i>et al.</i> . . . . . (A)	676
[Analysis of 335 new outpatient cases of leprosy.] Sun, H.-T., <i>et al.</i> . . . . . (A)	150
[Analysis of 545 active cases of leprosy in Shandong.] Li, B., <i>et al.</i> . . . . . (A)	694

[Effects of MDT on leprosy in Wuhan area.] Chen, L.-F., <i>et al.</i> . . . . . (A)	120
Meeting of Editorial Board of "China Leprosy Journal" held in Dalian. Ye, G.-Y. . . . . (N)	493
National conference on MDT held in Hangzhou. Ye, G.-Y. . . . . (N)	110
[Observation on retreatment with MDT in 657 cases of MB leprosy cured with DDS.] Zhou, D.-H., <i>et al.</i> . . . . . (A)	124
[Observations on two-year therapeutic effect of leprosy MDT of 1482 cases in Jiangsu Province (China).] Lou, H.-Y., <i>et al.</i> . . . . . (A)	296
[Results of monitoring 657 ex-patients with MB leprosy in the first year after stop of MDT.] Hu, L.-F., <i>et al.</i> . . . . . (A)	121
<b>Chromatography,</b>	
Gas chromatography-mass spectrometry methods for analysis of secondary alcohols present in the <i>M. avium</i> complex. Alugupalli, S., <i>et al.</i> . . . . . (A)	689
Thin-layer chromatography systems for the identification of <i>M. tuberculosis</i> , <i>M. bovis</i> BCG, <i>M. kansasii</i> , <i>M. gastri</i> , and <i>M. marinum</i> . Laszlo, A., <i>et al.</i> . . . . . (A)	703
<b>Chromosome(s),</b>	
Towards the integration of foreign DNA into the chromosome of <i>M. leprae</i> . Eiglmeier, K., <i>et al.</i> . . . . . (A)	142
<b>Cimetidine,</b>	
Inhibition of dapsone-induced methaemoglobinaemia by cimetidine in the presence of thrimethoprim in the rat. Coleman, M. D., <i>et al.</i> . . . . . (A)	295
<b>Ciprofloxacin,</b>	
Clarithromycin-ciprofloxacin-amikacin for therapy of <i>M. avium-M. intracellulare</i> bac- teremia in patients with AIDS. Delalla, R., <i>et al.</i> . . . . . (A)	699
<b>Classification,</b>	
Clinico-pathological correlation in Indian Consensus Classification. Desikan, K. V. . . . (A)	504
<b>Clinic(s),</b>	
Attitudes towards leprosy in the outpatient population of dermatology clinics in Trin- idad. Suite, M. and Gittens, C. . . . . (A)	499
<b>Clinical,</b>	
[A study of subclinical infection with <i>M. leprae</i> , the factors influencing the subclinical infection.] Shu, H.-W., <i>et al.</i> . . . . . (A)	139
CI-960 (PD127391 or AM-1091), sparfloxacin, WINS7273, and isepamicin activity against clinical isolates of <i>M. avium-intracellulare</i> complex, <i>M. chelonae</i> , and <i>M.</i> <i>fortuitum</i> . Barrett, M. S., <i>et al.</i> . . . . . (A)	315
Characterization of a DNA probe for detection of <i>M. tuberculosis</i> complex in clinical samples by polymerase chain reaction. Altamirano, M., <i>et al.</i> . . . . . (A)	695
Clinical and epidemiological importance of typing of <i>M. avium</i> complex isolates. Tsang, A. Y., <i>et al.</i> . . . . . (A)	328
[Clinical application of Modulan in leprosy.] Yan, L.-B., <i>et al.</i> . . . . . (A)	151
Clinical biochemical studies in leprosy. Balakrishnan, S. . . . . (A)	503
Clinical observations on leprosy patients with HIV-1 infection in Zambia. Vreeburg, A. E. M. . . . . (A)	506
Comparison of PCR with different clinical forms of leprosy and with multibacillary patients on MDT. Gillis, T. P., <i>et al.</i> . . . . . (A)	716
Current concepts in the pathogenesis of leprosy; clinical, pathological, immunological and chemotherapeutic aspects. Meyers, W. M. and Marty, A. M. . . . . (A)	119
Disseminated <i>M. avium</i> complex infection: clinical identification and epidemiologic trends. Havlik, J. A., Jr., <i>et al.</i> . . . . . (A)	320
Electromyographic diagnosis of leprosy. DeFaria, C. R. and Silva, I. M. . . . . (A)	125
Immunoepidemiological studies on subclinical infection in leprosy. I. Clinical and im- munological findings in schoolchildren and adults in Okinawa. Abe, M., <i>et al.</i> . . . . (A)	692
Maxillary antrum involvement in multibacillary leprosy: a radiologic, sinusoscopic, and histologic assessment. Hauhnaar, C. Z., <i>et al.</i> . . . . . (O)	390
Pre-emptive diagnosis of leprosy. Okoro, A. N. . . . . (A)	126
Pulmonary tuberculosis in Kigali, Rwanda—impact of human immunodeficiency virus infection on clinical and radiographic presentation. Batungwanayo, J., <i>et al.</i> . . . . . (A)	696

Rapid, simple method for treating clinical specimens containing <i>M. tuberculosis</i> to remove DNA for polymerase chain reaction. Buck, G. E., <i>et al.</i> . . . . . (A)	316
Significance of nail changes in leprosy; a clinical review. Patki, A. H. and Baran, R. . . . . (A)	127
Specificity of IgG subclass antibodies in different clinical manifestations of leprosy. Dhandayuthanpani, S., <i>et al.</i> . . . . . (A)	302
<b>Clofazimine,</b>	
A rapid and sensitive high performance liquid chromatographic analysis of clofazimine in plasma. Krishnan, T. R. and Abraham, I. . . . . (O)	549
Bull's eye retinopathy and clofazimine. Forster, D. J., <i>et al.</i> . . . . . (A)	450
CIBA-GEIGY combination capsules postponed. . . . . (N)	292
Clofazimine crystals in alveolar macrophages from a patient with the acquired immunodeficiency syndrome. Sandler, E. D., <i>et al.</i> . . . . . (A)	297
Clofazimine: a review of its use in leprosy and <i>M. avium</i> complex infection. Garrelts, J. C. . . . . (A)	121
Comment: clofazimine-induced lymphoedema. Oommen, T., <i>et al.</i> . . . . . (A)	122
Effect of antileprosy drugs on superoxide anion production by rat peritoneal macrophage with special reference to light exposed clofazimine. Sahu, A., <i>et al.</i> . . . . . (A)	123
Red discoloration of the sputum by clofazimine simulating haemoptysis. Girdhar, A., <i>et al.</i> . . . . . (A)	505
Role of rifampin and clofazimine ointments in the treatment of leprosy. Venkateswarlu, B., <i>et al.</i> . . . . . (E)	269
Short-term trial of clofazimine in previously untreated lepromatous leprosy. Jamet, P., <i>et al.</i> . . . . . (O)	542
Wettability study of clofazimine and poly (vinyl methyl ether/maleic anhydride) copolymer coevaporates. Krishnan, T. R., <i>et al.</i> . . . . . (A)	502
<b>Cloning,</b>	
Citrate synthase from <i>M. smegmatis</i> ; cloning, sequence determination and expression in <i>Escherichia coli</i> . David, M., <i>et al.</i> . . . . . (A)	154
Cloning and expression of <i>M. aurum</i> carotenogenesis genes in <i>M. smegmatis</i> . Houssaini-Iraqi, M., <i>et al.</i> . . . . . (A)	321
Cloning and expression of the gene for the Avi-3 antigen of <i>M. avium</i> and mapping of its epitopes. Yamaguchi, R., <i>et al.</i> . . . . . (A)	330
Dendritic cells efficiently immunoselect mycobacterial-reactive T-cells in human blood, including clonable antigen-reactive precursors. Pancholi, P., <i>et al.</i> . . . . . (A)	684
Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Salgame, P., <i>et al.</i> . . . . . (A)	137
Evidence for clonal selection of gamma/delta T cells in response to a human pathogen. Uyemura, K., <i>et al.</i> . . . . . (A)	140
Molecular cloning of the alpha-antigen gene from <i>M. leprae</i> and its application to serodiagnosis of leprosy. Makino, M. and Suzuki, Y. . . . . (A)	721
Mouse T cell clones against <i>M. avium</i> : identification of clones that modify resistance against atypical mycobacteria infection. Denis, M. . . . . (A)	302
Peptide recognition, T-cell receptor usage and HLA restriction elements of human heat-shock protein (hsp)-60 and mycobacterial 65-kDa hsp-reactive T-cell clones from rheumatoid synovial fluid. Quayle, A. J., <i>et al.</i> . . . . . (A)	684
Sero-Immunoreactivity of cloned protein antigens of <i>M. leprae</i> . Khan, M. B., <i>et al.</i> . . . . (O)	195
Soluble CD4 suppress the antigen driven proliferative response of certain T cell clones specific for mycobacteria and for peptides by monoclonal heat shock proteins. Gidlund, M., <i>et al.</i> . . . . . (A)	507
The genes coding for the antigen 85 complexes of <i>M. bovis</i> BCG are members of a gene family: cloning, sequence determination, and genomic organization of the gene coding for antigen 85-C of <i>M. tuberculosis</i> . Content, J., <i>et al.</i> . . . . . (A)	153
<b>Commonwealth of Independent States, (formerly U.S.S.R.),</b>	
Leprosy in southern Russia. . . . . (N)	292
<b>Complement,</b>	
Anti-leprosy drugs inhibit the complement-mediated solubilization of pre-formed immune complexes <i>in vitro</i> . Kashyap, A., <i>et al.</i> . . . . . (A)	501

- Human phagocyte respiratory burst by *M. bovis* BCG and *M. leprae*: functional activation by BCG is mediated by complement and its receptors on monocytes. Launois, P., *et al.* ..... (O) 225
- The pathophysiology of the complement system in leprosy. Ramanathan, V. D. .... (A) 509
- Congresses,**
- First International Conference on the Pathogenesis of Mycobacterial Infections: a summary. Rastogi, N., *et al.* ..... (A) 308
- International Leprosy Seminar, Istanbul, Turkey. .... (N) 495
- The International Conference of Leprosy 1992 in Egypt. El-Shiemy, S. .... (N) 110
- Third Asian Dermatological Congress 1993 in Hong Kong. .... (N) 111
- Twenty-Seventh Joint Leprosy Research Conference, U.S.-Japan Cooperative Medical Science Program, Matsue, Japan, 4–7 August 1992. .... (–) 710
- XVII Biennial Conference of the Indian Association of Leprologists (IAL). .... (B) 493
- Control of leprosy,**
- A quantitative basis for sustainable anti-*M. leprae* chemotherapy in leprosy control programs. Almeida, J. G. .... (E) 255
- ALERT-India 1981–89: nine years' experience in leprosy control in the slums of Bombay. Samy, A. A., *et al.* .... (A) 149
- An educational approach to leprosy control: an evaluation of knowledge, attitudes and practice in two poor localities in Bombay, India. Crook, N., *et al.* .... (A) 147
- Child-to-parent education: a pilot study. Bhore, P. D., *et al.* .... (A) 294
- Control of leprosy in India in the background of urbanization. Ganapati, R. .... (A) 516
- Impact of multidrug therapy on the treatment and control of leprosy. Chatterjee, B. R. (C) 271
- Leprosy control through multidrug therapy (MDT). Noordeen, S. K. .... (A) 119
- Recent developments in leprosy control. Noordeen, S. K. .... (A) 502
- Report of the First Meeting of the WHO Working Group on Leprosy Control. .... (N) 114
- Social Sciences Research and Social Action for Better Leprosy Control* edited by H. Srinivasan. Frist, T. F. .... (B) 491
- Some indices pertaining to the leprosy control programme in Tamil Nadu (India), based on data from the random sample of 14 governmental control units. Nair, N. G. K., *et al.* .... (A) 148
- Time lag between case registration and commencement of treatment in a leprosy control unit. Krishna Murthy, P., *et al.* .... (A) 299
- Corticosteroids,**
- Skin, soft tissue, and bone infections due to *M. chelonae chelonae*—importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. Wallace, R. J., *et al.* .... (A) 707
- Cuba,**
- International course in Cuba. .... (N) 667
- Cultivation,**
- [Energy production in *M. lepraemurium* cultivated *in vitro*.] Ishaque, M. .... (A) 322
- Water-soluble complexes of palmitic acid and palmitates for metabolic studies and cultivation trials of *M. leprae*. Kato, L., *et al.* .... (C) 105
- Cutaneous,**
- Association of the mycobacterial 30-kDa region proteins with the cutaneous infiltrates of leprosy lesions—evidence for the involvement of the major mycobacterial secreted proteins in the local immune response of leprosy. Rambukkana, A., *et al.* .... (A) 685
- [Contribution to the study of two infectious granulomatous diseases (leprosy and cutaneous and mucous leishmaniasis) by scintigraphic methods.] Braga, F. J. H. N., *et al.* .... (A) 504
- Effect of cutaneous cell-mediated immune response to rIFN $\gamma$  on *M. leprae* viability in the lesions of lepromatous leprosy. Damasco, M. H. S., *et al.* .... (A) 681
- Cyclosporine,**
- Resolution of type 1 reaction in multibacillary Hansen's disease as a result of treatment with cyclosporine. Frankel, R. I., *et al.* .... (O) 8

**Dapsone (DDS),**

- Anticonvulsive effect of dapsone (4, 4'-diaminodiphenyl sulfone) on amygdala-kindled seizures in rats and cats. Hamada, K., *et al.* ..... (A) 296
- Comparing the anticonvulsive effects of dapsone on amygdala-kindled seizures and hippocampal-kindled seizures in rats. Ishida, S., *et al.* ..... (A) 322
- Dapsone suppresses integrin-mediated neutrophil adherence function. Booth, S. A., *et al.* ..... (A) 294
- Does isoniazid increase the hepatotoxicity of the combination prothionamide-dapsone? Isoprodiol Study Group. .... (O) 536
- Human liver microsomal N-hydroxylation of dapsone by cytochrome-P-4503A. Fleming, C. M., *et al.* ..... (A) 676
- Inhibition of dapsone-induced methaemoglobinaemia by cimetidine in the presence of trimethoprim in the rat. Coleman, M. D., *et al.* ..... (A) 295
- [Observation on retreatment with MDT in 657 cases of MB leprosy cured with DDS.] Zhou, D.-H., *et al.* ..... (A) 124
- Relapses in leprosy patients after release from dapsone monotherapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Bexx-Bleumink, M. .... (O) 161
- Risk of relapse among non-lepromatous patients released from treatment after dapsone monotherapy. Pandian, T. D., *et al.* ..... (A) 122
- The disposition of dapsone in cirrhosis. May, D. G., *et al.* ..... (A) 676
- The protective effect of vitamin E on the hemolysis associated with dapsone treatment in patients with dermatitis herpetiformis. Prussick, R., *et al.* ..... (A) 297
- Use of a metabolic inhibitor to reduce dapsone-dependent haematological toxicity. Coleman, M. D. and Tingle, M. D. .... (A) 295

**Deformity, disability,**

- [A sociomedical investigation on leprosy disability—a survey of marriage in patients with leprosy disability.] Chen, X.-S., *et al.* ..... (A) 695
- [Epidemiological investigation of disability in leprosy. (II) Analysis of disability.] Zhang, G.-C., *et al.* ..... (A) 151
- Psychosocial aspects of deformed leprosy patients undergoing surgical correction. Ramanathan, U., *et al.* ..... (A) 151
- Shrinkage of the below-knee stump in leprosy. Mahaisavariya, B., *et al.* ..... (A) 313

**Dermal,**

- Autoradiographic evidence of reduced epidermal cell proliferation in leprosy patients. Palmero, M. H. R., *et al.* ..... (C) 283
- Cellular oxidative responses and mycobacterial growth inhibition in aerosol and intradermal BCG-immunized guinea-pigs. Lagranderie, M., *et al.* ..... (A) 323
- Protective effect of intradermal BCG against leprosy; a case-control study in central Brazil. Rodrigues, M. L. O., *et al.* ..... (O) 335

**Dermatology,**

- Attitudes towards leprosy in the outpatient population of dermatology clinics in Trinidad. Suite, M. and Gittens, C. .... (A) 499

**DNA,**

- A search for mycobacterial DNA in granulomatous tissues from patients with sarcoidosis using the polymerase chain reaction. Bocart, D., *et al.* ..... (A) 697
- Amplification of a species-specific DNA fragment of *M. tuberculosis* and its possible use in diagnosis. Del Portillo, P., *et al.* ..... (A) 154
- Characterization of a DNA probe for detection of *M. tuberculosis* complex in clinical samples by polymerase chain reaction. Altamirano, M., *et al.* ..... (A) 695
- DNA hybridization analysis of mycobacterial DNA using the 18-kDa protein gene of *M. leprae*. Moudgil, K. D., *et al.* ..... (A) 514
- DNA polymorphisms in strains of *M. tuberculosis* analyzed by pulsed-field gel electrophoresis—a tool for epidemiology. Zhang, Y. S., *et al.* ..... (A) 709
- Detection of mycobacterial DNA in sarcoidosis and tuberculosis with polymerase chain reaction. Saboor, S. A., *et al.* ..... (A) 326
- Identification of *M. kansasii* by DNA hybridization. Huang, Z. H., *et al.* ..... (A) 157
- M. paratuberculosis* DNA in Crohn's disease tissue. Sanderson, J. D., *et al.* ..... (A) 705

- Polymerase chain reaction amplifying DNA coding to species-specific rRNA of *M. leprae*. Pattyn, S. R., *et al.* ..... (O) 234
- Rapid, simple method for treating clinical specimens containing *M. tuberculosis* to remove DNA for polymerase chain reaction. Buck, G. E., *et al.* ..... (A) 316
- Towards the integration of foreign DNA into the chromosome of *M. leprae*. Eiglmeier, K., *et al.* ..... (A) 142
- Drugs** (see also specific drugs),
- [A thermoindicative nasal test for detecting allergy to antituberculosis drugs.] Buseva, T. A. and Koryakin, V. A. .... (A) 152
- Anti-leprosy drugs inhibit the complement-mediated solubilization of pre-formed immune complexes *in vitro*. Kashyap, A., *et al.* ..... (A) 501
- Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against *M. leprae* in mice. Ji, B., *et al.* ..... (O) 556
- Bacteriostatic and bactericidal activity of anti-tuberculosis drugs against *M. tuberculosis*, *M. avium*, *M. intracellulare* complex and *M. kansasii* in different growth phases. Yamori, S., *et al.* ..... (A) 331
- Delayed clearance of circulating immune complexes in mice following administration of antileprosy drugs. Kashyap, A., *et al.* ..... (O) 404
- Development of effective drug combinations for the inhibition of multiply resistant mycobacteria, especially of the *M. avium* complex. Seydel, J. K., *et al.* ..... (A) 706
- Effect of antileprosy drugs on superoxide anion production by rat peritoneal macrophage with special reference to light exposed clofazimine. Sahu, A., *et al.* ..... (A) 123
- Impact of multidrug therapy on the treatment and control of leprosy. Chatterjee, B. R. (C) 271
- In vivo* effects of anti-leprosy drugs on the rat peritoneal macrophages and lymphocyte subpopulations. Sahu, A., *et al.* ..... (A) 686
- Prevalence of dementia amongst elderly Japanese with leprosy—apparent effect of chronic drug therapy. McGeer, P. L., *et al.* ..... (A) 678
- Reactive oxygen intermediates in the phagocytes from leprosy patients: correlation with reactional states and variation drug treatment. Santos, D. O., *et al.* ..... (C) 92
- The fluoroquinolones. Walker, R. C. and Wright, A. J. .... (A) 123
- Update on rifampin drug interactions. Bocherding, S. M., *et al.* ..... (A) 295
- WHO Model Prescribing Information; Drugs Used in Mycobacterial Diseases.* ..... (B) 117
- Edema,**
- Comment: clofazimine-induced lymphoedema. Oommen, T., *et al.* ..... (A) 122
- Egypt,**
- The International Conference of Leprosy 1992 in Egypt. El-Shiemy, S. .... (N) 110
- ELISA (enzyme-linked immunosorbent assay),**
- [A comparison between agglutination test with gelatin particles sensitized by NT-P-BSA and ELISA.] Tang, Q.-C., *et al.* ..... (A) 694
- An appraisal of enzyme linked immunosorbent assay (ELISA) and serum antibody competition test (SACT) in leprosy. Kanchana, M. A., *et al.* ..... (A) 304
- Comparison of bis-di-octadecylamide of trehalose dicarboxylic acid (BDA.TDA) with glycolipid SL-IV as ELISA antigens for the serodiagnosis of leprosy. Laszlo, A., *et al.* (O) 376
- Detection of antibodies to human nerve antigens in sera from leprosy patients by ELISA. Park, J. Y., *et al.* ..... (A) 307
- Dot-ELISA for detection of phenolic glycolipid PGL-Tb1 and diacyl-trehalose antigens of *M. tuberculosis*. Papa, F., *et al.* ..... (A) 326
- Enzyme linked immunosorbent assay of a 12-kDa protein of *M. leprae* with sera from leprosy patients. Navalkar, R. G., *et al.* ..... (O) 382
- Evaluation of gelatin particle agglutination assay for the detection of anti-PGL-I antibodies. Comparison with ELISA method and applicability on a large scale study using blood collected on filter paper. Chanteau, S., *et al.* ..... (A) 131
- Follow-up of multibacillary leprosy patients using a phenolic glycolipid-I-based ELISA. Do increasing ELISA-values after discontinuation of treatment indicate relapse? Chin-A-Lien, R., *et al.* ..... (A) 507
- [UltramicroELISA assay for the detection of human IgM antibodies to *M. leprae*.] Laferte, J., *et al.* ..... (A) 508

Use of a different buffer system in the phenolic glycolipid-I ELISA. Sticht-Groh, V., <i>et al.</i> . . . . .	(O)	570
<b>Enzyme(s),</b>		
[Antituberculous antibodies in enzyme immunoassay in relation to the efficacy of tuberculosis chemotherapy.] Chukanov, V. I., <i>et al.</i> . . . . .	(A)	131
Diagnosis of mycobacterial infections by PCR and restriction enzyme digestion. Rodrigo, G., <i>et al.</i> . . . . .	(A)	705
Renal brushborder membrane vesicle study of marker enzymes and uptake of nutrients in <i>M. leprae</i> infected mice. Kohli, M., <i>et al.</i> . . . . .	(A)	146
<b>Epidemiology,</b>		
<i>An Epidemiological Review of Pune Urban Leprosy Investigation Centre</i> by J. M. Mehta, M. P. Dandare and D. G. Jogaikar. . . . .	(B)	491
[An estimate of the prevalence of hanseniasis by means of investigation into nonspecific demand for health services.] Opromolla, D. V., <i>et al.</i> . . . . .	(A)	148
Clinical and epidemiological importance of typing of <i>M. avium</i> complex isolates. Tsang, A. Y., <i>et al.</i> . . . . .	(A)	328
DNA polymorphisms in strains of <i>M. tuberculosis</i> analyzed by pulsed-field gel electrophoresis—a tool for epidemiology. Zhang, Y. S., <i>et al.</i> . . . . .	(A)	709
Disseminated <i>M. avium</i> complex infection: clinical identification and epidemiologic trends. Havlik, J. A., Jr. <i>et al.</i> . . . . .	(A)	320
Elimination of leprosy as a public health problem. Noordeen, S. K. . . . .	(A)	517
[Epidemiological investigation of disability in leprosy. (II) Analysis of disability.] Zhang, G.-C., <i>et al.</i> . . . . .	(A)	151
Epidemiology of infection by nontuberculosis mycobacteria; <i>M. avium</i> , <i>M. intracellulare</i> , and <i>M. scrofulaceum</i> in acid, brown-water swamps of the Southeastern United States and their association with environmental variables. Kirschner, R. A., Jr., <i>et al.</i> . . . . .	(A)	323
Immunoepidemiological studies on subclinical infection in leprosy. I. Clinical and immunological findings in schoolchildren and adults in Okinawa. Abe, M., <i>et al.</i> . . . . .	(A)	692
Imported leprosy in the United States, 1987 through 1988—an epidemic without secondary transmission. Mastro, T. D., <i>et al.</i> . . . . .	(A)	694
On reflections on the elimination of leprosy. Boerrigter, G. . . . .	(C)	656
Postulated epidemiology of <i>M. ulcerans</i> infection. Hayman, J. . . . .	(A)	321
Recent advances in the development of techniques for diagnosis and epidemiology of leprosy. Katoch, V. M. . . . .	(A)	513
Recent trends in the epidemiology of tuberculosis and leprosy. Smith, P. G. . . . .	(A)	517
Reflections on the elimination of leprosy. Fjñe, P. E. M. . . . .	(E)	71
Relationships between titers of antibodies immunoreacting against glycolipid antigens from <i>M. leprae</i> and <i>M. tuberculosis</i> , the Mitsuda and Mantoux reactions, and bacteriological loads: implications in the pathogenesis, epidemiology and serodiagnosis of leprosy and tuberculosis. David, H. L., <i>et al.</i> . . . . .	(O)	208
<b>Erythema nodosum leprosum (ENL),</b>		
ENL quantification—a proposal. Salafia, A. and Shah, J. K. . . . .	(A)	129
Erythema nodosum leprosum: a possible cause of oral destruction in leprosy. Scheepers, A. and Lemmer, J. . . . .	(C)	641
Immune complexes and antibody levels in blisters over human leprosy skin lesions with or without erythema nodosum leprosum. Scollard, D. M., <i>et al.</i> . . . . .	(A)	510
Prolonged treatment with recombinant interferon-gamma induces erythema nodosum leprosum in lepromatous leprosy patients. Sampaio, E. P., <i>et al.</i> . . . . .	(A)	686
Soluble interleukin-2 receptors: levels in leprosy, and during and after type 1 (lepra) and type 2 (ENL) reactions. Sehgal, B. N., <i>et al.</i> . . . . .	(A)	138
Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood. Shannon, E. J., <i>et al.</i> . . . . .	(A)	510
<b>Erythromycin,</b>		
Comparison of the intracellular activities of clarithromycin and erythromycin against <i>M. avium</i> complex strains in J774 cells and in alveolar macrophages from human immunodeficiency virus type 1-infected individuals. Yajko, D. M., <i>et al.</i> . . . . .	(A)	708

***Escherichia coli*,**

- An *Escherichia coli*-*Mycobacterium* shuttle cosmic vector. Hinshelwood, S. and Stoker, N. G. . . . . (A) 311
- Citrate synthase from *M. smegmatis*; cloning, sequence determination and expression in *Escherichia coli*. David, M., *et al.* . . . . . (A) 154
- Fluorescein diacetate and ethidium bromide staining to determine the viability of *M. smegmatis* and *Escherichia coli*. Jayapal, V., *et al.* . . . . . (A) 143

**Ethionamide,**

- Mycolic acid synthesis—a target for ethionamide in mycobacteria. Quemard, A., *et al.* (A) 691

**Ethiopia,**

- A survey of HTLV-I and HIVs in Ethiopian leprosy patients. Tekle-Haimanot, R., *et al.* . . . . . (A) 129
- ALERT seeks candidates for two positions. . . . . (N) 667
- Attitudes of rural people in central Ethiopia towards leprosy and a brief comparison with observations on epilepsy. Tekle-Haimanot, R., *et al.* . . . . . (A) 499

**Experimental leprosy,**

- Does Convit vaccine (BCG + *M. leprae*) afford protection against biochemical changes in renal brush border membrane in experimental leprosy? Kohli, M., *et al.* . . . . . (A) 135
- Evolution and contribution of animal models in leprosy. Rees, R. J. W. . . . . (A) 516
- Nonhuman sources of leprosy. Meyers, W. M., *et al.* . . . . . (SS) 477

**Eye(s),**

- [Acute uveitis in the course of reversal reactions.] Spindler, E., *et al.* . . . . . (A) 129
- Bull's eye retinopathy and clofazimine. Forster, D. J., *et al.* . . . . . (A) 450
- Chronic anterior uveitis in leprosy: insidious cause of blindness. Espiritu, C. G., *et al.* (A) 142
- Considerations in the integration of eye care into leprosy care services. Courtright, P. and Lewallen, S. . . . . (A) 504
- Glaucoma in Hansen's disease. Walton, R. C., *et al.* . . . . . (A) 129
- Intraocular penetration of rifampin in humans. Outman, W. R., *et al.* . . . . . (A) 677
- Subcorneal pustular dermatosis in type 1 lepra reaction. Pavithran, K. . . . . (C) 89

**Finger(s),**

- Cold fingers in leprosy. Abbot, N. C., *et al.* . . . . . (O) 580

**Foot,**

- IAL-sponsored 1991 training workshop on foot care. . . . . (N) 112
- [Progressive dislocations of the foot joints in leprosy.] Carayon, A. and Chevillard, A. (A) 150
- Radiological changes in hands and feet in disabled leprosy patients: a clinico-radiological correlation. Thappa, D. M., *et al.* . . . . . (A) 313

**Foot pad(s),**

- Activity of sparflloxacin against *M. leprae* inoculated into foot pads of nude mice. Gidoh, M. and Tsutsumi, S. . . . . (A) 501
- Comparison of PGL-I level with AFB numbers in foot pad suspension. Cho, S.-N., *et al.* . . . . . (C) 96
- Inoculation of foot pads of severe combined immunodeficient mice with *M. leprae*. Ishaque, M. . . . . (C) 661

**Genetics,**

- Genetic and biochemical analysis of ribosomal proteins of minocycline-susceptible and -resistant *M. smegmatis*. Yamada, T., *et al.* . . . . . (A) 519
- Genetic control of innate resistance to mycobacterial infections. Schurr, E., *et al.* . . . . (A) 138
- Genetic vaccines against genetically infective macromolecules? Corcos, M. G. . . . . (C) 659
- Genetics and resistance to tuberculosis—could resistance be enhanced by genetic engineering. Stead, W. W. . . . . (A) 706
- [Immunogenetic grounds for the development of local forms of primary tuberculosis in children.] Vasilyev, A. V. and Dovgalyuk, I. F. . . . . (A) 329
- Morphometric analysis of *M. tuberculosis* infection in mice suggests a genetic influence on the generation of the granulomatous inflammatory response. Orrell, J. M., *et al.* (A) 325
- The antibody repertoire to proteins of *M. leprae*: genetic influences at the antigen and epitope level. Adeleye, T. A., *et al.* . . . . . (A) 679

The genes coding for the antigen 85 complexes of <i>M. bovis</i> BCG are members of a gene family: cloning, sequence determination, and genomic organization of the gene coding for antigen 85-C of <i>M. tuberculosis</i> . Content, J., <i>et al.</i> . . . . . (A)	153
[Use of dimephosphone in a pathogenetic therapy of experimental tuberculosis.] Alexandrova, A. E., <i>et al.</i> . . . . . (A)	151
<b>Genome,</b>	
The genes coding for the antigen 85 complexes of <i>M. bovis</i> BCG are members of a gene family: cloning, sequence determination, and genomic organization of the gene coding for antigen 85-C of <i>M. tuberculosis</i> . Content, J., <i>et al.</i> . . . . . (A)	153
<b>Granuloma(s),</b>	
A search for mycobacterial DNA in granulomatous tissues from patients with sarcoidosis using the polymerase chain reaction. Bocart, D., <i>et al.</i> . . . . . (A)	697
[Contribution to the study of two infectious granulomatous diseases (leprosy and cutaneous and mucous leishmaniasis) by scintigraphic methods.] Braga, F. J. H. N., <i>et al.</i> . . . . . (A)	504
Granulomatous prostatitis due to <i>M. avium</i> complex. Mikolich, D. J. and Mates, S. M. (A)	326
Ia antigen-positive epithelioid cells in experimentally induced granulomatous inflammations. Izaki, S., <i>et al.</i> . . . . . (A)	157
Morphometric analysis of <i>M. tuberculosis</i> infection in mice suggests a genetic influence on the generation of the granulomatous inflammatory response. Orrell, J. M., <i>et al.</i> (A)	325
<b>Guadeloupe,</b>	
[Leprosy in Guadeloupe (FWI) 1980–1990: evolution and management in a general hospital.] Strobel, M., <i>et al.</i> . . . . . (A)	499
<b>Hand(s),</b>	
Palmar involvement in histoid leprosy. Baslas, R. G., <i>et al.</i> . . . . . (A)	504
Radiological changes in hands and feet in disabled leprosy patients: a clinico-radiological correlation. Thappa, D. M., <i>et al.</i> . . . . . (A)	313
<b>Hepatotoxicity,</b>	
Does isoniazid increase the hepatotoxicity of the combination prothionamide-dapsone? Isoprodian Study Group. . . . . (O)	536
<b>Histoid leprosy,</b>	
Giant histoid tumor. Pavithran, K. . . . . (C)	274
Palmar involvement in histoid leprosy. Baslas, R. G., <i>et al.</i> . . . . . (A)	504
<b>Histology,</b>	
Intralesional variation in histology. Chatterjee, B. R. . . . . (C)	82
<b>Histopathology,</b>	
Histopathological monitoring of an immunotherapeutic trial with <i>Mycobacterium w.</i> Mukherjee, A., <i>et al.</i> . . . . . (O)	28
Hypopigmented macules in leprosy—a histopathological and histochemical study of melanocytes. Shereef, P. H. . . . . (A)	511
<b>History of leprosy,</b>	
A contribution to the history of tuberculosis and leprosy in 19th century Norway. Wood, S. R. . . . . (A)	120
Armauer Hansen Jubilee Symposium, October 1992, Bergen, Norway. . . . . (SS)	465
Hansen, 150 years after his birth, the context of a medical discovery. Irgens, L. M. . . (SS)	466
How leprosy is depicted in Ben-Hur. Thomsen, R. J. . . . . (A)	120
In memoriam to Armauer Hansen (1841–1912). . . . . (SS)	481
Text and documents; a medieval Arab medical certificate. Isaacs, H. D. . . . . (A)	118
[To the history of leprosy in Erfurt.] Abe, H. R. . . . . (A)	118
<b>HLA (see also Genetics),</b>	
Association of HLA antigens with differential responsiveness to <i>Mycobacterium w</i> vaccine in multibacillary leprosy patients. Rani, R., <i>et al.</i> . . . . . (A)	308
Binding of a major T-cell epitope of mycobacteria to a specific pocket within HLA-DRw17 (DR3) molecules. Geluk, A., <i>et al.</i> . . . . . (C)	304

- Peptide recognition, T-cell receptor usage and HLA restriction elements of human heat-shock protein (hsp)-60 and mycobacterial 65-kDa hsp-reactive T-cell clones from rheumatoid synovial fluid. Quayle, A. J., *et al.* ..... (A) 684
- ILEP (International Federation of Anti-Leprosy Associations),**  
First elected President of ILEP. .... (N) 674
- Immune complexes,**  
Analysis of circulating immune complexes from leprosy patients for *M. leprae* antigens. Sinha, S., *et al.* ..... (O) 396  
Anti-leprosy drugs inhibit the complement-mediated solubilization of pre-formed immune complexes *in vitro*. Kashyap, A., *et al.* ..... (A) 501  
Delayed clearance of circulating immune complexes in mice following administration of antileprosy drugs. Kashyap, A., *et al.* ..... (O) 404  
Immune complexes and antibody levels in blisters over human leprosy skin lesions with or without erythema nodosum leprosum. Scollard, D. M., *et al.* ..... (A) 510  
Suppressive effect of circulating immune complexes from leprosy patients on the lymphocyte proliferation induced by *M. leprae* antigens in healthy responders. Tyagi, P., *et al.* ..... (O) 562
- Immune responses,**  
Association of the mycobacterial 30-kDa region proteins with the cutaneous infiltrates of leprosy lesions—evidence for the involvement of the major mycobacterial secreted proteins in the local immune response of leprosy. Rambukkana, A., *et al.* ..... (A) 685  
Cellular immune response to the cell walls of *M. leprae* in leprosy patients and healthy subjects exposed to leprosy. Roche, P. W., *et al.* ..... (A) 686  
Cellular immune responses of mycobacterial heat shock proteins in Nepali leprosy patients and controls. Roche, P. W., *et al.* ..... (O) 36  
Effect of cutaneous cell-mediated immune response to rIFN $\gamma$  on *M. leprae* viability in the lesions of lepromatous leprosy. Damasco, M. H. S., *et al.* ..... (A) 681  
Humoral immune response of tuberculous patients against the three components of the *M. bovis* BCG 85 complex separated by isoelectric focusing. Van Vooren, J. P., *et al.* (A) 159  
The variable C-terminal region of the *M. leprae* 70-kilodalton heat shock protein is the target for humoral immune responses. Davenport, M. P., *et al.* ..... (A) 302
- Immunoglobulins,**  
Immunoglobulin-A (IgA) and IgG serum antibodies to mycobacterial antigens in Crohn's disease patients and their relatives. Wayne, L. G., *et al.* ..... (A) 707  
Prevalence of IgM antibodies to phenolic glycolipid-I among household contacts and controls in Korea and The Philippines. Cho, S.-N., *et al.* ..... (A) 507  
Serology and leprosy: immunoassays comparing immunoglobulin G antibody responses to 28- and 30-kilodalton proteins purified from *M. bovis*. Pessolani, M. C. V., *et al.* (A) 136  
Specificity of IgG subclass antibodies in different clinical manifestations of leprosy. Dhandayuthanpani, S., *et al.* ..... (A) 302  
The pathogenesis of leprosy in the nine-banded armadillo and the significance of IgM antibodies in PGL-I. Job, C. K., *et al.* ..... (A) 515  
Time course of anti-SL-IV immunoglobulin-G antibodies in patients with tuberculosis and tuberculosis-associated AIDS. Martin-Casabona, N., *et al.* ..... (A) 324  
[UltramicroELISA assay for the detection of human IgM antibodies to *M. leprae*.] Laferte, J., *et al.* ..... (A) 508
- Immunology,**  
Autoimmunity associated with infection: leprosy, acute rheumatic fever and Lyme disease. Ehrenstein, M. and Isenberg, D. .... (A) 303  
Current concepts in the pathogenesis of leprosy: clinical, pathological, immunological and chemotherapeutic aspects. Meyers, W. M. and Marty, A. M. .... (A) 119  
Immunoepidemiological studies on subclinical infection in leprosy. I. Clinical and immunological findings in schoolchildren and adults in Okinawa. Abe, M., *et al.* ..... (A) 692  
Immunological upgrading with combined immunotherapy and chemotherapy in a lepromatous leprosy patient: a case report. Zaheer, S. A., *et al.* ..... (A) 130  
Immunology of a burnt-out lepromatous leprosy patient. Balina, L. N., *et al.* ..... (C) 102

[Influence of tuberculin therapy on the immunologic parameters in adolescents with pulmonary tuberculosis.] Knoring, B. E., <i>et al.</i> . . . . . (A)	323
Molecular and immunological analysis of a fibronectin-binding protein antigen secreted by <i>M. leprae</i> . Thole, J. E. R., <i>et al.</i> . . . . . (A)	312
Protein antigens of mycobacteria studied by quantitative immunologic techniques. Harboe, M., <i>et al.</i> . . . . . (A)	304
Tumor necrosis factor production in patients with leprosy. Barnes, P. F., <i>et al.</i> . . . . . (A)	300
<b>Immunotherapy,</b>	
Immunological upgrading with combined immunotherapy and chemotherapy in a lepromatous leprosy patient: a case report. Zaheer, S. A., <i>et al.</i> . . . . . (A)	130
<b>Indeterminate leprosy,</b>	
Indeterminate leprosy; a therapeutic evaluation. Kar, P. K., <i>et al.</i> . . . . . (A)	501
<b>India,</b>	
1990–1991 Annual Report of the ICMR Director-General. . . . . (N)	668
1991 Workshop of Voluntary Leprosy Institutions of Andhra Pradesh. Tare, S. P. . . . . (N)	113
ALERT-India 1981–89: nine years' experience in leprosy control in the slums of Bombay. Samy, A. A., <i>et al.</i> . . . . . (A)	149
An educational approach to leprosy control: an evaluation of knowledge, attitudes and practice in two poor localities in Bombay, India. Crook, N., <i>et al.</i> . . . . . (A)	147
Bombay Leprosy Project completed 15 years. Ganapati, R. . . . . (N)	111
Can leprosy be eradicated from India? Kotecha, P. and Harpham, T. . . . . (A)	693
Central Leprosy Teaching and Research Institute (CLTRI) staff changes. . . . . (N)	493
Clinico-pathological correlation in Indian Consensus Classification. Desikan, K. V. . . . . (A)	504
Control of leprosy in India in the background of urbanization. Ganapati, R. . . . . (A)	516
GLRA takes active part in National Leprosy Eradication Program (NLEP) of Indian government. . . . . (N)	112
IAL-sponsored 1991 training workshop on foot care. . . . . (N)	112
ICMR awards for leprosy scientists. . . . . (N)	113
<i>Leprosy in India; a Compendium of Statistics, 1992.</i> Hastings, R. C. . . . . (B)	664
<i>Mycobacterium w</i> vaccine being tried in New Delhi, India. . . . . (N)	113
Problems and needs of women leprosy patients in Bombay and Goa—a preliminary report. Naik, S. S., <i>et al.</i> . . . . . (A)	151
Some indices pertaining to the leprosy control programme in Tamil Nadu (India), based on data from the random sample of 14 governmental control units. Nair, N. G. K., <i>et al.</i> . . . . . (A)	148
Susceptibility of south Indian strains of <i>M. tuberculosis</i> to tuberactinomycin. Selvakumar, N., <i>et al.</i> . . . . . (A)	519
The factors influencing the operational efficiency of leprosy case detection programme. Kumar, A., <i>et al.</i> . . . . . (A)	147
XVII All India Leprosy Workers Conference. . . . . (N)	114
XVII Biennial Conference of the Indian Association of Leprologists (IAL). . . . . (B)	493
<b>Indonesia,</b>	
Beliefs of leprosy patients about their illness—a study in the province of South Sulawesi, Indonesia. Elissen, M. C. C. A. . . . . (A)	299
Distribution of anti-PGL-I and anti-LAM-B antibodies among inhabitants of leprosy-endemic villages in South Sulawesi, Indonesia. Izumi, S., <i>et al.</i> . . . . . (A)	719
<b>Indomethacin,</b>	
Effect of indomethacin on the modulation of <i>M. avium</i> growth in human macrophages by interferon gamma, retinoic acid and 1,25(OH) <sub>2</sub> -vitamin-D <sub>3</sub> . DeSousa, J. P. C., <i>et al.</i> . . . . . (A)	681
<b>Inoculation,</b>	
Activity of sparflloxacin against <i>M. leprae</i> inoculated into foot pads of nude mice. Gidoh, M. and Tsutsumi, S. . . . . (A)	501
Inoculation of foot pads of severe combined immunodeficient mice with <i>M. leprae</i> . Ishaque, M. . . . . (C)	661
Resistance to intravenous inoculation of <i>M. tuberculosis</i> H37Rv in mice of different inbred strains following immunization with a leprosy vaccine based on <i>Mycobacterium w</i> . Singh, I. G., <i>et al.</i> . . . . . (A)	146

**Interferon,**

- Effect of indomethacin on the modulation of *M. avium* growth in human macrophages by interferon gamma, retinoic acid and 1,25(OH)<sub>2</sub>-vitamin-D<sub>3</sub>. DeSousa, J. P. C., *et al.* ..... (A) 681
- Interferon-gamma and macrophage inflammatory proteins (MIP)-1 and (MIP)-2 are involved in the regulation of the T-cell-dependent chronic peritoneal neutrophilia of mice infected with mycobacteria. Appelberg, R. .... (A) 679
- Long-term follow up of lepromatous leprosy patients receiving intralesional recombinant gamma-interferon. Mathur, N. K., *et al.* ..... (C) 98
- Lysis of interferon-gamma activated Schwann cell by cross-reactive CD8 + alpha/beta T cells with specificity for the mycobacterial 65 kd heat shock protein. Steinhoff, U., *et al.* ..... (A) 139
- Mechanisms involved in mycobacterial growth inhibition by gamma interferon-activated bone marrow macrophages: role of reactive nitrogen intermediates. Fleisch, I. E. A. and Kaufmann, S. H. E. .... (A) 132
- Prolonged treatment with recombinant interferon-gamma induces erythema nodosum leprosum in lepromatous leprosy patients. Sampaio, E. P., *et al.* ..... (A) 686

**Interleukin(s),**

- Differential release of interleukin (IL)-1 alpha, IL-1 beta, and IL-6 from normal human monocytes stimulated with a virulent and an avirulent isogenic variant of *M. avium-intracellulare* complex. Michelini-Norris, M. B., *et al.* ..... (A) 325
- Increase in tumor necrosis factor alpha- and interleukin-6-secreting cells in peripheral blood mononuclear cells from subjects infected with *M. tuberculosis*. Ogawa, T., *et al.* ..... (A) 158
- Interleukin-10 production in response to *M. leprae*: evidence for an immunosuppressive role in leprosy. Sieling, P. A., *et al.* ..... (A) 725
- Interleukin-6 is used as a growth factor by virulent *M. avium*: presence of specific receptors. Denis, M. .... (A) 311
- Mycobacterial induction of activated killer cells—possible role of tyrosine kinase activity in interleukin-2 receptor alpha expression. Blanchard, D. K., *et al.* ..... (A) 680
- Serum tumor necrosis factor and interleukin 1 in leprosy and during lepra reactions. Parida, S. K., *et al.* ..... (A) 306
- Soluble interleukin-2 receptors: levels in leprosy, and during and after type 1 (lepra) and type 2 (ENL) reactions. Sehgal, B. N., *et al.* ..... (A) 138
- Supernatants derived from CD8+ lymphocytes activated by mycobacterial fractions inhibit cytokine production; the role of interleukin-6. Sussman, G. and Wadee, A. A. (A) 512
- The systemic influence of recombinant interleukin 2 on the manifestations of lepromatous leprosy. Kaplan, G., *et al.* ..... (A) 134

**INTERNATIONAL JOURNAL OF LEPROSY (IJL),**

- Index to Volume 60 ..... (–) 733
- Reviewers ..... (–) 730
- Statement of Financial Condition ..... (–) 521
- Statement of Ownership, Management, and Circulation ..... (–) 731

**Isoniazid,**

- Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Grosset, J., *et al.* ..... (A) 320
- Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis. Pretet, S., *et al.* ..... (A) 705
- Does isoniazid increase the hepatotoxicity of the combination prothionamide-dapsone? Isoprodiad Study Group. .... (O) 536
- The catalase peroxidase gene and isoniazid resistance of *M. tuberculosis*. Zhang, Y., *et al.* ..... (A) 709

**Italy,**

- Activity of antimicrobial agents against *M. avium intracellulare* complex (MAC) strains isolated in Italy from AIDS patients. Fattorini, L., *et al.* ..... (A) 699

**Japan,**

- Leprosy situation in selected countries: abstracts from the 64th General Meeting of the Japanese Leprosy Association held in March 1991. .... (A) 693

Prevalence of dementia amongst elderly Japanese with leprosy—apparent effect of chronic drug therapy. McGeer, P. L., <i>et al.</i> . . . . . (A)	678
Twenty-Seventh Joint Leprosy Research Conference, U.S.-Japan Cooperative Medical Science Program, Matsue, Japan, 4–7 August 1992. . . . . (–)	710
<b>Kidney(s),</b>	
Does Convit vaccine (BCG + <i>M. leprae</i> ) afford protection against biochemical changes in renal brush border membrane in experimental leprosy? Kohli, M., <i>et al.</i> . . . . . (A)	135
Hypoadrenalism in patients with pulmonary tuberculosis in Tanzania: an undiagnosed complication? Mugusi, F., <i>et al.</i> . . . . . (A)	158
Intravascular hemolysis and acute renal failure following intermittent rifampin therapy. Gupta, A., <i>et al.</i> . . . . . (O)	185
Renal brushborder membrane vesicle study of marker enzymes and uptake of nutrients in <i>M. leprae</i> infected mice. Kohli, M., <i>et al.</i> . . . . . (A)	146
<b>Korea,</b>	
“Leprosy in Korea, Past and Present” by Joon Lew. Goodman, D. D. . . . . (N)	291
Prevalence of IgM antibodies to phenolic glycolipid-I among household contacts and controls in Korea and The Philippines. Cho, S.-N., <i>et al.</i> . . . . . (A)	507
<b>Larynx,</b>	
[A leprosy reaction involving the esophagus and the larynx.] Alvarado, M. and Saul, A. (A)	298
<b>Leishmaniasis,</b>	
[Contribution to the study of two infectious granulomatous diseases (leprosy and cutaneous and mucous leishmaniasis) by scintigraphic methods.] Braga, F. J. H. N., <i>et al.</i> . . . . . (A)	504
<b>Lepromatous leprosy,</b>	
A clinical trial of minocycline in lepromatous leprosy. Gelber, R. H., <i>et al.</i> . . . . . (A)	500
[Autoantibodies in lepromatous leprosy.] Graninger, W., <i>et al.</i> . . . . . (A)	126
Effect of cutaneous cell-mediated immune response to rIFN $\gamma$ on <i>M. leprae</i> viability in the lesions of lepromatous leprosy. Damasco, M. H. S., <i>et al.</i> . . . . . (A)	681
High antibody levels to the mycobacterial fibronectin-binding antigen of 30-31 kD in tuberculosis and lepromatous leprosy. Espitia, C., <i>et al.</i> . . . . . (A)	303
Immunological upgrading with combined immunotherapy and chemotherapy in a lepromatous leprosy patient: a case report. Zaheer, S. A., <i>et al.</i> . . . . . (A)	130
Immunology of a burnt-out lepromatous leprosy patient. Balina, L. N., <i>et al.</i> . . . . . (C)	102
Lepromatous leprosy in a Saudi female from central region. Al-Majed, S. A. . . . . (A)	125
Lepromatous leprosy: nasal manifestations and treatment with minocycline. Lalwani, A. K., <i>et al.</i> . . . . . (A)	505
[Lepromatous leprosy; an unusual form of presentation.] Achenbach, R. E., <i>et al.</i> . . . . (A)	124
Long-term follow up of lepromatous leprosy patients receiving intralesional recombinant gamma-interferon. Mathur, N. K., <i>et al.</i> . . . . . (C)	98
Prolonged treatment with recombinant interferon-gamma induces erythema nodosum leprosum in lepromatous leprosy patients. Sampaio, E. P., <i>et al.</i> . . . . . (A)	686
Short-term trial of clofazimine in previously untreated lepromatous leprosy. Jamet, P., <i>et al.</i> . . . . . (O)	542
Subgroups among lepromatous leprosy—a viewpoint. Mathur, N. K., <i>et al.</i> . . . . . (C)	100
The systemic influence of recombinant interleukin 2 on the manifestations of lepromatous leprosy. Kaplan, G., <i>et al.</i> . . . . . (A)	134
<b>Lepromin,</b>	
Lepromin reaction in patients with falciparum malaria. Tin-Shwe and Pe-Tham-Myint. (A)	688
<b>Lesion(s),</b>	
Association of the mycobacterial 30-kDa region proteins with the cutaneous infiltrates of leprosy lesions—evidence for the involvement of the major mycobacterial secreted proteins in the local immune response of leprosy. Rambukkana, A., <i>et al.</i> . . . . . (A)	685
Central nervous system lesions in leprosy—immunohistochemical study using anti-PGL-I antibody. Goto, M., <i>et al.</i> . . . . . (A)	718
<i>Cryptococcus neoformans</i> can be misidentified as a microsporidian: studies of lung lesions in leprosy patients. Furuta, M., <i>et al.</i> . . . . . (A)	299
Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Yamamura, M., <i>et al.</i> . . . . . (A)	141

- Effect of cutaneous cell-mediated immune response to rIFN $\gamma$  on *M. leprae* viability in the lesions of lepromatous leprosy. Damasco, M. H. S., *et al.* ..... (A) 681
- Hyperkeratotic and verrucous skin lesions on lower extremities of leprosy patients. Patki, A. H. and Mehta, J. M. .... (A) 506
- Immune complexes and antibody levels in blisters over human leprosy skin lesions with or without erythema nodosum leprosum. Scollard, D. M., *et al.* ..... (A) 510
- [Immunohistochemical study of leprosy skin lesions using S-100 protein and alpha-antichymotrypsin.] Ye, F., *et al.* ..... (A) 689
- Intralesional variation in histology. Chatterjee, B. R. .... (C) 82
- Long-term follow up of lepromatous leprosy patients receiving intralesional recombinant gamma-interferon. Mathur, N. K., *et al.* ..... (C) 98
- Levamisole,**
- Displacement of rifampicin bound to serum proteins by addition of levamisole. Perez Gallardo, L., *et al.* ..... (A) 677
- Lipid(s),**
- [Activities of polar glycopeptidolipids from *M. chelonae* in the reversal of a chemically induced leucopenia.] Neway, T., *et al.* ..... (A) 703
- Assessment of the diagnostic value of the native PGLTB1, its synthetic neoglycoconjugate PGLTB0 and the sulfolipid IV antigens for the serodiagnosis of tuberculosis. Chanteau, S., *et al.* ..... (O) 1
- Comparison of bis-di-octadecylamide of trehalose dicarboxylic acid (BDA.TDA) with glycolipid SL-IV as ELISA antigens for the serodiagnosis of leprosy. Laszlo, A., *et al.* (O) 376
- Correlation of serum lipids and lipoproteins in leprosy. Ahaley, S. K., *et al.* ..... (A) 298
- Does previous BCG vaccination interfere with the serodiagnosis of tuberculosis using *M. tuberculosis*-specific glycolipid antigens? Salem, J. I., *et al.* ..... (C) 87
- Evaluation of synthetic pseudo cord-factor-like glycolipids for the serodiagnosis of tuberculosis. Laszlo, A., *et al.* ..... (A) 702
- Humoral response to nerve glycolipid antigen in sera of leprosy patients. Sahasrabudhe, R. V., *et al.* ..... (C) 488
- Immunoreactivity of nerve lipid antigens in leprosy. Vemuri, N. and Mukherjee, R. . . (A) 140
- Isolation and structural characteristics of monoclonal antibody-defined cross-reactive phospholipid antigen from *M. tuberculosis* and *M. leprae*. Fournie, J. J., *et al.* ..... (A) 132
- Lipid-laden macrophages in bone marrow of leprosy patients. Sen, P., *et al.* ..... (A) 138
- Relationships between titers of antibodies immunoreacting against glycolipid antigens from *M. leprae* and *M. tuberculosis*, the Mitsuda and Mantoux reactions, and bacteriological loads: implications in the pathogenesis, epidemiology and serodiagnosis of leprosy and tuberculosis. David, H. L., *et al.* ..... (O) 208
- Lipoarabinomannan (LAM),**
- Cytokine production induced by *M. tuberculosis* lipoarabinomannan—relationship to chemical structure. Barnes, P. F., *et al.* ..... (A) 680
- Distribution of anti-PGL-I and anti-LAM-B antibodies among inhabitants of leprosy-endemic villages in South Sulawesi, Indonesia. Izumi, S., *et al.* ..... (A) 719
- Evaluation of lipoarabinomannan for the serological diagnosis of tuberculosis. Sada, E., *et al.* ..... (A) 159
- Lipoarabinomannan of *M. tuberculosis*; capping with mannosyl residues in some strains. Chatterjee, D., *et al.* ..... (A) 317
- Lipoarabinomannan, a possible virulence factor involved in persistence of *M. tuberculosis* within macrophages. Chan, J., *et al.* ..... (A) 130
- Lipoarabinomannan; multiglycosylated form of the mycobacterial mannosylphosphatidylinositols. Chatterjee, D., *et al.* ..... (A) 317
- Specific inhibition of mRNA accumulation for lymphokines in human T cell line Jurkat by mycobacterial lipoarabinomannan antigen. Chujor, C. S. N., *et al.* ..... (A) 301
- Lipoprotein,**
- Correlation of serum lipids and lipoproteins in leprosy. Ahaley, S. K., *et al.* ..... (A) 298
- Liver,**
- CD30 expression by peripheral blood monocytes and hepatic macrophages in a child with miliary tuberculosis. Epstein, M. L., *et al.* ..... (A) 699

Does isoniazid increase the hepatotoxicity of the combination prothionamide-dapsone? Isoprodian Study Group. .... (O)	536
Human liver microsomal N-hydroxylation of dapsone by cytochrome-P-4503A. Fleming, C. M., <i>et al.</i> .... (A)	676
Immunoreactivity of a mammalian liver component with leprosy sera. Despande, R. G., <i>et al.</i> .... (A)	681
<b>Lucio phenomenon,</b>	
[Leprosy reaction in Lucio's phenomenon; treatment with griseofulvin.] Ramirez, M. M. .... (A)	299
<b>Lupus,</b>	
Thalidomide for systemic lupus erythematosus. Bessis, D., <i>et al.</i> .... (A)	518
<b>Lymph node(s),</b>	
Mycobacterial spindle cell pseudotumor of lymph nodes. Chen, K. T. K. .... (A)	318
<b>Lymphocyte(s),</b>	
Characterization of circulating lymphocytes by monoclonal antibodies in childhood and adult leprosy. Sehgal, V. N., <i>et al.</i> .... (A)	138
Effect of <i>in vivo</i> T lymphocyte subset depletion on mycobacterial infections in mice. Flory, C. M., <i>et al.</i> .... (A)	320
High frequency of cord blood lymphocytes against mycobacterial 65-kDa heat-shock proteins. Fischer, H. P., <i>et al.</i> .... (A)	700
<i>In vivo</i> effects of anti-leprosy drugs on the rat peritoneal macrophages and lymphocyte subpopulations. Sahu, A., <i>et al.</i> .... (A)	686
Mycobacteria and human heat shock protein-specific cytotoxic T lymphocytes in rheumatoid synovial inflammation. Li, S.-G., <i>et al.</i> .... (A)	324
Opportunist mycobacteria express ligands that stimulate production of human V-gamma-9V-delta-2 lymphocytes-T. Hacker, F., <i>et al.</i> .... (A)	683
Quantitation of the soluble E-receptor of human T lymphocytes by rocket electrophoresis in the serum of patients with lepromatous and tuberculoid leprosy. Longo, I. M., <i>et al.</i> .... (A)	135
Role of Th-1 lymphocytes in the development of protective immunity against <i>M. leprae</i> ; analysis of lymphocyte function by polymerase chain reaction detection of cytokine messenger RNA. Walker, K. B., <i>et al.</i> .... (A)	309
Secreted antigens of <i>M. tuberculosis</i> —characterization with lymphocytes-T from patients and contacts after two-dimensional separation. Daugelat, S., <i>et al.</i> .... (A)	698
Supernatants derived from CD8+ lymphocytes activated by mycobacterial fractions inhibit cytokine production; the role of interleukin-6. Sussman, G. and Wadee, A. A. (A)	512
Suppressive effect of circulating immune complexes from leprosy patients on the lymphocyte proliferation induced by <i>M. leprae</i> antigens in healthy responders. Tyagi, P., <i>et al.</i> .... (O)	562
<b>Lysozyme,</b>	
Use of serum antibody and lysozyme levels for diagnosis of leprosy and tuberculosis. Near, K. A. and Lefford, M. J. .... (A)	306
<b>Macrophage(s),</b>	
Activity <i>in vitro</i> of rifabutin, FCE 22807, rifapentine, and rifampin against <i>M. microti</i> and <i>M. tuberculosis</i> and their penetration into mouse peritoneal macrophages. Dhillon, J. and Mitchison, D. A. .... (A)	319
CD30 expression by peripheral blood monocytes and hepatic macrophages in a child with miliary tuberculosis. Epstein, M. L., <i>et al.</i> .... (A)	699
Clofazimine crystals in alveolar macrophages from a patient with the acquired immunodeficiency syndrome. Sandler, E. D., <i>et al.</i> .... (A)	297
Comparison of the intracellular activities of clarithromycin and erythromycin against <i>M. avium</i> complex strains in J774 cells and in alveolar macrophages from human immunodeficiency virus type 1-infected individuals. Yajko, D. M., <i>et al.</i> .... (A)	708
Effect of antileprosy drugs on superoxide anion production by rat peritoneal macrophage with special reference to light exposed clofazimine. Sahu, A., <i>et al.</i> .... (A)	123

- Effect of indomethacin on the modulation of *M. avium* growth in human macrophages by interferon gamma, retinoic acid and 1,25(OH)<sub>2</sub>-vitamin-D<sub>3</sub>. DeSousa, J. P. C., *et al.* ..... (A) 681
- Effects of activated macrophages on *M. leprae*. Ramasesh, N., *et al.* ..... (A) 137
- In vivo* effects of anti-leprosy drugs on the rat peritoneal macrophages and lymphocyte subpopulations. Sahu, A., *et al.* ..... (A) 686
- Interferon-gamma and macrophage inflammatory proteins (MIP)-1 and (MIP)-2 are involved in the regulation of the T-cell-dependent chronic peritoneal neutrophilia of mice infected with mycobacteria. Appelberg, R. .... (A) 679
- Intracellular growth of *M. avium* in human macrophages is linked to the increased synthesis of prostaglandin E<sub>2</sub> and inhibition of the phagosome-lysosome fusions. Rastogi, N., *et al.* ..... (A) 685
- Killing of virulent *M. tuberculosis* by reactive nitrogen intermediates produced by activated murine macrophages. Chan, J., *et al.* ..... (A) 310
- L-Arginine-dependent macrophage effector functions inhibit metabolic activity of *M. leprae*. Adams, L. B., *et al.* ..... (A) 130
- Lipid-laden macrophages in bone marrow of leprosy patients. Sen, P., *et al.* ..... (A) 138
- Lipoarabinomannan, a possible virulence factor involved in persistence of *M. tuberculosis* within macrophages. Chan, J., *et al.* ..... (A) 130
- M. leprae* 65hsp antigen expressed from a retroviral vector in a macrophage cell line is presented to T cells in association with MHC class II in addition to MHC class I. Silva, C. L., *et al.* ..... (A) 511
- Macrophage and epithelioid cell nuclear morphology in leprosy. Campbell, G. and Cree, I. A. .... (A) 680
- Mechanisms involved in mycobacterial growth inhibition by gamma interferon-activated bone marrow macrophages: role of reactive nitrogen intermediates. Flesch, I. E. A. and Kaufmann, S. H. E. .... (A) 132
- T-cell mediated cytotoxicity against mycobacterium antigen-pulsed autologous macrophages in leprosy patients. Sasiain, M. D., *et al.* ..... (A) 687
- Malawi,**
- Efficacy of BCG vaccine against leprosy and tuberculosis in Malawi. Ponnighaus, J. M., *et al.* ..... (A) 307
- Metabolism,**
- L-Arginine-dependent macrophage effector functions inhibit metabolic activity of *M. leprae*. Adams, L. B., *et al.* ..... (A) 130
- Use of a metabolic inhibitor to reduce dapsone-dependent haematological toxicity. Coleman, M. D. and Tingle, M. D. .... (A) 295
- Water-soluble complexes of palmitic acid and palmitates for metabolic studies and cultivation trials of *M. leprae*. Kato, L., *et al.* ..... (C) 105
- Mice, murine, (see also Mice, nude)**
- Activity *in vitro* of rifabutin, FCE 22807, rifapentine, and rifampin against *M. microti* and *M. tuberculosis* and their penetration into mouse peritoneal macrophages. Dhillon, J. and Mitchison, D. A. .... (A) 319
- Activity of azithromycin against *M. avium* infection in beige mice. Cynamon, M. H. and Klemens, S. P. .... (A) 698
- Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Grosset, J., *et al.* ..... (A) 320
- Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against *M. leprae* in mice. Ji, B., *et al.* ..... (O) 556
- Characterization of the B-cell epitope on hsp65 in the immunized mice and autoimmune patients. Nomaguchi, H., *et al.* ..... (A) 723
- Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against *M. avium* complex infection induced in mice. Tomioka, H., *et al.* ..... (A) 297
- Clarithromycin at very low levels and on intermittent administration inhibits the growth of *M. leprae* in mice. Gelber, R. H., *et al.* ..... (C) 485
- Delayed clearance of circulating immune complexes in mice following administration of antileprosy drugs. Kashyap, A., *et al.* ..... (O) 404

Effect of <i>in vivo</i> T lymphocyte subset depletion on mycobacterial infections in mice. Flory, C. M., <i>et al.</i> . . . . . (A)	320
Effect of local ultraviolet irradiation on infections of mice with <i>Candida albicans</i> , <i>M. bovis</i> BCG, and <i>Schistosoma mansoni</i> . Jeevan, A., <i>et al.</i> . . . . . (A)	702
Evidence for an alpha/beta T cell-independent mechanism of resistance to mycobacteria. Bacillus Calmette-Guérin causes progressive infection in severe combined immunodeficient mice, but not in nude mice or in mice depleted of CD4+ and CD8+ T cells. Izzo, A. A. and North, R. J. . . . . (A)	507
Immunization of mice with mycobacterial culture filtrate proteins. Hubbard, R. D., <i>et al.</i> . . . . . (A)	321
Immunization of mice with antigen A60 of <i>M. bovis</i> BCG. Hubbard, R. D., <i>et al.</i> . . . . (A)	322
Induction and expression of protective T cells during <i>M. avium</i> infections in mice. Appelberg, R. and Pedrosa, J. . . . . (A)	313
[Infection and elimination of <i>M. leprae</i> in the SCID mouse.] Xabier, M. G., <i>et al.</i> . . . . (A)	313
Inoculation of foot pads of severe combined immunodeficient mice with <i>M. leprae</i> . Ishaque, M. . . . . (C)	661
Interferon-gamma and macrophage inflammatory proteins (MIP)-1 and (MIP)-2 are involved in the regulation of the T-cell-dependent chronic peritoneal neutrophilia of mice infected with mycobacteria. Appelberg, R. . . . . (A)	679
Killing of virulent <i>M. tuberculosis</i> by reactive nitrogen intermediates produced by activated murine macrophages. Chan, J., <i>et al.</i> . . . . . (A)	310
Minimal bactericidal dietary concentration of minocycline for <i>M. leprae</i> -infected mice is very low and similar to its minimal inhibitory dietary concentration. Gelber, R. H., <i>et al.</i> . . . . . (C)	276
Morphometric analysis of <i>M. tuberculosis</i> infection in mice suggests a genetic influence on the generation of the granulomatous inflammatory response. Orrell, J. M., <i>et al.</i> (A)	325
Mouse T cell clones against <i>M. avium</i> : identification of clones that modify resistance against atypical mycobacteria infection. Denis, M. . . . . (A)	302
[Panteleeva—effectiveness of a liposomal form of rifampicin in the treatment of experimental mouse tuberculosis.]. Yu, N., <i>et al.</i> . . . . . (A)	709
Protection of mice from <i>M. leprae</i> infection by T cells and protein vaccines. Gelber, R. H., <i>et al.</i> . . . . . (A)	715
Renal brushborder membrane vesicle study of marker enzymes and uptake of nutrients in <i>M. leprae</i> infected mice. Kohli, M., <i>et al.</i> . . . . . (A)	146
Resistance to intravenous inoculation of <i>M. tuberculosis</i> H37Rv in mice of different inbred strains following immunization with a leprosy vaccine based on <i>Mycobacterium w.</i> Singh, I. G., <i>et al.</i> . . . . . (A)	146
Screening gene expression libraries for epitopes recognized in <i>M. leprae</i> by mouse T cells. Villarreal-Ramos, B., <i>et al.</i> . . . . . (A)	688
The activity of amoxicillin plus clavulanic acid against <i>M. leprae</i> in mice. Gelber, R. H. . . . . (A)	121
Vaccination of mice with a soluble protein fraction of <i>M. leprae</i> provides consistent and long-term protection against <i>M. leprae</i> infection. Gelber, R. H., <i>et al.</i> . . . . . (A)	303
<b>Mice, nude,</b>	
Activity of sparflloxacin against <i>M. leprae</i> inoculated into foot pads of nude mice. Gidoh, M. and Tsutsumi, S. . . . . (A)	501
Chemotherapy of leprosy in multibacillary nude mice. Hastings, R. C. and Chehl, S. K. (A)	501
Evidence for an alpha/beta T cell-independent mechanism of resistance to mycobacteria. Bacillus Calmette-Guérin causes progressive infection in severe combined immunodeficient mice, but not in nude mice or in mice depleted of CD4+ and CD8+ T cells. Izzo, A. A. and North, R. J. . . . . (A)	507
<b>Microbiology,</b>	
Gene manipulation in mycobacterium. Konicek, J., <i>et al.</i> . . . . . (A)	311
Multiple forms of O-methyltransferase involved in the microbial conversion of abietic acid into methyl abeitate by <i>Mycobacterium</i> sp. Orpizewski, J., <i>et al.</i> . . . . . (A)	143
Phylogeny of rapidly growing members of the genus <i>Mycobacterium</i> . Pitulle, C., <i>et al.</i> (A)	704
<b>Minocycline,</b>	
A clinical trial of minocycline in lepromatous leprosy. Gelber, R. H., <i>et al.</i> . . . . . (A)	500

- Genetic and biochemical analysis of ribosomal proteins of minocycline-susceptible and -resistant *M. smegmatis*. Yamada, T., *et al.* ..... (A) 519
- Lepromatous leprosy: nasal manifestations and treatment with minocycline. Lalwani, A. K., *et al.* ..... (A) 505
- Minimal bactericidal dietary concentration of minocycline for *M. leprae*-infected mice is very low and similar to its minimal inhibitory dietary concentration. Gelber, R. H., *et al.* ..... (C) 276
- Molecular biology,**
- Binding of a major T-cell epitope of mycobacteria to a specific pocket within HLA-DRw17 (DR3) molecules. Geluk, A., *et al.* ..... (C) 304
- Composition and immunogenicity of the polysaccharide components of the thermostable macromolecular antigen group of mycobacterial antigens. Bruneteau, M., *et al.* ..... (A) 512
- Genetic vaccines against genetically infective macromolecules? Corcos, M. G. .... (C) 659
- Molecular and immunological analysis of a fibronectin-binding protein antigen secreted by *M. leprae*. Thole, J. E. R., *et al.* ..... (A) 312
- Molecular cloning of the alpha-antigen gene from *M. leprae* and its application to serodiagnosis of leprosy. Makino, M. and Suzuki, Y. .... (A) 721
- Mycobacterial heat-shock proteins as carrier molecules. 2. The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and bacillus-Calmette-Guérin priming. Barrios, C., *et al.* ..... (A) 695
- The 14,000-molecular-weight antigen of *M. tuberculosis* is related to the alpha-crystallin family of low-molecular-weight heat shock proteins. Verbon, A., *et al.* ..... (A) 309
- Monocyte(s),**
- CD30 expression by peripheral blood monocytes and hepatic macrophages in a child with miliary tuberculosis. Epstein, M. L., *et al.* ..... (A) 699
- Differential release of interleukin (IL-)-1 alpha, IL-1 beta, and IL-6 from normal human monocytes stimulated with a virulent and an avirulent isogenic variant of *M. avium-intracellulare* complex. Michelini-Norris, M. B., *et al.* ..... (A) 325
- Human phagocyte respiratory burst by *M. bovis* BCG and *M. leprae*: functional activation by BCG is mediated by complement and its receptors on monocytes. Launois, P., *et al.* ..... (O) 225
- Ultraviolet-irradiated monocytes efficiently inhibit the intracellular replication of *M. avium intracellulare*. Miranda, W. S., *et al.* ..... (A) 509
- Morbidity,**
- Tuberculosis morbidity in the United States: final data, 1990. Jereb, J. A., *et al.* ..... (A) 322
- Morphology,**
- Lack of correlation between colony morphology and lipooligosaccharide content in *M. tuberculosis* complex. Lemassu, A., *et al.* ..... (A) 703
- Macrophage and epithelioid cell nuclear morphology in leprosy. Campbell, G. and Cree, I. A. .... (A) 680
- Multidrug therapy (MDT),**
- About reactivation of the anti-Hansenian programs through early detection of patients and systematic multidrug therapy. Nebout, M. .... (C) 653
- [Adverse, nonsevere side effects seen in leprosy patients implementing multidrug therapy.] Carrazana Hernandez, G. B. and Castano Hernandez, S. T. .... (A) 120
- [An observation of multibacillary cases of leprosy the second year after stopping MDT in Xichang City, Sichuan Province.] Hu, L.-F., *et al.* ..... (A) 676
- Comparison of PCR with different clinical forms of leprosy and with multibacillary patients on MDT. Gillis, T. P., *et al.* ..... (A) 716
- Duration of multidrug therapy in paucibacillary leprosy patients; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Bexx-Bleumink, M. .... (O) 436
- [Effects of MDT on leprosy in Wuhan area.] Chen, L.-F., *et al.* ..... (A) 120
- Impact of multidrug therapy on the treatment and control of leprosy. Chatterjee, B. R. (C) 271
- In vitro* and *in vivo* interactions of drugs used in multidrug therapy in leprosy. Dhople, A. M., *et al.* ..... (A) 121
- Leprosy control through multidrug therapy (MDT). Noordeen, S. K. .... (A) 119

Multidrug therapy in multibacillary leprosy; experience in an urban leprosy center. Ramesh, V., <i>et al.</i> . . . . . (O)	13
National conference on MDT held in Hangzhou. Ye, G.-Y. . . . . (N)	110
[Observation on retreatment with MDT in 657 cases of MB leprosy cured with DDS.] Zhou, D.-H., <i>et al.</i> . . . . . (A)	124
[Observations on two-year therapeutic effect of leprosy MDT of 1482 cases in Jiangsu Province (China).] Lou, H.-Y., <i>et al.</i> . . . . . (A)	296
Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Becx-Bleumink, M. and Berhe, D. . . . . (O)	173
Paucibacillary multidrug therapy in leprosy; 7½ years experience. Kaur, S., <i>et al.</i> . . . . . (A)	501
Problems of multidrug therapy. Ramu, G. . . . . (A)	503
Relapses among leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses. Becx-Bleumink, M. . . . . (O)	421
[Results of monitoring 657 ex-patients with MB leprosy in the first year after stop of MDT.] Hu, L.-F., <i>et al.</i> . . . . . (A)	121
<b>Myanmar (Burma).</b>	
Lepromin reaction in patients with falciparum malaria. Tin-Shwe and Pe-Tham-Myint. (A)	688
<b>Mycobacteria</b> (see also individual species),	
A lectin-binding, protease-resistant mycobacterial ligand specifically activates Vgamma9+ and human gamma/delta T cells. Pfeffer, K., <i>et al.</i> . . . . . (A)	307
A rapid microbead method for breaking pathogenic mycobacteria—application in SDS-PAGE and Western blot analysis. Rastogi, N., <i>et al.</i> . . . . . (A)	691
A search for mycobacterial DNA in granulomatous tissues from patients with sarcoidosis using the polymerase chain reaction. Bocart, D., <i>et al.</i> . . . . . (A)	697
Agents of newly recognized or infrequently encountered mycobacterial diseases. Wayne, L. G. and Sramek, H. A. . . . . (A)	330
Association of the mycobacterial 30-kDa region proteins with the cutaneous infiltrates of leprosy lesions—evidence for the involvement of the major mycobacterial secreted proteins in the local immune response of leprosy. Rambukkana, A., <i>et al.</i> . . . . . (A)	685
Binding of a major T-cell epitope of mycobacteria to a specific pocket within HLA-DRw17 (DR3) molecules. Geluk, A., <i>et al.</i> . . . . . (C)	304
Cell-mediated immunity to mycobacteria: the effect of cytolysis on parasite viability. Molloy, A., <i>et al.</i> . . . . . (A)	722
Cellular immune responses of mycobacterial heat shock proteins in Nepali leprosy patients and controls. Roche, P. W., <i>et al.</i> . . . . . (O)	36
Cellular oxidative responses and mycobacterial growth inhibition in aerosol and intradermal BCG-immunized guinea-pigs. Lagranderie, M., <i>et al.</i> . . . . . (A)	323
Comparative <i>in vitro</i> and <i>in vivo</i> activity of fleroxacin and ofloxacin against various mycobacteria. Tomioka, H., <i>et al.</i> . . . . . (A)	146
Composition and immunogenicity of the polysaccharide components of the thermostable macromolecular antigen group of mycobacterial antigens. Bruneteau, M., <i>et al.</i> . . . . . (A)	512
Control and location of acyl-hydrolysing phospholipase activity in pathogenic mycobacteria. Wheeler, P. R. and Ratledge, C. . . . . (A)	330
Control of acyl-CoA carboxylase activity in mycobacteria. Wheeler, P. R., <i>et al.</i> . . . . . (A)	312
DNA hybridization analysis of mycobacterial DNA using the 18-kDa protein gene of <i>M. leprae</i> . Moudgil, K. D., <i>et al.</i> . . . . . (A)	514
Dendritic cells efficiently immunoselect mycobacterial-reactive T-cells in human blood, including clonable antigen-reactive precursors. Pancholi, P., <i>et al.</i> . . . . . (A)	684
Detection and identification of mycobacteria by amplification of a segment of the gene coding for the 32-kilodalton protein. Soini, H., <i>et al.</i> . . . . . (A)	692
Detection of mycobacterial DNA in sarcoidosis and tuberculosis with polymerase chain reaction. Saboor, S. A., <i>et al.</i> . . . . . (A)	326
Detection of mycobacterial rRNA in sarcoidosis with liquid-phase hybridisation. Mitchell, I. C., <i>et al.</i> . . . . . (A)	325
Development of effective drug combinations for the inhibition of multiply resistant mycobacteria, especially of the <i>M. avium</i> complex. Seydel, J. K., <i>et al.</i> . . . . . (A)	706

Diagnosis of mycobacterial infections by PCR and restriction enzyme digestion. Rodrigo, G., <i>et al.</i> . . . . . (A)	705
Disease association of antibodies to human and mycobacterial hsp70 and hsp60 stress proteins. Elsaghier, A., <i>et al.</i> . . . . . (A)	682
Effect of <i>in vivo</i> T lymphocyte subset depletion on mycobacterial infections in mice. Flory, C. M., <i>et al.</i> . . . . . (A)	320
Effect of mycobacteria on sensitivity to the cytotoxic effects of tumor necrosis factor. Filley, E. A. and Rook, G. A. W. . . . . (A)	132
[Enzymatic release of mycobacteria from the environment.] Thorel, M. F., <i>et al.</i> . . . . (A)	327
Epidemiology of infection by nontuberculosis mycobacteria; <i>M. avium</i> , <i>M. intracellulare</i> , and <i>M. scrofulaceum</i> in acid, brown-water swamps of the Southeastern United States and their association with environmental variables. Kirschner, R. A., Jr., <i>et al.</i> . . . . (A)	323
Evidence for an alpha/beta T cell-independent mechanism of resistance to mycobacteria. Bacillus Calmette-Guérin causes progressive infection in severe combined immunodeficient mice, but not in nude mice or in mice depleted of CD4+ and CD8+ T cells. Izzo, A. A. and North, R. J. . . . . (A)	507
Extraction and characterization of mRNA from mycobacteria: implication for virulence gene identification. Patel, B. K. R., <i>et al.</i> . . . . . (A)	144
First International Conference on the Pathogenesis of Mycobacterial Infections: a summary. Rastogi, N., <i>et al.</i> . . . . . (A)	308
Genetic control of innate resistance to mycobacterial infections. Schurr, E., <i>et al.</i> . . . . (A)	138
High antibody levels to the mycobacterial fibronectin-binding antigen of 30-31 kD in tuberculosis and lepromatous leprosy. Espitia, C., <i>et al.</i> . . . . . (A)	303
IS900-promoted stable integration of a foreign gene into mycobacteria. England, P. M., <i>et al.</i> . . . . . (A)	142
Immunization of mice with mycobacterial culture filtrate proteins. Hubbard, R. D., <i>et al.</i> . . . . . (A)	321
Immunoglobulin-A (IgA) and IgG serum antibodies to mycobacterial antigens in Crohn's disease patients and their relatives. Wayne, L. G., <i>et al.</i> . . . . . (A)	707
Increase of T-cell receptor gamma/delta-bearing T cells in cord blood of newborn babies obtained by <i>in vitro</i> stimulation with mycobacterial cord factor. Tsuyuguchi, I., <i>et al.</i> (A)	139
Interferon-gamma and macrophage inflammatory proteins (MIP)-1 and (MIP)-2 are involved in the regulation of the T-cell-dependent chronic peritoneal neutrophilia of mice infected with mycobacteria. Appelberg, R. . . . . (A)	679
Isolation of cultivable mycobacteria from feces and lungs of armadillos infected with <i>M. leprae</i> . Dhople, A. M., <i>et al.</i> . . . . . (O)	244
Lipoarabinomannan; multiglycosylated form of the mycobacterial mannosylphosphatidylinositols. Chatterjee, D., <i>et al.</i> . . . . . (A)	317
Live but not heat-killed mycobacteria cause rapid chemotaxis of large numbers of eosinophils <i>in vivo</i> and are ingested by the attracted granulocytes. Castro, A. G., <i>et al.</i> . . . . . (A)	152
Location of the mycolyl ester substituents in the cell walls of mycobacteria. McNeil, M., <i>et al.</i> . . . . . (A)	143
Lysis of interferon-gamma activated Schwann cell by cross-reactive CD8 + alpha/beta T cells with specificity for the mycobacterial 65 kd heat shock protein. Steinhoff, U., <i>et al.</i> . . . . . (A)	139
Major proteins of mycobacterial strain ICRC and <i>M. leprae</i> identified by antibodies in sera from leprosy patients and their contacts. Chiplunkar, S. V., <i>et al.</i> . . . . . (A)	301
Mechanisms involved in mycobacterial growth inhibition by gamma interferon-activated bone marrow macrophages: role of reactive nitrogen intermediates. Flesch, I. E. A. and Kaufmann, S. H. E. . . . . (A)	132
Method for high yield preparation in large and small scale of nucleic acids from mycobacteria. Santos, A. R., <i>et al.</i> . . . . . (A)	691
Modulation of expression of delayed hypersensitivity by mycobacterial antigen-85 fibronectin-binding proteins. Godfrey, H. P., <i>et al.</i> . . . . . (A)	682
Modulation of pristane-induced arthritis by mycobacterial antigens. Thompson, S. J., <i>et al.</i> . . . . . (A)	327
Monoclonal antibody epitopes of mycobacterial 65-kD heat-shock protein defined by epitope scanning. Hajeer, A. H., <i>et al.</i> . . . . . (A)	683
Mouse T cell clones against <i>M. avium</i> : identification of clones that modify resistance against atypical mycobacteria infection. Denis, M. . . . . (A)	302

Mycobacteria and human heat shock protein-specific cytotoxic T lymphocytes in rheumatoid synovial inflammation. Li, S.-G., <i>et al.</i> . . . . . (A)	324
Mycobacteria contain two groEL genes—the second <i>M. leprae</i> groEL gene is arranged in an operon with groES. Dewit, T. F. R., <i>et al.</i> . . . . . (A)	690
Mycobacteria contain two groEL genes: the second <i>M. leprae</i> groEL gene is arranged in an operon with groES. Rinke de Wit, T. B., <i>et al.</i> . . . . . (A)	514
Mycobacterial brain abscess possibly due to bacille Calmette-Guérin in an immunocompromised child. Coppes, M. J., <i>et al.</i> . . . . . (A)	318
Mycobacterial diseases other than tuberculosis. Wolinsky, E. . . . . (A)	708
Mycobacterial heat-shock proteins as carrier molecules. 2. The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and bacillis-Calmette-Guérin priming. Barrios, C., <i>et al.</i> . . . . . (A)	695
Mycobacterial induction of activated killer cells—possible role of tyrosine kinase activity in interleukin-2 receptor alpha expression. Blanchard, D. K., <i>et al.</i> . . . . . (A)	680
Mycobacterial protein antigens: a compilation. Young, D. B., <i>et al.</i> . . . . . (A)	312
Mycobacterial research at the N. H. Swellengrebel Laboratory of Tropical Hygiene. Terpstra, W. J. . . . . (A)	499
Mycobacterial spindle cell pseudotumor of lymph nodes. Chen, K. T. K. . . . . (A)	318
Mycolic acid synthesis—a target for ethionamide in mycobacteria. Quemard, A., <i>et al.</i> (A)	691
Nontuberculous mycobacterial keratitis—report of two cases and review of the literature. Bullington, R. H., <i>et al.</i> . . . . . (A)	317
On structural aspects of peptidoglycan of bacterial cell wall with special attention on mycobacteria by computer modeling. Pain, S., <i>et al.</i> . . . . . (A)	311
Opportunist mycobacteria express ligands that stimulate production of human V-gamma-9V-delta-2 lymphocytes-T. Hacker, F., <i>et al.</i> . . . . . (A)	683
Peptide recognition, T-cell receptor usage and HLA restriction elements of human heat-shock protein (hsp)-60 and mycobacterial 65-kDa hsp-reactive T-cell clones from rheumatoid synovial fluid. Quayle, A. J., <i>et al.</i> . . . . . (A)	684
Prevention of adjuvant arthritis in rats by a nonapeptide from the 65-kDa mycobacterial heat shock protein: specificity and mechanism. Yang, X.-D., <i>et al.</i> . . . . . (A)	331
Protein antigens of mycobacteria studied by quantitative immunologic techniques. Harboe, M., <i>et al.</i> . . . . . (A)	304
Refractile mycobacteria in Ramanowsky-stained bone marrow smears; a comparison of acid-fast-stained tissue sections and Romanowsky-stained smears. Torlakovic, E., <i>et al.</i> . . . . . (A)	328
Selection of a human T helper type 1-like T cell subset by mycobacteria. Haanen, J. B. A. G., <i>et al.</i> . . . . . (A)	133
Serological response to purified mycobacterial phosphatidylinositol mannoside in healthy controls and in patients with tuberculosis and leprosy. Mullins, R. J., <i>et al.</i> . . . . . (O)	353
Soluble CD4 suppress the antigen driven proliferative response of certain T cell clones specific for mycobacteria and for peptides by monoclonal heat shock proteins. Gidlund, M., <i>et al.</i> . . . . . (A)	507
Specific inhibition of mRNA accumulation for lymphokines in human T cell line Jurkat by mycobacterial lipoarabinomannan antigen. Chujor, C. S. N., <i>et al.</i> . . . . . (A)	301
Supernatants derived from CD8+ lymphocytes activated by mycobacterial fractions inhibit cytokine production; the role of interleukin-6. Sussman, G. and Wadee, A. A. (A)	512
The significance of proteins actively secreted by <i>M. tuberculosis</i> in relation to immunity and complications of mycobacterial diseases. Harboe, M. . . . . (SS)	470
The use of radiometric tests in the speciation of mycobacteria—a review. Smid, I., <i>et al.</i> . . . . . (A)	692
WHO Model Prescribing Information; Drugs Used in Mycobacterial Diseases. . . . . (B)	117
<b><i>Mycobacterium aurum</i>,</b>	
Cloning and expression of <i>M. aurum</i> carotenogenesis genes in <i>M. smegmatis</i> . Houssaini-Iraqi, M., <i>et al.</i> . . . . . (A)	321
<b><i>Mycobacterium avium</i>,</b>	
Activity of azithromycin against <i>M. avium</i> infection in beige mice. Cynamon, M. H. and Klemens, S. P. . . . . (A)	698
Activity of clarithromycin against <i>M. avium</i> infection in patients with the acquired immune deficiency syndrome; a controlled clinical trial. Dautzenberg, B., <i>et al.</i> . . . . (A)	153

Bacteriostatic and bactericidal activities of gentamicin alone and in combination with clarithromycin against <i>M. avium</i> . Heifets, L. B., <i>et al.</i> . . . . . (A)	683
Cloning and expression of the gene for the Avi-3 antigen of <i>M. avium</i> and mapping of its epitopes. Yamaguchi, R., <i>et al.</i> . . . . . (A)	330
Effect of indomethacin on the modulation of <i>M. avium</i> growth in human macrophages by interferon gamma, retinoic acid and 1,25(OH) <sub>2</sub> -vitamin-D <sub>3</sub> . DeSousa, J. P. C., <i>et al.</i> . . . . . (A)	681
Epidemiology of infection by nontuberculosis mycobacteria; <i>M. avium</i> , <i>M. intracellulare</i> , and <i>M. scrofulaceum</i> in acid, brown-water swamps of the Southeastern United States and their association with environmental variables. Kirschner, R. A., Jr., <i>et al.</i> . . . . . (A)	323
Induction and expression of protective T cells during <i>M. avium</i> infections in mice. Appelberg, R. and Pedrosa, J. . . . . (A)	313
Interleukin-6 is used as a growth factor by virulent <i>M. avium</i> : presence of specific receptors. Denis, M. . . . . (A)	311
Intracellular growth of <i>M. avium</i> in human macrophages is linked to the increased synthesis of prostaglandin E <sub>2</sub> and inhibition of the phagosome-lysosome fusions. Rastogi, N., <i>et al.</i> . . . . . (A)	685
Mouse T cell clones against <i>M. avium</i> : identification of clones that modify resistance against atypical mycobacteria infection. Denis, M. . . . . (A)	302
Susceptibility to infection with <i>M. avium</i> is paradoxically correlated with increased synthesis of specific anti-bacterial antibodies. Ferreira, P., <i>et al.</i> . . . . . (A)	155
Transforming growth factor beta (TGF-β1) plays a detrimental role in the progression of experimental <i>M. avium</i> infection; <i>in vivo</i> and <i>in vitro</i> evidence. Denis, M. and Ghadirian, E. . . . . (A)	318
<b><i>Mycobacterium avium</i> complex,</b>	
Absence of <i>M. avium</i> complex disease in patients with AIDS in Uganda. Morrissey, A. B., <i>et al.</i> . . . . . (A)	325
Activity of antimicrobial agents against <i>M. avium intracellulare</i> complex (MAC) strains isolated in Italy from AIDS patients. Fattorini, L., <i>et al.</i> . . . . . (A)	699
CI-960 (PD127391 or AM-1091), sparfloxacin, WIN57273, and isepamicin activity against clinical isolates of <i>M. avium-intracellulare</i> complex, <i>M. chelonae</i> , and <i>M. fortuitum</i> . Barrett, M. S., <i>et al.</i> . . . . . (A)	315
Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against <i>M. avium</i> complex infection induced in mice. Tomioka, H., <i>et al.</i> . . . . . (A)	297
Clinical and epidemiological importance of typing of <i>M. avium</i> complex isolates. Tsang, A. Y., <i>et al.</i> . . . . . (A)	328
Clofazimine: a review of its use in leprosy and <i>M. avium</i> complex infection. Garrelts, J. C. . . . . (A)	121
Comparison of the intracellular activities of clarithromycin and erythromycin against <i>M. avium</i> complex strains in J774 cells and in alveolar macrophages from human immunodeficiency virus type 1-infected individuals. Yajko, D. M., <i>et al.</i> . . . . . (A)	708
Comprehensive approach to identification of serovars of <i>M. avium</i> complex. Denner, J. C., <i>et al.</i> . . . . . (A)	319
Development of effective drug combinations for the inhibition of multiply resistant mycobacteria, especially of the <i>M. avium</i> complex. Seydel, J. K., <i>et al.</i> . . . . . (A)	706
Differential release of interleukin (IL-)-1 alpha, IL-1 beta, and IL-6 from normal human monocytes stimulated with a virulent and an avirulent isogenic variant of <i>M. avium-intracellulare</i> complex. Michelini-Norris, M. B., <i>et al.</i> . . . . . (A)	325
Disseminated <i>M. avium</i> complex infection: clinical identification and epidemiologic trends. Havlik, J. A., Jr., <i>et al.</i> . . . . . (A)	320
Extracellular and intracellular activities of sparfloxacin against <i>M. avium</i> complex and <i>M. xenopi</i> . Gevandan, M. J., <i>et al.</i> . . . . . (A)	701
Gas chromatography-mass spectrometry methods for analysis of secondary alcohols present in the <i>M. avium</i> complex. Alugupalli, S., <i>et al.</i> . . . . . (A)	689
Granulomatous prostatitis due to <i>M. avium</i> complex. Mikolich, D. J. and Mates, S. M. (A)	326
Survival of patients with acquired immune deficiency syndrome and disseminated <i>M. avium</i> complex infection with and without antimycobacterial chemotherapy. Horsburgh, C. R., Jr., <i>et al.</i> . . . . . (A)	156

**Mycobacterium bovis** (see also BCG),

- Effect of local ultraviolet irradiation on infections of mice with *Candida albicans*, *M. bovis* BCG, and *Schistosoma mansoni*. Jeevan, A., *et al.* ..... (A) 702
- Human phagocyte respiratory burst by *M. bovis* BCG and *M. leprae*: functional activation by BCG is mediated by complement and its receptors on monocytes. Launois, P., *et al.* ..... (O) 225
- Humoral immune response of tuberculous patients against the three components of the *M. bovis* BCG 85 complex separated by isoelectric focusing. Van Vooren, J. P., *et al.* (A) 159
- Humoral responses against the 85A and 85B antigens of *M. bovis* BCG in patients with leprosy and tuberculosis. Van Vooren, J. P., *et al.* ..... (A) 688
- Immunization of mice with the antigen A60 of *M. bovis* BCG. Hubbard, R. D., *et al.* (A) 322
- Purification and characterization of an unusually large fatty acid synthase from *M. tuberculosis* var. *bovis* BCG. Kikuchi, S., *et al.* ..... (A) 513
- Secreted Antigens of *Mycobacterium tuberculosis* and *Mycobacterium bovis* BCG by H. G. Wiker ..... (B) 665
- Serological reactivity to *M. bovis* protein antigens in cattle. Fifis, T., *et al.* ..... (A) 319
- Serology and leprosy: immunoassays comparing immunoglobulin G antibody responses to 28- and 30-kilodalton proteins purified from *M. bovis*. Pessolani, M. C. V., *et al.* (A) 136
- Specific binding of phenolic glycolipid antigens from *M. bovis* BCG with antibodies. Vercellone, A., *et al.* ..... (A) 706
- The genes coding for the antigen 85 complexes of *M. bovis* BCG are members of a gene family: cloning, sequence determination, and genomic organization of the gene coding for antigen 85-C of *M. tuberculosis*. Content, J., *et al.* ..... (A) 153
- Thin-layer chromatography systems for the identification of *M. tuberculosis*, *M. bovis* BCG, *M. kansasii*, *M. gastri*, and *M. marinum*. Laszlo, A., *et al.* ..... (A) 703

**Mycobacterium chelonae**,

- Activities of four macrolides, including clarithromycin, against *M. fortuitum*, *M. chelonae*, and *M. chelonae*-line organisms. Brown, B. A., *et al.* ..... (A) 316
- [Activities of polar glycopeptidolipids from *M. chelonae* in the reversal of a chemically induced leucopenia.] Neway, T., *et al.* ..... (A) 703
- CI-960 (PD127391 or AM-1091), sparfloxacin, WIN57273, and isepamicin activity against clinical isolates of *M. avium-intracellulare* complex, *M. chelonae*, and *M. fortuitum*. Barrett, M. S., *et al.* ..... (A) 315
- Fatal case of disseminated infection with the turtle bacillus *M. chelonae*. Paul, J., *et al.* (A) 704
- Skin, soft tissue, and bone infections due to *M. chelonae chelonae*— importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. Wallace, R. J., *et al.* ..... (A) 707
- Successful treatment of pulmonary infection due to *M. chelonae*; case report and review. Singh, N. and Yu, V. L. .... (A) 327

**Mycobacterium fortuitum**,

- Activities of four macrolides, including clarithromycin, against *M. fortuitum*, *M. chelonae*, and *M. chelonae*-like organisms. Brown, B. A., *et al.* ..... (A) 316
- CI-960 (PD127391 or AM-1091), sparfloxacin, WIN57273, and isepamicin activity against clinical isolates of *M. avium-intracellulare* complex, *M. chelonae*, and *M. fortuitum*. Barrett, M. S., *et al.* ..... (A) 315
- Characterization of the specific antigenicity of *M. fortuitum*. Besra, G. S., *et al.* ..... (A) 696
- Interactions of *M. fortuitum* with solid sterol substrate particles. Atrat, P., *et al.* ..... (A) 314
- Resistance to beta-lactams in *M. fortuitum*. Fattorini, L., *et al.* ..... (A) 700

**Mycobacterium gastri**,

- Thin-layer chromatography systems for the identification of *M. tuberculosis*, *M. bovis* BCG, *M. kansasii*, *M. gastri*, and *M. marinum*. Laszlo, A., *et al.* ..... (A) 703

**Mycobacterium intracellulare**,

- Epidemiology of infection by nontuberculosis mycobacteria; *M. avium*, *M. intracellulare*, and *M. scrofulaceum* in acid, brown-water swamps of the Southeastern United States and their association with environmental variables. Kirschner, R. A., Jr., *et al.* ..... (A) 323
- Nucleotide sequence analysis and serologic characterization of the *M. intracellulare* homologue of the *M. tuberculosis* 19-kDa antigen. Nair, J., *et al.* ..... (A) 603

***Mycobacterium kansasii*,**

- Bacteriostatic and bactericidal activity of anti-tuberculosis drugs against *M. tuberculosis*, *M. avium*, *M. intracellulare* complex and *M. kansasii* in different growth phases. Yamori, S., *et al.* ..... (A) 331
- Identification of *M. kansasii* by DNA hybridization. Huang, Z. H., *et al.* ..... (A) 157
- Thin-layer chromatography systems for the identification of *M. tuberculosis*, *M. bovis* BCG, *M. kansasii*, *M. gastri*, and *M. marinum*. Laszlo, A., *et al.* ..... (A) 703

***Mycobacterium leprae*,**

- A major T cell antigen of *M. leprae* is a 10-kD heat-shock cognate protein. Mehra, V., *et al.* ..... (A) 305
- [A preliminary analysis of antigen components of *M. leprae* with SDS-PAGE.] Li, X.-Y., *et al.* ..... (A) 135
- A quantitative basis for sustainable anti-*M. leprae* chemotherapy in leprosy control programs. Almeida, J. G. .... (E) 255
- [A study of subclinical infection with *M. leprae*, the factors influencing the subclinical infection.] Shu, H.-W., *et al.* ..... (A) 139
- [A study of subclinical infection with *M. leprae*. (IV) The result of follow-up over three years of the household contacts with leprosy.] Shu, H.-W., *et al.* ..... (A) 687
- A unique type of GABA binding by *M. leprae*. Prabhakaran, K., *et al.* ..... (A) 514
- Activity of sparfloxacin against *M. leprae* inoculated into foot pads of nude mice. Gidoh, M. and Tsutsumi, S. .... (A) 501
- An experimental study to evaluate the bactericidal activity of ofloxacin against an established *M. leprae* infection. Banerjee, D. K. and McDermott-Lancaster, R. D. .... (O) 410
- Analysis of circulating immune complexes from leprosy patients for *M. leprae* antigens. Sinha, S., *et al.* ..... (O) 396
- Antibody responses to the 18-kDa protein of *M. leprae* in leprosy and tuberculosis patients. Roche, P. W., *et al.* ..... (O) 201
- Antigens of *M. leprae* in the cerebrospinal fluid of leprosy patients: detection by monoclonal-antibody-based sandwich immunoradiometric assay and avidin/biotin immunoblotting. Patil, S. A., *et al.* ..... (A) 127
- Assessing the viability of *M. leprae* by the fluorescein diacetate/ethidium bromide staining technique. Palomino, J. C., *et al.* ..... (A) 144
- Avidin-biotin immunoblotting studies on reactivity of leprosy sera with *M. leprae* antigen. Patil, S. A., *et al.* ..... (C) 280
- Bactericidal activities of single or multiple doses of various combinations of new anti-leprosy drugs and/or rifampin against *M. leprae* in mice. Ji, B., *et al.* ..... (O) 556
- Cellular immune response to the cell walls of *M. leprae* in leprosy patients and healthy subjects exposed to leprosy. Roche, P. W., *et al.* ..... (A) 686
- Characteristics of *M. leprae* Thai-53 strain. Matsuoka, M., *et al.* ..... (A) 722
- Clarithromycin at very low levels and on intermittent administration inhibits the growth of *M. leprae* in mice. Gelber, R. H., *et al.* ..... (C) 485
- Comparison of polymerase chain reaction technique with other methods for detection of *M. leprae* in tissues of wild nine-banded armadillos. Job, C. K., *et al.* ..... (A) 145
- Competency of human-derived *M. leprae* to use palmitic acid in the synthesis of phenolic glycolipid-I and phthiocerol dimycoerolate and to release CO<sub>2</sub> in axenic culture. Shannon, E. J., *et al.* ..... (A) 515
- DNA hybridization analysis of mycobacterial DNA using the 18-kDa protein gene of *M. leprae*. Moudgil, K. D., *et al.* ..... (A) 514
- Delipidified cell components of *M. leprae* and its applications. Mahadevan, P. R., *et al.* (A) 509
- Detection of *M. leprae* in biopsy specimens from leprosy patients by polymerase chain reaction. Yoon, K.-H., *et al.* ..... (A) 727
- Detection of a *M. leprae* cell wall antigen in the urine of untreated and treated patients. Sharma, V. K., *et al.* ..... (A) 511
- Does Convit vaccine (BCG + *M. leprae*) afford protection against biochemical changes in renal brush border membrane in experimental leprosy? Kohli, M., *et al.* ..... (A) 135
- Effect of cutaneous cell-mediated immune response to rIFN $\gamma$  on *M. leprae* viability in the lesions of lepromatous leprosy. Damasco, M. H. S., *et al.* ..... (A) 681
- Effect of skin test with *M. leprae* soluble antigen on reaction to a subsequent test with the same antigen. Gupte, M. D., *et al.* ..... (O) 54

Effects of activated macrophages on <i>M. leprae</i> . Ramasesh, N., <i>et al.</i> . . . . .	(A)	137
Enzyme linked immunosorbent assay of a 12-kDa protein of <i>M. leprae</i> with sera from leprosy patients. Navalkar, R. G., <i>et al.</i> . . . . .	(O)	382
Evaluation of <i>M. leprae</i> particle agglutination test, using eluates of filter paper blood spots. Sekar, B. and Anadan, D. . . . .	(A)	510
Fusidic acid is highly active against extracellular and intracellular <i>M. leprae</i> . Franzblau, S. G., <i>et al.</i> . . . . .	(A)	296
[GPAT with dried blood specimens for detection of antibody to PGI of <i>M. leprae</i> .] Weng, S.-M., <i>et al.</i> . . . . .	(A)	679
Hsp 70 synthesis in Schwann cells in response to heat shock and infection with <i>M. leprae</i> . Mistry, Y., <i>et al.</i> . . . . .	(A)	684
Human phagocyte respiratory burst by <i>M. bovis</i> BCG and <i>M. leprae</i> : functional activation by BCG is mediated by complement and its receptors on monocytes. Launois, P., <i>et al.</i> . . . . .	(O)	225
Immunoprophylactic trial and combined <i>M. leprae</i> /BCG vaccine against leprosy: preliminary results. Convit, J., <i>et al.</i> . . . . .	(A)	301
Improved method for purification of <i>M. leprae</i> from armadillo tissues. Rodde, C., <i>et al.</i> . . . . .	(C)	277
[Infection and elimination of <i>M. leprae</i> in the SCID mouse.] Xabier, M. G., <i>et al.</i> . . . . .	(A)	313
Inoculation of foot pads of severe combined immunodeficient mice with <i>M. leprae</i> . Ishaque, M. . . . .	(C)	661
Interleukin-10 production in response to <i>M. leprae</i> : evidence for an immunosuppressive role in leprosy. Sieling, P. A., <i>et al.</i> . . . . .	(A)	725
Isolation and structural characteristics of monoclonal antibody-defined cross-reactive phospholipid antigen from <i>M. tuberculosis</i> and <i>M. leprae</i> . Fournie, J. J., <i>et al.</i> . . . . .	(A)	132
Isolation of cultivable mycobacteria from feces and lungs of armadillos infected with <i>M. leprae</i> . Dhople, A. M., <i>et al.</i> . . . . .	(O)	244
L-Arginine-dependent macrophage effector functions inhibit metabolic activity of <i>M. leprae</i> . Adams, L. B., <i>et al.</i> . . . . .	(A)	130
Limited T-cell receptor repertoire in the delayed-type hypersensitivity response to <i>M. leprae</i> . Wang, X.-H., <i>et al.</i> . . . . .	(A)	726
<i>M. leprae</i> 65hsp antigen expressed from a retroviral vector in a macrophage cell line is presented to T cells in association with MHC class II in addition to MHC class I. Silva, C. L., <i>et al.</i> . . . . .	(A)	511
<i>M. leprae</i> express extracellular homologs of the antigen 85 complex. Pessolani, M. C. V. and Brennan, P. J. . . . .	(A)	723
Major proteins of mycobacterial strain ICRC and <i>M. leprae</i> identified by antibodies in sera from leprosy patients and their contacts. Chiplunkar, S. V., <i>et al.</i> . . . . .	(A)	301
Minimal bactericidal dietary concentration of minocycline for <i>M. leprae</i> -infected mice is very low and similar to its minimal inhibitory dietary concentration. Gelber, R. H., <i>et al.</i> . . . . .	(C)	276
Modern sensitive techniques for the detection of <i>M. leprae</i> . Ayliffe, P. R. . . . .	(E)	451
Molecular and immunological analysis of a fibronectin-binding protein antigen secreted by <i>M. leprae</i> . Thole, J. E. R., <i>et al.</i> . . . . .	(A)	312
Molecular cloning of the alpha-antigen gene from <i>M. leprae</i> and its application to serodiagnosis of leprosy. Makino, M. and Suzuki, Y. . . . .	(A)	721
Mycobacteria contain two groEL genes—the second <i>M. leprae</i> groEL gene is arranged in an operon with groES. Dewit, T. F. R., <i>et al.</i> . . . . .	(A)	690
Mycobacteria contain two groEL genes: the second <i>M. leprae</i> groEL gene is arranged in an operon with groES. Rinke de Wit, T. B., <i>et al.</i> . . . . .	(A)	514
On the cross-immunoreactivity of the receptor for beta-glucuronidase (BGR) of <i>M. leprae</i> with the extracts of beans. Matsuo, E., <i>et al.</i> . . . . .	(A)	721
One-carbon requirements of <i>M. leprae</i> : need for the folate pathway. Wheeler, P. R. . . . .	(E)	445
Phospholipase activity of <i>M. leprae</i> harvested from experimentally infected armadillo tissue. Wheeler, P. R. and Ratledge, C. . . . .	(A)	144
Polymerase chain reaction amplifying DNA coding to species-specific rRNA of <i>M. leprae</i> . Pattyn, S. R., <i>et al.</i> . . . . .	(O)	234
Preliminary study of cellular immunity to <i>M. leprae</i> protein in contacts and leprosy patients. Rada S., E. M., <i>et al.</i> . . . . .	(O)	189

- Protection of mice from *M. leprae* infection by T cells and protein vaccines. Gelber, R. H., *et al.* ..... (A) 715
- Recognition of *M. leprae* recombinant 18-kDa proteins in leprosy. Hussain, R., *et al.* (O) 368
- Relationships between titers of antibodies immunoreacting against glycolipid antigens from *M. leprae* and *M. tuberculosis*, the Mitsuda and Mantoux reactions, and bacteriological loads: implications in the pathogenesis, epidemiology and serodiagnosis of leprosy and tuberculosis. David, H. L., *et al.* ..... (O) 208
- Renal brushborder membrane vesicle study of marker enzymes and uptake of nutrients in *M. leprae* infected mice. Kohli, M., *et al.* ..... (A) 146
- Role of Th-1 lymphocytes in the development of protective immunity against *M. leprae*; analysis of lymphocyte function by polymerase chain reaction detection of cytokine messenger RNA. Walker, K. B., *et al.* ..... (A) 309
- Screening gene expression libraries for epitopes recognized in *M. leprae* by mouse T cells. Villarreal-Ramos, B., *et al.* ..... (A) 688
- Sensitization potential and reactogenicity of BCG with and without various doses of killed *M. leprae*. Gupte, M. D., *et al.* ..... (O) 340
- Sequence and immunogenicity of the 70-kDa heat shock protein of *M. leprae*. McKenzie, K. R., *et al.* ..... (A) 136
- Sero-Immunoreactivity of cloned protein antigens of *M. leprae*. Khan, M. B., *et al.* ... (O) 195
- Species-specific assessment of *M. leprae* in skin biopsies by *in situ* hybridization and polymerase chain reaction. Arnoldi, J., *et al.* ..... (A) 689
- Suppressive effect of circulating immune complexes from leprosy patients on the lymphocyte proliferation induced by *M. leprae* antigens in healthy responders. Tyagi, P., *et al.* ..... (O) 562
- T-cell responses of leprosy patients and healthy contacts toward separated protein antigens of *M. leprae*. Gulle, H., *et al.* ..... (O) 44
- TNF-alpha failed to reverse the *M. leprae*-induced defective chemiluminescence response of human mononuclear cells. Launois, P., *et al.* ..... (A) 305
- The activity of amoxicillin plus clavulanic acid against *M. leprae* in mice. Gelber, R. H. .... (A) 121
- The activity of rifabutin against *M. leprae*. Yoder, L. J., *et al.* ..... (A) 124
- The antibody repertoire to proteins of *M. leprae*: genetic influences at the antigen and epitope level. Adeleye, T. A., *et al.* ..... (A) 679
- The nucleotide sequence of the promoter, 16S rRNA and spacer region of the ribosomal RNA operon of *M. tuberculosis* and comparison with *M. leprae* precursor rRNA. Kempell, K. E., *et al.* ..... (A) 690
- The susceptibility testing of 13 strains of *M. leprae* to rifampicin and the determination of minimal effective dosage. Wang, H., *et al.* ..... (A) 123
- The variable C-terminal region of the *M. leprae* 70-kilodalton heat shock protein is the target for humoral immune responses. Davenport, M. P., *et al.* ..... (A) 302
- Towards the integration of foreign DNA into the chromosome of *M. leprae*. Eiglmeier, K., *et al.* ..... (A) 142
- [UltramicroELISA assay for the detection of human IgM antibodies to *M. leprae*.] Laferte, J., *et al.* ..... (A) 508
- Use of synthetic peptides corresponding to sequences of *M. leprae* proteins to study delayed-type hypersensitivity response in sensitized guinea pigs. Estrada-G., I. C. E., *et al.* ..... (O) 18
- Vaccination of mice with a soluble protein fraction of *M. leprae* provides consistent and long-term protection against *M. leprae* infection. Gelber, R. H., *et al.* ..... (A) 303
- Water soluble palmitic acid-methylated cyclodextrin complex; a substrate oxidized by *M. leprae*. Ishaque, M. .... (C) 279
- Water-soluble complexes of palmitic acid and palmitates for metabolic studies and cultivation trials of *M. leprae*. Kato, L., *et al.* ..... (C) 105
- Mycobacterium lepraemurium*,**
- Cyclophosphamide treatment antagonizes the *in vitro* development of *M. lepraemurium*-induced suppressor cell precursors. Gosselin, D., *et al.* ..... (A) 701
- Energy generation mechanisms in the *in vitro*-grown *M. lepraemurium*. Ishaque, M. ... (O) 61
- [Energy production in *M. lepraemurium* cultivated *in vitro*.] Ishaque, M. .... (A) 322

<b><i>Mycobacterium marinum</i>,</b>		
Thin-layer chromatography systems for the identification of <i>M. tuberculosis</i> , <i>M. bovis</i> BCG, <i>M. kansasii</i> , <i>M. gastri</i> , and <i>M. marinum</i> . Laszlo, A., <i>et al.</i> . . . . . (A)		703
<b><i>Mycobacterium microti</i>,</b>		
Activity <i>in vitro</i> of rifabutin, FCE 22807, rifapentine, and rifampin against <i>M. microti</i> and <i>M. tuberculosis</i> and their penetration into mouse peritoneal macrophages. Dhillon, J. and Mitchison, D. A. . . . . (A)		319
<b><i>Mycobacterium paratuberculosis</i>,</b>		
Amplification of 16Ss rRNA sequences to detect <i>M. paratuberculosis</i> . Vandergiessen, J. W. B., <i>et al.</i> . . . . . (A)		329
<i>M. paratuberculosis</i> binds fibronectin. Valentin-Weigand, P. and Moriarty, K. M. . . . . (A)		328
<i>M. paratuberculosis</i> DNA in Crohn's disease tissue. Sanderson, J. D., <i>et al.</i> . . . . . (A)		705
<b><i>Mycobacterium phlei</i>,</b>		
Diagnostic accuracy of a <i>M. phlei</i> -absorbed serum enzyme-linked immunosorbent assay for diagnosis of bovine paratuberculosis in dairy cows. Bech-Nielsen, S., <i>et al.</i> . . . . . (A)		315
<b><i>Mycobacterium psychrophilum</i>,</b>		
Adaptation of <i>M. psychrophilum</i> (L) to mesophilic growth on water-soluble palmitic acid complex agar media. Kato, L. . . . . (C)		662
<b><i>Mycobacterium scrofulaceum</i>,</b>		
Epidemiology of infection by nontuberculosis mycobacteria; <i>M. avium</i> , <i>M. intracellulare</i> , and <i>M. scrofulaceum</i> in acid, brown-water swamps of the Southeastern United States and their association with environmental variables. Kirschner, R. A., Jr., <i>et al.</i> . . . . . (A)		323
Immunophenotypic analysis of histiocytes involved in AIDS-associated <i>M. scrofulaceum</i> infection: similarities with lepromatous lepra. Delabie, J., <i>et al.</i> . . . . . (A)		125
<b><i>Mycobacterium smegmatis</i>,</b>		
Citrate synthase from <i>M. smegmatis</i> ; cloning, sequence determination and expression in <i>Escherichia coli</i> . David, M., <i>et al.</i> . . . . . (A)		154
Cloning and expression of <i>M. aurum</i> carotenogenesis genes in <i>M. smegmatis</i> . Houssaini-Iraqi, M., <i>et al.</i> . . . . . (A)		321
Fluorescein diacetate and ethidium bromide staining to determine the viability of <i>M. smegmatis</i> and <i>Escherichia coli</i> . Jayapal, V., <i>et al.</i> . . . . . (A)		143
Genetic and biochemical analysis of ribosomal proteins of minocycline-susceptible and -resistant <i>M. smegmatis</i> . Yamada, T., <i>et al.</i> . . . . . (A)		519
Purification and partial characterization of a penicillin-binding protein from <i>M. smegmatis</i> . Basu, J., <i>et al.</i> . . . . . (A)		690
<b><i>Mycobacterium tuberculosis</i>,</b>		
Activity <i>in vitro</i> of rifabutin, FCE 22807, rifapentine, and rifampin against <i>M. microti</i> and <i>M. tuberculosis</i> and their penetration into mouse peritoneal macrophages. Dhillon, J. and Mitchison, D. A. . . . . (A)		319
Bacteriostatic and bactericidal activity of anti-tuberculosis drugs against <i>M. tuberculosis</i> , <i>M. avium</i> , <i>M. intracellulare</i> complex and <i>M. kansasii</i> in different growth phases. Yamori, S., <i>et al.</i> . . . . . (A)		331
Beta-Lactamase inhibitors and the inducibility of the beta-lactamase of <i>M. tuberculosis</i> . Zhang, S. K., <i>et al.</i> . . . . . (A)		298
Characterization of a DNA probe for detection of <i>M. tuberculosis</i> complex in clinical samples by polymerase chain reaction. Altamirano, M., <i>et al.</i> . . . . . (A)		695
Cytokine production induced by <i>M. tuberculosis</i> lipoarabinomannan—relationship to chemical structure. Barnes, P. F., <i>et al.</i> . . . . . (A)		680
DNA polymorphisms in strains of <i>M. tuberculosis</i> analyzed by pulsed-field gel electrophoresis—a tool for epidemiology. Zhang, Y. S., <i>et al.</i> . . . . . (A)		709
Differentiation of slowly growing mycobacterium species, including <i>M. tuberculosis</i> , by gene amplification and restriction fragment length polymorphism analysis. Plikaytis, B. B., <i>et al.</i> . . . . . (A)		704
Does previous BCG vaccination interfere with the serodiagnosis of tuberculosis using <i>M. tuberculosis</i> -specific glycolipid antigens? Salem, J. I., <i>et al.</i> . . . . . (C)		87

Dot-ELISA for detection of phenolic glycolipid PGL-Tb1 and diacyl-trehalose antigens of <i>M. tuberculosis</i> . Papa, F., <i>et al.</i> . . . . . (A)	326
Heat shock proteins and antigens of <i>M. tuberculosis</i> . Young, D. B. and Garbe, T. R. . . (A)	145
Heterogeneity of the repertoire of T cells of tuberculosis patients and healthy contacts to <i>M. tuberculosis</i> antigens separated by high-resolution techniques. Schoel, B., <i>et al.</i> (A)	326
Identification of B- and T-cell epitopes within the MTP40 protein of <i>M. tuberculosis</i> and their correlation with the disease course. Falla, J. C., <i>et al.</i> . . . . . (A)	154
Identification of a novel B-cell epitope of restricted specificity on the hsp 65-kDa protein of <i>M. tuberculosis</i> . Rambukkana, A., <i>et al.</i> . . . . . (A)	137
Immunoreactivity of a 120-kDa antigen of <i>M. tuberculosis</i> . Barnes, P. F., <i>et al.</i> . . . . (A)	315
<i>In vitro</i> and <i>in vivo</i> activities of sparflaxacin (AT-4140) against <i>M. tuberculosis</i> . Ji, B., <i>et al.</i> . . . . . (A)	157
Increase in tumor necrosis factor alpha- and interleukin-6-secreting cells in peripheral blood mononuclear cells from subjects infected with <i>M. tuberculosis</i> . Ogawa, T., <i>et al.</i> . . . . . (A)	158
Isolation and structural characteristics of monoclonal antibody-defined cross-reactive phospholipid antigen from <i>M. tuberculosis</i> and <i>M. leprae</i> . Fournie, J. J., <i>et al.</i> . . . . (A)	132
Killing of virulent <i>M. tuberculosis</i> by reactive nitrogen intermediates produced by activated murine macrophages. Chan, J., <i>et al.</i> . . . . . (A)	310
Lack of correlation between colony morphology and lipooligosaccharide content in <i>M. tuberculosis</i> complex. Lemassu, A., <i>et al.</i> . . . . . (A)	703
Lipoarabinomannan of <i>M. tuberculosis</i> ; capping with mannosyl residues in some strains. Chatterjee, D., <i>et al.</i> . . . . . (A)	317
Lipoarabinomannan, a possible virulence factor involved in persistence of <i>M. tuberculosis</i> within macrophages. Chan, J., <i>et al.</i> . . . . . (A)	130
<i>M. tuberculosis</i> -complex specific T-cell stimulation and DTH reactions induced with a peptide from the 38-kDa protein. Vordermeier, H. M., <i>et al.</i> . . . . . (A)	707
Mapping of T helper cell epitopes by using peptides spanning the 19-kDa protein of <i>M. tuberculosis</i> : evidence for unique and shared epitopes in the stimulation of antibody and delayed-type hypersensitivity. Ashbridge, K. R., <i>et al.</i> . . . . . (A)	314
Morphometric analysis of <i>M. tuberculosis</i> infection in mice suggests a genetic influence on the generation of the granulomatous inflammatory response. Orrell, J. M., <i>et al.</i> (A)	325
Nucleotide sequence analysis and serologic characterization of the <i>M. intracellulare</i> homologue of the <i>M. tuberculosis</i> 19-kDa antigen. Nair, J., <i>et al.</i> . . . . . (A)	603
Purification and characterization of an unusually large fatty acid synthase from <i>M. tuberculosis</i> var. <i>bovis</i> BCG. Kikuchi, S., <i>et al.</i> . . . . . (A)	513
Pyrazinamide sterilizing activity <i>in vitro</i> against semidormant <i>M. tuberculosis</i> bacterial populations. Heifets, L. and Lindholm-Levy, P. . . . . (A)	701
Rapid, simple method for treating clinical specimens containing <i>M. tuberculosis</i> to remove DNA for polymerase chain reaction. Buck, G. E., <i>et al.</i> . . . . . (A)	316
Reduced anti- <i>M. tuberculosis</i> antibody response in tuberculosis patients with acquired immunodeficiency syndrome. Figueiredo, J. F. A. and Machado, A. A. . . . . (A)	700
Relationships between titers of antibodies immunoreacting against glycolipid antigens from <i>M. leprae</i> and <i>M. tuberculosis</i> , the Mitsuda and Mantoux reactions, and bacteriological loads: implications in the pathogenesis, epidemiology and serodiagnosis of leprosy and tuberculosis. David, H. L., <i>et al.</i> . . . . . (O)	208
Resistance to intravenous inoculation of <i>M. tuberculosis</i> H37Rv in mice of different inbred strains following immunization with a leprosy vaccine based on <i>Mycobacterium</i> w. Singh, I. G., <i>et al.</i> . . . . . (A)	146
Secreted Antigens of <i>Mycobacterium tuberculosis</i> and <i>Mycobacterium bovis</i> BCG by H. G. Wiker. . . . . (B)	665
Secreted antigens of <i>M. tuberculosis</i> —characterization with lymphocytes-T from patients and contacts after two-dimensional separation. Dugelat, S., <i>et al.</i> . . . . . (A)	698
Susceptibility of south Indian strains of <i>M. tuberculosis</i> to tuberactinomycin. Selvakumar, N., <i>et al.</i> . . . . . (A)	519
Synthesis of the trisaccharide-protein conjugate of the phenolic glycolipid of <i>M. tuberculosis</i> for the serodiagnosis of tuberculosis. Fujiwara, T. . . . . (A)	155
The 14,000-molecular-weight antigen of <i>M. tuberculosis</i> is related to the alpha-crystallin family of low-molecular-weight heat shock proteins. Verbon, A., <i>et al.</i> . . . . . (A)	309

The catalase peroxidase gene and isoniazid resistance of <i>M. tuberculosis</i> . Zhang, Y., <i>et al.</i> . . . . . (A)	709
The genes coding for the antigen 85 complexes of <i>M. bovis</i> BCG are members of a gene family: cloning, sequence determination, and genomic organization of the gene coding for antigen 85-C of <i>M. tuberculosis</i> . Content, J., <i>et al.</i> . . . . . (A)	153
The nucleotide sequence of the promoter, 16S rRNA and spacer region of the ribosomal RNA operon of <i>M. tuberculosis</i> and comparison with <i>M. leprae</i> precursor rRNA. Kempell, K. E., <i>et al.</i> . . . . . (A)	690
The significance of proteins actively secreted by <i>M. tuberculosis</i> in relation to immunity and complications of mycobacterial diseases. Harboe, M. . . . . (SS)	470
Thin-layer chromatography systems for the identification of <i>M. tuberculosis</i> , <i>M. bovis</i> BCG, <i>M. kansasii</i> , <i>M. gastri</i> , and <i>M. marinum</i> . Laszlo, A., <i>et al.</i> . . . . . (A)	703
Use of polymerase chain reaction for early identification of <i>M. tuberculosis</i> in positive cultures. Cormican, M. G., <i>et al.</i> . . . . . (A)	698
<b><i>Mycobacterium ulcerans</i>,</b>	
Postulated epidemiology of <i>M. ulcerans</i> infection. Hayman, J. . . . . (A)	321
The phenolic mycoside of <i>M. ulcerans</i> : structure and taxonomic implications. Daffe, M., <i>et al.</i> . . . . . (C)	310
<b><i>Mycobacterium w</i>,</b>	
Association of HLA antigens with differential responsiveness to <i>Mycobacterium w</i> vaccine in multibacillary leprosy patients. Rani, R., <i>et al.</i> . . . . . (A)	308
Histopathological monitoring of an immunotherapeutic trial with <i>Mycobacterium w</i> . Mukherjee, A., <i>et al.</i> . . . . . (O)	28
<i>Mycobacterium w</i> vaccine being tried in New Delhi, India. . . . . (N)	113
Resistance to intravenous inoculation of <i>M. tuberculosis</i> H37Rv in mice of different inbred strains following immunization with a leprosy vaccine based on <i>Mycobacterium w</i> . Singh, I. G., <i>et al.</i> . . . . . (A)	146
T-cell responses to fractionated antigens of <i>Mycobacterium w</i> , a candidate anti-leprosy vaccine, in leprosy patients. Yadava, A., <i>et al.</i> . . . . . (A)	141
<b><i>Mycobacterium xenopi</i>,</b>	
Extracellular and intracellular activities of sparfloxacin against <i>M. avium</i> complex and <i>M. xenopi</i> . Gevandan, M. J., <i>et al.</i> . . . . . (A)	701
<b>Nepal,</b>	
Cellular immune responses of mycobacterial heat shock proteins in Nepali leprosy patients and controls. Roche, P. W., <i>et al.</i> . . . . . (O)	36
<b>Nerve(s),</b>	
An ultrastructural study of Schwann cells in peripheral nerves of leprosy patients. Kumar, V., <i>et al.</i> . . . . . (A)	305
Detection of antibodies to human nerve antigens in sera from leprosy patients by ELISA. Park, J. Y., <i>et al.</i> . . . . . (A)	307
Diagnostic exploration of enlarged peripheral nerves in suspected cases of leprosy; an analysis of 55 cases. Dong, L., <i>et al.</i> . . . . . (A)	505
Early detection of damage to nerves in leprosy. Palande, D. D. and Bowden, R. E. M. (A)	506
Humoral response to nerve glycolipid antigen in sera of leprosy patients. Sahasrabudhe, R. V., <i>et al.</i> . . . . . (C)	488
Immunopathology of nerve involvement in leprosy. Turk, J. L., <i>et al.</i> . . . . . (A)	512
Immunoreactivity of nerve lipid antigens in leprosy. Vemuri, N. and Mukherjee, R. . . (A)	140
Reaction of peripheral nerves to vascular and bacterial injuries. Rasouli, I. and Mehta, L. N. . . . . (A)	308
<b>Netherlands, The,</b>	
INFOLEP: Leprosy Information Services. . . . . (N)	670
Mycobacterial research at the N. H. Swellengrebel Laboratory of Tropical Hygiene. Terpstra, W. J. . . . . (A)	499
<b>Neuritis,</b>	
Unusual cell of leprosy neuritis. Shetty, P. C. and Antia, N. H. . . . . (C)	483
<b>Neuropathy,</b>	
Perineurial involvement in tuberculoid leprosy neuropathy. Kimura, T., <i>et al.</i> . . . . . (A)	719

**Neutrophil(s),**

- Dapsone suppresses integrin-mediated neutrophil adherence function. Booth, S. A., *et al.* ..... (A) 294

**Nigeria,**

- Appraisal of the knowledge and attitude of Nigerian nurses toward leprosy. Awofeso, N. .... (A) 498

**Norway,**

- A contribution to the history of tuberculosis and leprosy in 19th century Norway. Wood, S. R. .... (A) 120  
Armauer Hansen Jubilee Symposium, October 1992, Bergen, Norway. .... (SS) 465

**Nose,**

- [A thermoindicative nasal test for detecting allergy to antituberculosis drugs.] Buseva, T. A. and Koryakin, V. A. .... (A) 152  
Lepromatous leprosy: nasal manifestations and treatment with minocycline. Lalwani, A. K., *et al.* .... (A) 505  
Nasal myiasis in leprosy. Husain, S., *et al.* .... (A) 126

**Obituaries,**

- P. N. Neelan. Desikan, K. V. .... (Ob) 108  
Roy Handel Thangaraj. Fritschi, E. .... (Ob) 109

**Ofloxacin,**

- An experimental study to evaluate the bactericidal activity of ofloxacin against an established *M. leprae* infection. Banerjee, D. K. and McDermott-Lancaster, R. D. .... (O) 410  
Comparative *in vitro* and *in vivo* activity of fleroxacin and ofloxacin against various mycobacteria. Tomioka, H., *et al.* .... (A) 146  
Ofloxacin for the treatment of leprosy. Ji, B. and Grosset, J. .... (A) 122

**Okinawa,**

- Immunoepidemiological studies on subclinical infection in leprosy. I. Clinical and immunological findings in schoolchildren and adults in Okinawa. Abe, M., *et al.* .... (A) 692

**Pakistan,**

- Detection of high titres of *Toxoplasma gondii* antibodies in sera of patients with leprosy in Pakistan. Hussain, R., *et al.* .... (A) 683

**Pathology,**

- Immunopathology of nerve involvement in leprosy. Turk, J. L., *et al.* .... (A) 512

**Peroxidase,**

- The catalase peroxidase gene and isoniazid resistance of *M. tuberculosis*. Zhang, Y., *et al.* .... (A) 709

**Phagocyte(s),**

- Human phagocyte respiratory burst by *M. bovis* BCG and *M. leprae*: functional activation by BCG is mediated by complement and its receptors on monocytes. Launois, P., *et al.* .... (O) 225  
Reactive oxygen intermediates in the phagocytes from leprosy patients: correlation with reactional states and variation drug treatment. Santos, D. O., *et al.* .... (C) 92

**Phenolic glycolipid(s),**

- Central nervous system lesions in leprosy—immunohistochemical study using anti-PGL-I antibody. Goto, M., *et al.* .... (A) 718  
Comparison of PGL-I level with AFB numbers in foot pad suspension. Cho, S.-N., *et al.* .... (C) 96  
Competency of human-derived *M. leprae* to use palmitic acid in the synthesis of phenolic glycolipid-I and phthiocerol dimycocerosate and to release CO<sub>2</sub> in axenic culture. Shannon, E. J., *et al.* .... (A) 515  
Distribution of anti-PGL-I and anti-LAM-B antibodies among inhabitants of leprosy-endemic villages in South Sulawesi, Indonesia. Izumi, S., *et al.* .... (A) 719  
Dot-ELISA for detection of phenolic glycolipid PGL-Tb1 and diacyl-trehalose antigens of *M. tuberculosis*. Papa, F., *et al.* .... (A) 326

Evaluation of gelatin particle agglutination assay for the detection of anti-PGL-I antibodies. Comparison with ELISA method and applicability on a large scale study using blood collected on filter paper. Chanteau, S., <i>et al.</i> . . . . . (A)	131
Follow-up of multibacillary leprosy patients using a phenolic glycolipid-I-based ELISA. Do increasing ELISA-values after discontinuation of treatment indicate relapse? Chin-A-Lien, R., <i>et al.</i> . . . . . (A)	507
Prevalence of IgM antibodies to phenolic glycolipid-I among household contacts and controls in Korea and The Philippines. Cho, S.-N., <i>et al.</i> . . . . . (A)	507
Specific binding of phenolic glycolipid antigens from <i>M. bovis</i> BCG with antibodies. Vercellone, A., <i>et al.</i> . . . . . (A)	706
Synthesis of the trisaccharide-protein conjugate of the phenolic glycolipid of <i>M. tuberculosis</i> for the serodiagnosis of tuberculosis. Fujiwara, T. . . . . (A)	155
The pathogenesis of leprosy in the nine-banded armadillo and the significance of IgM antibodies in PGL-I. Job, C. K., <i>et al.</i> . . . . . (A)	515
Use of a different buffer system in the phenolic glycolipid-I ELISA. Sticht-Groh, V., <i>et al.</i> . . . . . (O)	570
<b>Philippines, The,</b>	
Prevalence of IgM antibodies to phenolic glycolipid-I among household contacts and controls in Korea and The Philippines. Cho, S.-N., <i>et al.</i> . . . . . (A)	507
Society and leprosy: a study of knowledge, attitudes and practices of Philippine Ilocanos. Valencia, L. B., <i>et al.</i> . . . . . (A)	506
<b>Phospholipid(s),</b>	
Control and location of acyl-hydrolysing phospholipase activity in pathogenic mycobacteria. Wheeler, P. R. and Ratledge, C. . . . . (A)	330
Isolation and structural characteristics of monoclonal antibody-defined cross-reactive phospholipid antigen from <i>M. tuberculosis</i> and <i>M. leprae</i> . Fournie, J. J., <i>et al.</i> . . . . (A)	132
Phospholipase activity of <i>M. leprae</i> harvested from experimentally infected armadillo tissue. Wheeler, P. R. and Ratledge, C. . . . . (A)	144
<b>Phthiocerol,</b>	
Competency of human-derived <i>M. leprae</i> to use palmitic acid in the synthesis of phenolic glycolipid-I and phthiocerol dimycocerosate and to release CO <sub>2</sub> in axenic culture. Shannon, E. J., <i>et al.</i> . . . . . (A)	515
<b>Polymerase chain reaction (PCR),</b>	
A search for mycobacterial DNA in granulomatous tissues from patients with sarcoidosis using the polymerase chain reaction. Bocart, D., <i>et al.</i> . . . . . (A)	697
Characterization of DNA probe for detection of <i>M. tuberculosis</i> complex in clinical samples by polymerase chain reaction. Altamirano, M., <i>et al.</i> . . . . . (A)	695
Comparison of PCR with different clinical forms of leprosy and with multibacillary patients on MDT. Gillis, T. P., <i>et al.</i> . . . . . (A)	716
Comparison of polymerase chain reaction technique with other methods for detection of <i>M. leprae</i> in tissues of wild nine-banded armadillos. Job, C. K., <i>et al.</i> . . . . . (A)	145
Detection of <i>M. leprae</i> in biopsy specimens from leprosy patients by polymerase chain reaction. Yoon, K.-H., <i>et al.</i> . . . . . (A)	727
Detection of mycobacterial DNA in sarcoidosis and tuberculosis with polymerase chain reaction. Saboor, S. A., <i>et al.</i> . . . . . (A)	326
Diagnosis of mycobacterial infections by PCR and restriction enzyme digestion. Rodrigo, G., <i>et al.</i> . . . . . (A)	705
Polymerase chain reaction amplifying DNA coding to species-specific rRNA of <i>M. leprae</i> . Pattyn, S. R., <i>et al.</i> . . . . . (O)	234
Polymerase chain reaction applied to biopsies from paucibacillary leprosy. Pattyn, S. R., <i>et al.</i> . . . . . (C)	482
Rapid, simple method for treating clinical specimens containing <i>M. tuberculosis</i> to remove DNA for polymerase chain reaction. Buck, G. E., <i>et al.</i> . . . . . (A)	316
Species-specific assessment of <i>M. leprae</i> in skin biopsies by <i>in situ</i> hybridization and polymerase chain reaction. Arnoldi, J., <i>et al.</i> . . . . . (A)	689
Suitability of a skin-smear examination needle for leprosy screening by PCR. Sugita, Y., <i>et al.</i> . . . . . (C)	658

The use of the polymerase chain reaction test in the diagnosis of tuberculosis. van Helden, P. D., <i>et al.</i> . . . . . (A)	329
Use of polymerase chain reaction for early identification of <i>M. tuberculosis</i> in positive cultures. Cormican, M. G., <i>et al.</i> . . . . . (A)	698
<b>Prostaglandin,</b>	
Intracellular growth of <i>M. avium</i> in human macrophages is linked to the increased synthesis of prostaglandin E2 and inhibition of the phagosome-lysosome fusions. Rastogi, N., <i>et al.</i> . . . . . (A)	685
<b>Protein(s),</b>	
A major T cell antigen of <i>M. leprae</i> is a 10-kD heat-shock cognate protein. Mehra, V., <i>et al.</i> . . . . . (A)	305
Antibody responses to the 18-kDa protein of <i>M. leprae</i> in leprosy and tuberculosis patients. Roche, P. W., <i>et al.</i> . . . . . (O)	201
Association of the mycobacterial 30-kDa region proteins with the cutaneous infiltrates of leprosy lesions—evidence for the involvement of the major mycobacterial secreted proteins in the local immune response of leprosy. Rambukkana, A., <i>et al.</i> . . . . . (A)	685
Cellular immune responses of mycobacterial heat shock proteins in Nepali leprosy patients and controls. Roche, P. W., <i>et al.</i> . . . . . (O)	36
DNA hybridization analysis of mycobacterial DNA using the 18-kDa protein gene of <i>M. leprae</i> . Moudgil, K. D., <i>et al.</i> . . . . . (A)	514
Detection and identification of mycobacteria by amplification of a segment of the gene coding for the 32-kilodalton protein. Soini, H., <i>et al.</i> . . . . . (A)	692
Disease association of antibodies to human and mycobacterial hsp70 and hsp60 stress proteins. Elsaghier, A., <i>et al.</i> . . . . . (A)	682
Enzyme linked immunosorbent assay of a 12-kDa protein of <i>M. leprae</i> with sera from leprosy patients. Navalkar, R. G., <i>et al.</i> . . . . . (O)	382
Genetic and biochemical analysis of ribosomal proteins of minocycline-susceptible and -resistant <i>M. smegmatis</i> . Yamada, T., <i>et al.</i> . . . . . (A)	519
Heat shock proteins and antigens of <i>M. tuberculosis</i> . Young, D. B. and Garbe, T. R. . . . . (A)	145
Heat-shock proteins and leprosy. Sinha, S. . . . . (A)	515
High frequency of cord blood lymphocytes against mycobacterial 65-kDa heat-shock proteins. Fischer, H. P., <i>et al.</i> . . . . . (A)	700
Identification of B- and T-cell epitopes within the MTP40 protein of <i>M. tuberculosis</i> and their correlation with the disease course. Falla, J. C., <i>et al.</i> . . . . . (A)	154
Identification of a novel B-cell epitope of restricted specificity on the hsp 65-kDa protein of <i>M. tuberculosis</i> . Rambukkana, A., <i>et al.</i> . . . . . (A)	137
[Immunohistochemical study of leprosy skin lesions using S-100 protein and alpha-antichymotrypsin.] Ye, F., <i>et al.</i> . . . . . (A)	689
Interferon-gamma and macrophage inflammatory proteins (MIP)-1 and (MIP)-2 are involved in the regulation of the T-cell-dependent chronic peritoneal neutrophilia of mice infected with mycobacteria. Appelberg, R. . . . . (A)	679
Lysis of interferon-gamma activated Schwann cell by cross-reactive CD8 + alpha/beta T cells with specificity for the mycobacterial 65 kd heat shock protein. Steinhoff, U., <i>et al.</i> . . . . . (A)	139
<i>M. tuberculosis</i> -complex specific T-cell stimulation and DTH reactions induced with a peptide from the 38-kDa protein. Vordermeier, H. M., <i>et al.</i> . . . . . (A)	707
Major proteins of mycobacterial strain ICRC and <i>M. leprae</i> identified by antibodies in sera from leprosy patients and their contacts. Chiplunkar, S. V., <i>et al.</i> . . . . . (A)	301
Mapping of T helper cell epitopes by using peptides spanning the 19-kDa protein of <i>M. tuberculosis</i> : evidence for unique and shared epitopes in the stimulation of antibody and delayed-type hypersensitivity. Ashbridge, K. R., <i>et al.</i> . . . . . (A)	314
Modulation of expression of delayed hypersensitivity by mycobacterial antigen-85 fibronectin-binding proteins. Godfrey, H. P., <i>et al.</i> . . . . . (A)	682
Molecular and immunological analysis of a fibronectin-binding protein antigen secreted by <i>M. leprae</i> . Thole, J. E. R., <i>et al.</i> . . . . . (A)	312
Monoclonal antibody epitopes of mycobacterial 65-kD heat-shock protein defined by epitope scanning. Hajeer, A. H., <i>et al.</i> . . . . . (A)	683
Mycobacteria and human heat shock protein-specific cytotoxic T lymphocytes in rheumatoid synovial inflammation. Li, S.-G., <i>et al.</i> . . . . . (A)	324

Mycobacterial heat-shock proteins as carrier molecules. 2. The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and bacillus-Calmette-Guérin priming. Barrios, C., <i>et al.</i> . . . . . (A)	695
Mycobacterial protein antigens: a compilation. Young, D. B., <i>et al.</i> . . . . . (A)	312
Peptide recognition, T-cell receptor usage and HLA restriction elements of human heat-shock protein (hsp)-60 and mycobacterial 65-kDa hsp-reactive T-cell clones from rheumatoid synovial fluid. Quayle, A. J., <i>et al.</i> . . . . . (A)	684
Preliminary study of cellular immunity to <i>M. leprae</i> protein in contacts and leprosy patients. Rada S., E. M., <i>et al.</i> . . . . . (O)	189
Prevention of adjuvant arthritis in rats by nonapeptide from the 65-kDa mycobacterial heat shock protein: specificity and mechanism. Yang, X.-D., <i>et al.</i> . . . . . (A)	331
Protection of mice from <i>M. leprae</i> infection by T cells and protein vaccines. Gelber, R. H., <i>et al.</i> . . . . . (A)	715
Protein antigens of mycobacteria studied by quantitative immunologic techniques. Harboe, M., <i>et al.</i> . . . . . (A)	304
Purification and partial characterization of a penicillin-binding protein from <i>M. smegmatis</i> . Basu, J., <i>et al.</i> . . . . . (A)	690
Recognition of <i>M. leprae</i> recombinant 18-kDa proteins in leprosy. Hussain, R., <i>et al.</i> (O)	368
Sequence and immunogenicity of the 70-kDa heat shock protein of <i>M. leprae</i> . McKenzie, K. R., <i>et al.</i> . . . . . (A)	136
Sero-Immunoreactivity of cloned protein antigens of <i>M. leprae</i> . Khan, M. B., <i>et al.</i> . . . (O)	195
Serological reactivity to <i>M. bovis</i> protein antigens in cattle. Fifis, T., <i>et al.</i> . . . . . (A)	319
Serology and leprosy: immunoassays comparing immunoglobulin G antibody responses to 28- and 30-kilodalton proteins purified from <i>M. bovis</i> . Pessolani, M. C. V., <i>et al.</i> (A)	136
Soluble CD4 suppress the antigen driven proliferative response of certain T cell clones specific for mycobacteria and for peptides by monoclonal heat shock proteins. Gidlund, M., <i>et al.</i> . . . . . (A)	507
T-cell responses of leprosy patients and healthy contacts toward separated protein antigens of <i>M. leprae</i> . Gulle, H., <i>et al.</i> . . . . . (O)	44
The 14,000-molecular-weight antigen of <i>M. tuberculosis</i> is related to the alpha-crystallin family of low-molecular-weight heat shock proteins. Verbon, A., <i>et al.</i> . . . . . (A)	309
The antibody repertoire to proteins of <i>M. leprae</i> : genetic influences at the antigen and epitope level. Adeleye, T. A., <i>et al.</i> . . . . . (A)	679
The significance of proteins actively secreted-by <i>M. tuberculosis</i> in relation to immunity and complications of mycobacterial diseases. Harboe, M. . . . . (SS)	470
The variable C-terminal region of the <i>M. leprae</i> 70-kilodalton heat shock protein is the target for humoral immune responses. Davenport, M. P., <i>et al.</i> . . . . . (A)	302
Use of synthetic peptides corresponding to sequences of <i>M. leprae</i> proteins to study delayed-type hypersensitivity response in sensitized guinea pigs. Estrada-G., I. C. E., <i>et al.</i> . . . . . (O)	18
Vaccination of mice with soluble protein fraction of <i>M. leprae</i> provides consistent and long-term protection against <i>M. leprae</i> infection. Gelber, R. H., <i>et al.</i> . . . . . (A)	303
<b>Prothionamide,</b>	
Does isoniazid increase the hepatotoxicity of the combination prothionamide-dapsone? Isoprodian Study Group. . . . . (O)	536
<b>Psoriasis,</b>	
Leprosy and psoriasis occurring together. Nigam, P. K., <i>et al.</i> . . . . . (A)	126
<b>Psychosocial,</b>	
[Psychopathological aspects in Hansen's disease.] Baconcini, C. . . . . (A)	125
Psychosocial aspects of deformed leprosy patients undergoing surgical correction. Ramanathan, U., <i>et al.</i> . . . . . (A)	151
The explanatory model interview catalogue (EMIC)—contribution to crosscultural research methods from a study of leprosy and mental health. Weiss, M. G., <i>et al.</i> . . . . (A)	678
<b>Puerto Rico,</b>	
Leprosy in Puerto Rico: a decade later. Almodovar, P. I. and Figueroa, J. . . . . (A)	147
<b>Rat(s),</b>	
Effect of antileprosy drugs on superoxide anion production by rat peritoneal macrophage with special reference to light exposed clofazimine. Sahu, A., <i>et al.</i> . . . . . (A)	123

<i>In vivo</i> effects of anti-leprosy drugs on the rat peritoneal macrophages and lymphocyte subpopulations. Sahu, A., <i>et al.</i> . . . . . (A)	686
Inhibition of dapsone-induced methaemoglobinaemia by cimetidine in the presence of thrimethoprim in the rat. Coleman, M. D., <i>et al.</i> . . . . . (A)	295
<b>Reaction, leprosy,</b>	
[A leprosy reaction involving the esophagus and the larynx.] Alvarado, M. and Saul, A. . . . . (A)	298
[Acute uveitis in the course of reversal reactions.] Spindler, E., <i>et al.</i> . . . . . (A)	129
Leprosy in reaction: a medical emergency. Malin, A. S., <i>et al.</i> . . . . . (A)	126
[Leprosy reaction in Lucio's phenomenon; treatment with griseofulvin.] Ramirez, M. M. . . . . (A)	299
Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Becx-Bleumink, M. and Berhe, D. . . . . (O)	173
Reactive oxygen intermediates in the phagocytes from leprosy patients: correlation with reactional states and variation drug treatment. Santos, D. O., <i>et al.</i> . . . . . (C)	92
Resolution of type 1 reaction in multibacillary Hansen's disease as a result of treatment with cyclosporine. Frankel, R. I., <i>et al.</i> . . . . . (O)	8
Risk factors for type-1 reactions in borderline leprosy patients. Roche, P. W., <i>et al.</i> . . . . (A)	128
Serum tumor necrosis factor and interleukin 1 in leprosy and during lepra reactions. Parida, S. K., <i>et al.</i> . . . . . (A)	306
Soluble interleukin-2 receptors: levels in leprosy, and during and after type 1 (lepra) and type 2 (ENL) reactions. Sehgal, B. N., <i>et al.</i> . . . . . (A)	138
Subcorneal pustular dermatosis in type 1 lepra reaction. Pavithran, K. . . . . (C)	89
Sulpride and type II reaction. Salafia, A. and Menezes, M. . . . . (A)	128
<b>Rehabilitation,</b>	
Aspects of rehabilitation in leprosy. Gilbody, J. S. . . . . . (E)	608
Community-based rehabilitation: an evaluation study. Gershon, W. and Srinivasan, G. R. . . . . (A)	517
<b>Relapse(s),</b>	
Follow-up of multibacillary leprosy patients using a phenolic glycolipid-I-based ELISA. Do increasing ELISA-values after discontinuation of treatment indicate relapse? Chin-A-Lien, R., <i>et al.</i> . . . . . (A)	507
Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses. Becx-Bleumink, M. . . . . (O)	421
Relapses in multibacillary leprosy patients after stopping treatment with rifampin-containing combined regimens. Marchoux Chemotherapy Study Group. . . . . (O)	525
Risk of relapse among non-lepromatous patients released from treatment after dapsone monotherapy. Pandian, T. D., <i>et al.</i> . . . . . (A)	122
Study of the characteristics and causes of relapse amongst leprosy cases in an urban area (Calcutta). Saha, S. P. and Das, K. K. . . . . . (A)	498
<b>Rifampin,</b>	
Abnormal overnight dexamethasone suppression test in subjects receiving rifampin therapy. Kyriazopoulou, V. and Vagenakis, A. G. . . . . . (A)	677
Activity <i>in vitro</i> of rifabutin, FCE 22807, rifapentine, and rifampin against <i>M. microti</i> and <i>M. tuberculosis</i> and their penetration into mouse peritoneal macrophages. Dhillon, J. and Mitchison, D. A. . . . . . (A)	319
Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Grosset, J., <i>et al.</i> . . . . . (A)	320
Automated high-performance liquid chromatographic method for the determination of rifampicin in plasma. Swart, K. J. and Paggis, M. . . . . . (A)	503
Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against <i>M. leprae</i> in mice. Ji, B., <i>et al.</i> . . . . . (O)	556
Chemoprophylaxis of leprosy with a single dose of 25 mg per kg rifampin in the southern Marquesas; results after four years. Cartel, J.-L., <i>et al.</i> . . . . . (O)	416

Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis. Pretet, S., <i>et al.</i> . . . . . (A)	705
Comparative spectrophotometric analysis of rifampicin by chelate formation and charge-transfer complexation. Galal, S. M., <i>et al.</i> . . . . . (A)	500
Displacement of rifampicin bound to serum proteins by addition of levamisole. Perez Gallardo, L., <i>et al.</i> . . . . . (A)	677
Disseminated intravascular coagulopathy associated with rifampicin. Ip, M., <i>et al.</i> . . . . . (A)	322
How effective is monthly rifampin? Almeida, J. G. . . . . (C)	81
Intraocular penetration of rifampin in humans. Outman, W. R., <i>et al.</i> . . . . . (A)	677
Intravascular hemolysis and acute renal failure following intermittent rifampin therapy. Gupta, A., <i>et al.</i> . . . . . (O)	185
[Panteleva—effectiveness of a liposomal form of rifampicin in the treatment of experimental mouse tuberculosis.] Yu, N., <i>et al.</i> . . . . . (A)	709
Relapses in multibacillary leprosy patients after stopping treatment with rifampin-containing combined regimens. Marchoux Chemotherapy Study Group. . . . . (O)	525
Role of rifampin and clofazimine ointments in the treatment of leprosy. Venkateswarlu, B., <i>et al.</i> . . . . . (E)	269
Severe thrombocytopenia and intermittent use of rifampin. Nishioka, S. de A., <i>et al.</i> . . . . (O)	273
The susceptibility testing of 13 strains of <i>M. leprae</i> to rifampicin and the determination of minimal effective dosage. Wang, H., <i>et al.</i> . . . . . (A)	123
Treatment of early rheumatoid arthritis with rifampicin. Cox, N. L., <i>et al.</i> . . . . . (A)	318
Update on rifampin drug interactions. Bocherding, S. M., <i>et al.</i> . . . . . (A)	295
<b>Rifamycin,</b>	
Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against <i>M. avium</i> complex infection induced in mice. Tomioka, H., <i>et al.</i> . . . . . (A)	297
<i>In vitro</i> and <i>in vivo</i> antileprosy activities of benzoxazinorifamycin (KRM-1648) and clarithromycin. Saito, H., <i>et al.</i> . . . . . (A)	723
<b>Russia, (see Commonwealth of Independent States),</b>	
<b>Rwanda,</b>	
Pulmonary tuberculosis in Kigali, Rwanda—impact of human immunodeficiency virus infection on clinical and radiographic presentation. Batungwanayo, J., <i>et al.</i> . . . . . (A)	696
<b>Sarcoidosis,</b>	
A search for mycobacterial DNA in granulomatous tissues from patients with sarcoidosis using the polymerase chain reaction. Bocart, D., <i>et al.</i> . . . . . (A)	697
Detection of mycobacterial DNA in sarcoidosis and tuberculosis with polymerase chain reaction. Saboor, S. A., <i>et al.</i> . . . . . (A)	326
Detection of mycobacterial rRNA in sarcoidosis with liquid-phase hybridisation. Mitchell, I. C., <i>et al.</i> . . . . . (A)	325
<b>Screening,</b>	
Double-blind evaluation of BACTEC and Buddemeyer-type radiorespirometric assays for <i>in vitro</i> screening of antileprosy agents. Franzblau, S. G., <i>et al.</i> . . . . . (A)	513
Screening gene expression libraries for epitopes recognized in <i>M. leprae</i> by mouse T cells. Villarreal-Ramos, B., <i>et al.</i> . . . . . (A)	688
Suitability of a skin-smear examination needle for leprosy screening by PCR. Sugita, Y., <i>et al.</i> . . . . . (C)	658
<b>Senegal,</b>	
L'Institut de Leprologie Appliquee de Dakar troisieme cours annuel. . . . . (B)	494
<b>Serodiagnosis,</b>	
Assessment of the diagnostic value of the native PGLTB1, its synthetic neoglycoconjugate PGLTB0 and the sulfolipid IV antigens for the serodiagnosis of tuberculosis. Chanteau, S., <i>et al.</i> . . . . . (O)	1
Comparison of bis-di-octadecylamide of trehalose dicarboxylic acid (BDA.TDA) with glycolipid SL-IV as ELISA antigens for the serodiagnosis of leprosy. Laszlo, A., <i>et al.</i> (O)	376
Does previous BCG vaccination interfere with the serodiagnosis of tuberculosis using <i>M. tuberculosis</i> -specific glycolipid antigens? Salem, J. I., <i>et al.</i> . . . . . (C)	87

- Evaluation of MLPA test for the serodiagnosis of leprosy. Dhandayuthapani, S., *et al.* (C) 84
- Evaluation of synthetic pseudo cord-factor-like glycolipids for the serodiagnosis of tuberculosis. Laszlo, A., *et al.* (A) 702
- Molecular cloning of the alpha-antigen gene from *M. leprae* and its application to serodiagnosis of leprosy. Makino, M. and Suzuki, Y. (A) 721
- Relationships between titers of antibodies immunoreacting against glycolipid antigens from *M. leprae* and *M. tuberculosis*, the Mitsuda and Mantoux reactions, and bacteriological loads: implications in the pathogenesis, epidemiology and serodiagnosis of leprosy and tuberculosis. David, H. L., *et al.* (O) 208
- Synthesis of the trisaccharide-protein conjugate of the phenolic glycolipid of *M. tuberculosis* for the serodiagnosis of tuberculosis. Fujiwara, T. (A) 155
- Serum,**
- An appraisal of enzyme linked immunosorbent assay (ELISA) and serum antibody competition test (SACT) in leprosy. Kanchana, M. A., *et al.* (A) 304
- Avidin-biotin immunoblotting studies on reactivity of leprosy sera with *M. leprae* antigen. Patil, S. A., *et al.* (C) 280
- Detection of antibodies to human nerve antigens in sera from leprosy patients by ELISA. Park, J. Y., *et al.* (A) 307
- Detection of high titres of *Toxoplasma gondii* antibodies in sera of patients with leprosy in Pakistan. Hussain, R., *et al.* (A) 683
- Enzyme linked immunosorbent assay of a 12-kDa protein of *M. leprae* with sera from leprosy patients. Navalkar, R. G., *et al.* (O) 382
- Expression of a common idiotype PR4 in the sera of patients with leprosy. Zumla, A., *et al.* (A) 141
- Humoral response to nerve glycolipid antigen in sera of leprosy patients. Sahasrabudhe, R. V., *et al.* (C) 488
- Immunoglobulin-A (IgA) and IgG serum antibodies to mycobacterial antigens in Crohn's disease patients and their relatives. Wayne, L. G., *et al.* (A) 707
- Immunoreactivity of a mammalian liver component with leprosy sera. Deshpande, R. G., *et al.* (A) 681
- Major proteins of mycobacterial strain ICRC and *M. leprae* identified by antibodies in sera from leprosy patients and their contacts. Chiplunkar, S. V., *et al.* (A) 301
- Quantitation of the soluble E-receptor of human T lymphocytes by rocket electrophoresis in the serum of patients with lepromatous and tuberculoid leprosy. Longo, I. M., *et al.* (A) 135
- Serum tumor necrosis factor and interleukin 1 in leprosy and during lepra reactions. Parida, S. K., *et al.* (A) 306
- Use of serum antibody and lysozyme levels for diagnosis of leprosy and tuberculosis. Near, K. A. and Lefford, M. J. (A) 306
- Skin,**
- Hyperkeratotic and verrucous skin lesions on lower extremities of leprosy patients. Patki, A. H. and Mehta, J. M. (A) 506
- Immune complexes and antibody levels in blisters over human leprosy skin lesions with or without erythema nodosum leprosum. Scollard, D. M., *et al.* (A) 510
- [Immunohistochemical study of leprosy skin lesions using S-100 protein and alpha-antichymotrypsin.] Ye, F., *et al.* (A) 689
- Skin, soft tissue, and bone infections due to *M. chelonae chelonae*—importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. Wallace, R. J., *et al.* (A) 707
- Species-specific assessment of *M. leprae* in skin biopsies by *in situ* hybridization and polymerase chain reaction. Arnoldi, J., *et al.* (A) 689
- Suggested new technique for skin biopsy under field conditions. Chaturvedi, R. M. and Kartikeyan, S. (A) 677
- Skin smear(s),**
- Is bacteriological examination by skin smear necessary in all paucibacillary leprosy patients in mass control programmes? Rao, P. S., *et al.* (A) 127
- Suitability of a skin-smear examination needle for leprosy screening by PCR. Sugita, Y., *et al.* (C) 658

**Skin test(s),**

- Blastogenic response with autologous plasma and Mitsuda's reaction in leprosy patients and their unaffected sibs. Foss, N. T., *et al.* ..... (A) 132
- Effect of skin test with *M. leprae* soluble antigen on reaction to a subsequent test with the same antigen. Gupte, M. D., *et al.* ..... (O) 54
- Lepromin reaction in patients with falciparum malaria. Tin-Shwe and Pe-Than-Myint. (A) 688
- Relationships between titers of antibodies immunoreacting against glycolipid antigens from *M. leprae* and *M. tuberculosis*, the Mitsuda, and Mantoux reactions, and bacteriological loads: implications in the pathogenesis, epidemiology and serodiagnosis of leprosy and tuberculosis. David, H. L., *et al.* ..... (O) 208

**Spain,**

- Fontilles cursos internacional de leprologia. .... (N) 292

**Stain(s),**

- Acid-fast and H & E stainings can be combined better than in the TRIFF method. Miko, T. L. and Lucas, S. G. .... (A) 136
- Assessing the viability of *M. leprae* by the fluorescein diacetate/ethidium bromide staining technique. Palomino, J. C., *et al.* ..... (A) 144
- Fluorescein diacetate and ethidium bromide staining to determine the viability of *M. smegmatis* and *Escherichia coli*. Jayapal, V., *et al.* ..... (A) 143
- Refractile mycobacteria in Ramanowsky-stained bone marrow smears; a comparison of acid-fast-stained tissue sections and Romanowsky-stained smears. Torlakovic, E., *et al.* ..... (A) 328
- Significance of neither green nor red (NGR) bacilli in FDA-EB staining. Bhatia, V. N. and Mirmaladevi, B. .... (A) 142

**Subclinical,**

- [A study of subclinical infection with *M. leprae*, the factors influencing the subclinical infection.] Shu, H.-W., *et al.* ..... (A) 139
- Immunoepidemiological studies on subclinical infection in leprosy. I. Clinical and immunological findings in schoolchildren and adults in Okinawa. Abe, M., *et al.* ..... (A) 692

**Sulfone(s),**

- Anticonvulsive effect of dapsone (4,4'-diaminodiphenyl sulfone) on amygdala-kindled seizures in rats and cats. Hamada, K., *et al.* ..... (A) 296

**Superoxide,**

- Effect of antileprosy drugs on superoxide anion production by rat peritoneal macrophage with special reference to light exposed clofazimine. Sahu, A., *et al.* ..... (A) 123

**Switzerland,**

- Report of the First Meeting of the WHO Working Group on Leprosy Control. .... (N) 114
- TDR and IDRC prize for a paper on "Women and Tropical Diseases." ..... (B) 495
- TDR needs health education materials. .... (N) 671
- TDR regional linkage grants for research training. .... (N) 671
- TDR Steering Committee deadlines. .... (N) 673

**Tanzania,**

- Hypoadrenalism in patients with pulmonary tuberculosis in Tanzania: an undiagnosed complication? Mugusi, F., *et al.* ..... (A) 158

**Thalidomide,**

- Thalidomide for systemic lupus erythematosus. Bessis, D., *et al.* ..... (A) 518
- Thalidomide for the treatment of chronic graft-versus-host disease. Vogelsang, G. B., *et al.* ..... (A) 330
- Thalidomide treatment of chronic graft-versus-host disease. Henry, D., *et al.* ..... (A) 156
- Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood. Shannon, E. J., *et al.* ..... (A) 510

**The Leprosy Mission (TLM),**

- Paul Brand new President of TLM International. Hastings, R. C. .... (N) 673

**Therapy (see also Chemotherapy),**

- Abnormal overnight dexamethasone suppression test in subjects receiving rifampin therapy. Kyriazopoulou, V. and Vagenakis, A. G. .... (A) 677

- Ambulatory treatment of multibacillary leprosy with a regimen of 8 months duration. Pattyn, S. R., *et al.* ..... (A) 502
- Clarithromycin-ciprofloxacin-amikacin for therapy of *M. avium-M. intracellulare* bacteremia in patients with AIDS. Delalla, R., *et al.* ..... (A) 699
- Immunological upgrading with combined immunotherapy and chemotherapy in a lepromatous leprosy patient: a case report. Zaheer, S. A., *et al.* ..... (A) 130
- [Influence of tuberculin therapy on the immunologic parameters in adolescents with pulmonary tuberculosis.] Knoring, B. E., *et al.* ..... (A) 323
- Intravascular hemolysis and acute renal failure following intermittent rifampin therapy. Gupta, A., *et al.* ..... (O) 185
- Patient treatment compliance in leprosy; a critical review. Vadher, A. and Lalljee, M. (E) 587
- Prevalence of dementia amongst elderly Japanese with leprosy—apparent effect of chronic drug therapy. McGeer, P. L., *et al.* ..... (A) 678
- Relapses in leprosy patients after release from dapsone monotherapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Becx-Bleumink, M. .... (O) 161
- Risk of relapse among non-lepromatous patients released from treatment after dapsone monotherapy. Pandian, T. D., *et al.* ..... (A) 122
- Treatment of multibacillary leprosy with a regimen of 13 weeks duration. Pattyn, S. R., *et al.* ..... (A) 502
- Throat,**
- [A leprosy reaction involving the esophagus and the larynx.] Alvarado, M. and Saul, A. (A) 298
- Tissue(s),**
- A search for mycobacterial DNA in granulomatous tissues from patients with sarcoidosis using the polymerase chain reaction. Bocart, D., *et al.* ..... (A) 697
- Comparison of polymerase chain reaction technique with other methods for detection of *M. leprae* in tissues of wild nine-banded armadillos. Job, C. K., *et al.* ..... (A) 145
- Improved method for purification of *M. leprae* from armadillo tissues. Rodde, C., *et al.* ..... (C) 277
- M. paratuberculosis* DNA in Crohn's disease tissue. Sanderson, J. D., *et al.* ..... (A) 705
- Phospholipase activity of *M. leprae* harvested from experimentally infected armadillo tissue. Wheeler, P. R. and Ratledge, C. .... (A) 144
- Refractile mycobacteria in Ramanowsky-stained bone marrow smears; a comparison of acid-fast-stained tissue sections and Romanowsky-stained smears. Torlakovic, E., *et al.* ..... (A) 328
- Training,**
- A multi-media approach to health education. Friedericks, R. C. .... (A) 118
- An application of the LePSA methodology for health education in leprosy. Lennon, J. L. and Coombs, D. W. .... (A) 505
- Fontilles cursos internacional de leprologia. .... (N) 292
- Heiser Program for Research in Leprosy and Tuberculosis 1993. .... (N) 496
- IAL-sponsored 1991 training workshop on foot care. .... (N) 112
- L'Institut de Leprologie Appliquee de Dakar troisieme cours annuel. .... (B) 494
- Relationship problems between doctor and paramedical professionals working in leprosy with reference to a possible solution. Premkumar, R. and Dave, S. .... (A) 498
- TDR regional linkage grants for research training. .... (N) 671
- The leprosy game; a health education tool. Devasundaram, J. K. .... (C) 91
- [The level of knowledge about leprosy among university students.] Ramirez-Soltero, S., *et al.* ..... (A) 119
- The private GP and leprosy: a study. Uplekar, M. W. and Cash, R. A. .... (A) 129
- Transmission,**
- Can sandflies be the vector for leprosy? Sreevatsa, *et al.* ..... (C) 94
- Imported leprosy in the United States, 1987 through 1988—an epidemic without secondary transmission. Mastro, T. D., *et al.* ..... (A) 694
- Trial(s),**
- A clinical trial of minocycline in lepromatous leprosy. Gelber, R. H., *et al.* ..... (A) 500
- Activity of clarithromycin against *M. avium* infection in patients with the acquired immune deficiency syndrome; a controlled clinical trial. Dautzenberg, B., *et al.* ..... (A) 153

Histopathological monitoring of an immunotherapeutic trial with <i>Mycobacterium w.</i> Mukherjee, A., <i>et al.</i> . . . . . (O)	28
Immunoprophylactic trial with combined <i>M. leprae</i> /BCG vaccine against leprosy: pre- liminary results. Convit, J., <i>et al.</i> . . . . . (A)	301
Leprosy clinical trials of sparflloxacin and clarithromycin. Franzblau, S. G., <i>et al.</i> . . . . (A)	715
Short-term trial of clofazimine in previously untreated lepromatous leprosy. Jamet, P., <i>et al.</i> . . . . . (O)	542
Water-soluble complexes of palmitic acid and palmitates for metabolic studies and cultivation trials of <i>M. leprae</i> . Kato, L., <i>et al.</i> . . . . . (C)	105
<b>Trinidad,</b>	
Attitudes toward leprosy in the outpatient population of dermatology clinics in Trinidad. Suite, M. and Gittens, C. . . . . (A)	499
<b>Tuberculin,</b>	
[Influence of tuberculin therapy on the immunologic parameters in adolescents with pulmonary tuberculosis.] Knoring, B. E., <i>et al.</i> . . . . . (A)	323
<b>Tuberculoïd leprosy,</b>	
An attempt to produce experimental tuberculoïd leprosy in the nine-banded armadillo. Job, C. K., <i>et al.</i> . . . . . (A)	145
Chromoblastomycosis masquerading as tuberculoïd leprosy. Pavithran, K. . . . . (C)	657
Quantitation of the soluble E-receptor of human T lymphocytes by rocket electrophoresis in the serum of patients with lepromatous and tuberculoïd leprosy. Longo, I. M., <i>et</i> <i>al.</i> . . . . . (A)	135
<b>Tuberculosis,</b>	
A contribution to the history of tuberculosis and leprosy in 19th century Norway. Wood, S. R. . . . . (A)	120
A field evaluation of serological and cellular diagnostic tests for bovine tuberculosis. Wood, P. R., <i>et al.</i> . . . . . (A)	708
[A thermoindicative nasal test for detecting allergy to antituberculosis drugs.] Buseva, T. A. and Koryakin, V. A. . . . . (A)	152
Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Grosset, J., <i>et al.</i> . . . . . (A)	320
Antibody responses to the 18-kDa protein of <i>M. leprae</i> in leprosy and tuberculosis patients. Roche, P. W., <i>et al.</i> . . . . . (O)	201
[Antituberculosis care organization under conditions of a new economic system.] Kuch- erov, A. L. . . . . (A)	158
Antituberculous agents. van Scoy, R. E. and Wilkowske, C. J. . . . . (A)	329
[Antituberculous antibodies in enzyme immunoassay in relation to the efficacy of tu- berculosis chemotherapy.] Chukanov, V. I., <i>et al.</i> . . . . . (A)	131
Assessment of the diagnostic value of the native PGLTb1, its synthetic neoglycocon- jugate PGLTb0 and the sulfolipid IV antigens for the serodiagnosis of tuberculosis. Chanteau, S., <i>et al.</i> . . . . . (O)	1
Association of increased mycobacterium growth inhibitory factor with antituberculous immunity. Chandrasekhar, S. and Perumal, V. K. . . . . (A)	152
Bacteriostatic and bactericidal activity of anti-tuberculosis drugs against <i>M. tuberculosis</i> , <i>M. avium</i> , <i>M. intracellulare</i> complex and <i>M. kansasii</i> in different growth phases. Yamori, S., <i>et al.</i> . . . . . (A)	331
CD30 expression by peripheral blood monocytes and hepatic macrophages in a child with miliary tuberculosis. Epstein, M. L., <i>et al.</i> . . . . . (A)	699
Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pul- monary tuberculosis. Pretet, S., <i>et al.</i> . . . . . (A)	705
Detection of mycobacterial DNA in sarcoidosis and tuberculosis with polymerase chain reaction. Saboor, S. A., <i>et al.</i> . . . . . (A)	326
Does previous BCG vaccination interfere with the serodiagnosis of tuberculosis using <i>M. tuberculosis</i> -specific glycolipid antigens? Salem, J. I., <i>et al.</i> . . . . . (C)	87
Efficacy of BCG vaccine against leprosy and tuberculosis in Malawi. Ponnighaus, J. M., <i>et al.</i> . . . . . (A)	307

Evaluation of lipoarabinomannan for the serological diagnosis of tuberculosis. Sada, E., <i>et al.</i> . . . . . (A)	159
Evaluation of synthetic pseudo cord-factor-like glycolipids for the serodiagnosis of tuberculosis. Laszlo, A., <i>et al.</i> . . . . . (A)	702
Genetics and resistance to tuberculosis—could resistance be enhanced by genetic engineering. Stead, W. W. . . . . (A)	706
Heiser Program for Research in Leprosy and Tuberculosis 1993 . . . . . (N)	496
Heterogeneity of the repertoire of T cells of tuberculosis patients and healthy contacts to <i>M. tuberculosis</i> antigens separated by high-resolution techniques. Schoel, B., <i>et al.</i> (A)	326
High antibody levels to the mycobacterial fibronectin-binding antigen of 30-31 kD in tuberculosis and lepromatous leprosy. Espitia, C., <i>et al.</i> . . . . . (A)	303
Humoral responses against the 85A and 85B antigens of <i>M. bovis</i> BCG in patients with leprosy and tuberculosis. Van Vooren, J. P., <i>et al.</i> . . . . . (A)	688
Hypoadrenalism in patients with pulmonary tuberculosis in Tanzania: an undiagnosed complication? Mugusi, F., <i>et al.</i> . . . . . (A)	158
[Immunogenetic grounds for the development of local forms of primary tuberculosis in children.] Vasilyev, A. V. and Dovgalyuk, I. F. . . . . (A)	329
Increased proportions of peripheral blood gamma/delta T cells in patients with pulmonary tuberculosis. Ito, M., <i>et al.</i> . . . . . (A)	701
[Influence of tuberculin therapy on the immunologic parameters in adolescents with pulmonary tuberculosis.] Knoring, B. E., <i>et al.</i> . . . . . (A)	323
Neopterin in tuberculous and neoplastic pleural fluids. Baganha, M. F., <i>et al.</i> . . . . . (A)	299
[Panteleeva—effectiveness of a liposomal form of rifampicin in the treatment of experimental mouse tuberculosis.] Yu, N., <i>et al.</i> . . . . . (A)	709
[Pathomorphological evaluation of therapeutic effect of mycobacteriophages in tuberculosis.] Zemskova, Z. S. and Dorozhkova, I. R. . . . . (A)	331
Prevention and control of tuberculosis among homeless persons; recommendations of the Advisory Council for the Elimination of Tuberculosis. . . . . (A)	518
Prevention and control of tuberculosis in U.S. communities with at-risk minority populations; recommendations of the Advisory Council for the Elimination of Tuberculosis. . . . . (A)	519
Pulmonary eosinophilia in pulmonary tuberculosis. Vijayan, V. K., <i>et al.</i> . . . . . (A)	707
Pulmonary tuberculosis in Kigali, Rwanda—impact of human immunodeficiency virus infection on clinical and radiographic presentation. Batungwanayo, J., <i>et al.</i> . . . . . (A)	696
Radiological features of pulmonary tuberculosis in patients infected with human immunodeficiency virus. Noronha, D., <i>et al.</i> . . . . . (A)	158
Recent trends in the epidemiology of tuberculosis and leprosy. Smith, P. G. . . . . (A)	517
Reduced anti- <i>M. tuberculosis</i> antibody response in tuberculosis patients with acquired immunodeficiency syndrome. Figueiredo, J. F. A. and Machado, A. A. . . . . (A)	700
Relationships between titers of antibodies immunoreacting against glycolipid antigens from <i>M. leprae</i> and <i>M. tuberculosis</i> , the Mitsuda and Mantoux reactions, and bacteriological loads: implications in the pathogenesis, epidemiology and serodiagnosis of leprosy and tuberculosis. David, H. L., <i>et al.</i> . . . . . (O)	208
Role of TNFalpha in the pathogenesis of leprosy and tuberculosis. Kaplan, G. . . . . (A)	719
Serological response to purified mycobacterial phosphatidylinositol mannoside in healthy controls and in patients with tuberculosis and leprosy. Mullins, R. J., <i>et al.</i> . . . . . (O)	353
Synthesis of the trisaccharide-protein conjugate of the phenolic glycolipid of <i>M. tuberculosis</i> for the serodiagnosis of tuberculosis. Fujiwara, T. . . . . (A)	155
The use of the polymerase chain reaction test in the diagnosis of tuberculosis. van Helden, P. D., <i>et al.</i> . . . . . (A)	329
Time course of anti-SL-IV immunoglobulin-G antibodies in patients with tuberculosis and tuberculosis-associated AIDS. Martin-Casabona, N., <i>et al.</i> . . . . . (A)	324
Tuberculosis morbidity in the United States: final data, 1990. Jereb, J. A., <i>et al.</i> . . . . . (A)	322
[Use of dimephosphone in a pathogenetic therapy of experimental tuberculosis.] Alexandrova, A. E., <i>et al.</i> . . . . . (A)	151
Use of serum antibody and lysozyme levels for diagnosis of leprosy and tuberculosis. Near, K. A. and Lefford, M. J. . . . . (A)	306
Vaccination against tuberculosis and leprosy. Kaufmann, S. H. E. and Young, D. B. . . . . (A)	508

<b>Turkey,</b>		
International Leprosy Seminar, Istanbul, Turkey. . . . .	(N)	495
<b>Uganda,</b>		
Absence of <i>M. avium</i> complex disease in patients with AIDS in Uganda. Morrissey, A. B., <i>et al.</i> . . . . .	(A)	325
<b>U.K.,</b>		
New Director for LEPRA. . . . .	(N)	293
Prevention of Blindness in Leprosy. . . . .	(N)	114
Robert Cochrane Fund for Leprosy. . . . .	(N)	674
<b>Ulcer(s),</b>		
Squamous cell carcinoma in chronic ulcers in leprosy: a review of 38 consecutive cases. Richardus, J. H. and Smith, T. C. . . . .	(A)	128
<b>Urine,</b>		
Comparison of a urine spot test and blood tests as indicators of patient compliance. Yoder, L. J., <i>et al.</i> . . . . .	(A)	124
Detection of a <i>M. leprae</i> cell wall antigen in the urine of untreated and treated patients. Sharma, V.K., <i>et al.</i> . . . . .	(A)	511
<b>U.S.A.,</b>		
American Association for the Advancement of Science (AAAS). . . . .	(N)	495
Epidemiology of infection by nontuberculosis mycobacteria; <i>M. avium</i> , <i>M. intracellulare</i> , and <i>M. scrofulaceum</i> in acid, brown-water swamps of the Southeastern United States and their association with environmental variables. Kirschner, R. A., Jr., <i>et al.</i> . . . .	(A)	323
Federal funded and private sector sources of HD treatment. . . . .	(N)	114
Frist elected President of ILEP. . . . .	(N)	674
Hansen's disease cases in 1991. . . . .	(N)	114
Heiser Program for Research in Leprosy and Tuberculosis 1993. . . . .	(N)	496
Imported leprosy in the United States, 1987 through 1988—an epidemic without secondary transmission. Mastro, T. D., <i>et al.</i> . . . . .	(A)	694
International Medical Services for Health (INMED). . . . .	(N)	115
Jacobson new Carville Director. Hastings, R. C. and Goodman, D. D. . . . .	(N)	674
Leprosy in Puerto Rico: a decade later. Almodovar, P. I. and Figueroa, J. . . . .	(A)	147
"The Star" completes 50 years. . . . .	(N)	293
Tuberculosis morbidity in the United States: final data, 1990. Jereb, J. A., <i>et al.</i> . . . .	(A)	322
Video available on health workers and blindness prevention in leprosy. . . . .	(N)	115
<b>U.S.S.R. (see Commonwealth of Independent States),</b>		
<b>Vaccine(s), Vaccination,</b>		
Association of HLA antigens with differential responsiveness to <i>Mycobacterium w</i> vaccine in multibacillary leprosy patients. Rani, R., <i>et al.</i> . . . . .	(A)	308
Does Convit vaccine (BCG + <i>M. leprae</i> ) afford protection against biochemical changes in renal brush border membrane in experimental leprosy? Kohli, M., <i>et al.</i> . . . . .	(A)	135
Does previous BCG vaccination interfere with the serodiagnosis of tuberculosis using <i>M. tuberculosis</i> -specific glycolipid antigens? Salem, J. I., <i>et al.</i> . . . . .	(C)	87
Efficacy of BCG vaccine against leprosy and tuberculosis in Malawi. Ponnighaus, J. M., <i>et al.</i> . . . . .	(A)	307
Genetic vaccines against genetically infective macromolecules? Corcos, M. G. . . . .	(C)	659
Immunoprophylactic trial with combined <i>M. leprae</i> /BCG vaccine against leprosy: preliminary results. Convit, J., <i>et al.</i> . . . . .	(A)	301
Mycobacterial heat-shock proteins as carrier molecules. 2. The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and bacillus-Calmette-Guérin priming. Barrios, C., <i>et al.</i> . . . . .	(A)	695
<i>Mycobacterium w</i> vaccine being tried in New Delhi, India. . . . .	(N)	113
Protection of mice from <i>M. leprae</i> infection by T cells and protein vaccines. Gelber, R. H., <i>et al.</i> . . . . .	(A)	715
Resistance of intravenous inoculation of <i>M. tuberculosis</i> H37Rv in mice of different inbred strains following immunization with a leprosy vaccine based on <i>Mycobacterium w</i> . Singh, I. G., <i>et al.</i> . . . . .	(A)	146

T-cell responses to fractionated antigens of <i>Mycobacterium w</i> , a candidate anti-leprosy vaccine, in leprosy patients. Yadava, A., <i>et al.</i> . . . . . (A)	141
Vaccination against tuberculosis and leprosy. Kaufmann, S. H. E. and Young, D. B. . . (A)	508
Vaccination of mice with a soluble protein fraction of <i>M. leprae</i> provides consistent and long-term protection against <i>M. leprae</i> infection. Gelber, R. H., <i>et al.</i> . . . . . (A)	303
Vaccines against leprosy. Gupte, M. D. . . . . (A)	516
<b>Vanuatu,</b>	
Modification of multidrug treatment of leprosy in Vanuatu. Reeve, P. A., <i>et al.</i> . . . . . (C)	655
<b>Vitamin(s),</b>	
Effect of indomethacin on the modulation of <i>M. avium</i> growth in human macrophages by interferon gamma, retinoic acid and 1,25(OH) <sub>2</sub> -vitamin-D <sub>3</sub> . DeSousa, J. P. C., <i>et al.</i> . . . . . (A)	681
The protective effect of vitamin E on the hemolysis associated with dapsone treatment in patients with dermatitis herpetiformis. Prussick, R., <i>et al.</i> . . . . . (A)	297
<b>World Health Organization (WHO),</b>	
Report of the First Meeting of the WHO Working Group on Leprosy Control. . . . . (N)	114
<i>WHO Model Prescribing Information; Drugs Used in Mycobacterial Diseases.</i> . . . . . (B)	117
<b>Zambia,</b>	
Clinical observations on leprosy patients with HIV-1 infection in Zambia. Vreeburg, A. E. M. . . . . (A)	506